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Intense and prolonged inflammation correlates with the progression of various 
inflammatory diseases, ranging from cancer to sepsis. Sensitive detection and 
quantitative examination of the site of inflammation will, therefore, produce a wide-
ranging impact on disease diagnosis and treatment. Studies presented in this 
dissertation first attempt to design one nanoparticle that mimics the molecular 
interactions occurring between inflamed leukocytes and endothelium. To incorporate 
inflammation-sensitive molecular interactions, super paramagnetic iron oxide (SPIO) 
nanoparticles were conjugated with integrin lymphocyte function-associated antigen 
(LFA)-1 I domain, engineered to mimic activated leukocytes in physiology. We 
speculated such nanoparticles may possess selectivity toward diverse host 
inflammatory responses, which were then confirmed by whole body optical and 
magnetic resonance imaging (MRI) in vivo, in that leukocyte-mimetic nanoparticles 
(LMN) localized preferentially to the inflamed vasculature marked by high level of 
ICAM-1 within and in the invasive front of the tumor, as well as to the subcutaneous 
site of acute inflammation.  
The second part of the studies closely follow up with this finding, focusing on 
high resolution spatiotemporal imaging of inflammation in mice treated with systemic 
 injection of lipopolysaccharides (LPS) to mimic systemic inflammatory response or 
sepsis. Diagnosis of organ-level inflammation was achieved by MR imaging of LMN. 
Using a novel MRI quantitative susceptibility mapping (QSM) technique for non-
invasive quantification of SPIO, we observed a greater accumulation of LMN in the 
liver, specific to ICAM-1 induction due to LPS-induced inflammation. Overall, the 
amounts of organic nanoparticles estimated by QSM were in good agreement with the 
values measured by radioactivity, presenting the idea that spatiotemporal mapping of 
LMN by QSM may provide a reliable, rapid, non-invasive method for identifying 
organ-specific inflammation not offered by existing diagnostic techniques.  
Yeast surface display (YSD) has been a powerful tool in engineering the active 
I domain for LMN. The last part of this dissertation discusses utilizing YSD in 
generating new monoclonal antibody against ephrin-B2, one highly conserved antigen 
participating in tumor angiogenesis. Being independent investigations outside of our 
major focus on LMN and inflammation imaging, studies presented here demonstrate 
another example of molecular discoveries which are critical for future development of 
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On the evening of 29 December 1959, in one of his best known talks, titled 
‘There’s plenty of room at the bottom’, Richard Feynman probed into the exciting 
possibility of manipulating things at the molecular or even atomic level even before 
the existence of the buzz word ‘nanotechnology’. If we treat this paper as the blueprint 
for nanotechnology, many advances of nanobiotechnology today might have failed 
Mr. Feynman because they are still quite far from his original vision, unlike other 
important technological improvements such as the improved performance of electron 
microscopes and the miniaturization of computers. With our current tools, we are still 
limited in the small scale biological processes we can observe by simply ‘looking at 
the thing,’ not to mention tracking and controlling these processes in real time in situ. 
Since biological systems are exceedingly intricate and marvelous in the world of the 
small, we want to echo Mr. Feynman here by creating a biomimetic system at 
nanoscale that is also easy to maneuver. We endowed it with the traits of inflamed 
leukocytes, as they participate in almost every inflammatory response and 
inflammation is the key to a spectrum of human diseases. Through in vitro analysis of 
its cellular adherence followed by uptake as well as in vivo examination of its homing 
to artificially-induced inflammation, we want to provide a different approach for 
manipulating nanoscale machineries and propose a potential application of them in 
noninvasive quantitative diagnosis.   
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1.1 Nanoparticle-based biologic mimetics 
 Through interdisciplinary interactions between solid chemistry, biology and 
material science, bottom-up designs of biological mimics has been made possible. One 
particular example is metal nanoparticles (e.g., iron oxide [1], quantum dots [2] and 
gold [3]) conjugated to biologically relevant molecules (e.g., peptides, proteins and 
carbohydrates) with conformationally favorable orientations. Nanoparticles offer an 
easy way to present active parts of biomolecules as well as a large surface area for 
coupling multiple functional groups [4]. They can become stable and effective 
substitutes for current systems in applications such as drug delivery and biosensing, 
which typically require high spatial-temporal specificity at micron to nanometer 
scales. Even though the use of nanoparticles in biological systems has increased 
dramatically since the first water-soluble, ligand-capped nanoparticle developed 
almost 20 years ago [5]; we still have a long way to go towards true adaptation of 
them into ‘nanorobots’ functioning just like other biological units. While accurate 
mimicking of biologically important machineries under physiological conditions 
remains challenging, successful camouflaging of nanomaterials in order to bypass 
physiological barriers and evade immune surveillance takes a great amount of effort. 
Therefore, devising biologically ‘smart’ biomaterials which are benign and able to 
hold extensive surrogating from biological systems will create a significant impact.  
 
1.2 In vivo distribution of nanoparticles – size, composition and beyond 
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While metal nanoparticles have generated substantial interest and their 
properties have been thoroughly studied, they raise biodistribution and potential 
toxicity concerns because they can be quickly be sequestered by the 
reticuloendothelial system (RES) and can remain in organs, such as the liver and 
spleen, for prolonged periods of time [6]. Design considerations, such as size, shape, 
surface coating and dosing, can be manipulated to prolong blood circulation and 
enhance treatment efficacy; unfortunately nonspecific distribution has not been 
avoidable so far. Renal excretion of nanoparticles is size dependent (rapid excretion 
happens when the hydrodynamic diameter < 5.5 nm and can be prevented when the 
hydrodynamic diameter > 15 nm [7]). Studies on nanoparticles of 35 nm diameter 
showed 5–10% of retention in the blood stream even after 8 h of injection [8]. 
Nanoparticles greater than 200 nm will typically localize to liver, kidney, lung, spleen 
and to a lesser extent in bone marrow [9]. Most studies have reached a consensus that 
nanoparticles with a proper surface coating (such as pegylation) smaller than 100 nm 
have reduced plasma protein adsorption on their surface, reduced hepatic filtration, 
longer blood residence time and higher rate of extravasation into permeable tissues 
[10]. Surprisingly, the composition of nanomaterials, which strongly influences their 
physical properties, appears not to be the main determining factor for their behavior in 
biological environments [11]. So far, cytotoxicity effects have been more affirmed in 
certain materials such as cadmium-based quantum dots [12], compared with gold and 
iron oxide nanoparticles.  Nevertheless, awareness should be paid to implicit toxicity, 
which largely comes from the interaction of particles with immune cells and their 
effect on the innate and adaptive immune response [13-14]. Even though still poorly 
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Figure 1.1: Diagram of the entire process of leukocyte-endothelium interaction 
under inflammation. Serial events involve: Tethering and rolling – transient binding 
between selectin ligands (or carbohydrate) on leukocyte binds to selectins on 
endothelium, blood flow causes weakly bound leukocytes to roll along endothelial 
surface; Firm adhesion - activation of β2 integrin leads to tighter adhesion; 
Diapedesis - interaction with specific CAMs leads to extravasation. Image adapted 
from Figure 2-44 part 3 of 3 Immunology, 6/e (Garland Science 2005). 
 
 
 1.3 Biomimetics of leukocytes 
Leukocyte-endothelium interaction is the hallmark event of inflammation. It 
involves sequential steps from rolling, firm adhesion to diapedesis (Figure 1.1). Cell 
adhesion molecules (CAMs) such as selectins (E-selectin [15] & P-selectin [16]), the 
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immunoglobulin superfamily (IgSF) (intercellular adhesion molecule (ICAM)-1 [17-
18] & vascular cell adhesion molecule (VCAM)-1 [19]), as well as β2 integrins 
(lymphocyte function-associated antigen (LFA)-1 (αLβ2) [20] & macrophage antigen 
(Mac)-1 (αMβ2) [21]), play crucial roles during this process through sophisticated 
orchestration including a prompt upregulation of expression level [22-23], a drastic 
conformational change [24] as well as a concerted synergistic effect [25-26].  
These observations have led to a strong interest in the development of 
biological mimetics of leukocytes exploiting their strategies in achieving high 
selectivity towards disease tissue. Pioneering attempts include conjugating monoclonal 
antibodies (mAbs) against E-selectin, ICAM-1, VCAM-1, or selectin ligand sialyl-
Lewis
x
 to polymer particles, which demonstrated that they could preferentially deliver 
payloads to trauma-induced endothelium in vitro [27-28]. Using flow chamber assays, 
beneficial interplay between functional molecules was also observed when two 
distinct receptor-ligand pairs were employed [29-30].  
 
1.4 Current applications of leukocyte mimetics in biomedical imaging  
Directly named after them or not, a large number of existing designs of 
nanoparticles adopt a similar molecular mechanism of leukocytes recruited to 
inflamed tissue for biomedical imaging. Successful systems which have been validated 
in vivo include: microbubbles conjugated with antibodies against P-selectin [31], 
ICAM-1 [32] or VCAM-1 [33] for ultrasound imaging; paramagnetic liposomes, 
microparticles of iron oxide or dextran coated ultrasmall particles of iron oxide 




 [36] for magnetic resonance imaging (MRI); 
64
Cu-labeled polymer 
nanoparticles conjugated with antibodies against ICAM-1 [37] for positron emission 
tomography (PET); etc. Their diagnostic applications cover a plethora of inflammatory 
diseases, such as acute transplant rejection [32], autoimmune encephalomyelitis [33-
34], renal tissue injury [31], acute brain inflammation [35] and hepatitis [36]. All of 
these studies helped to unravel important components we can utilize for engineering 
particles mimicking leukocytes in their strategy for specific adherence. Nevertheless, 
potential caveats exist with both antibody and carbohydrate ligands, as they are not 
able to present the physiological dynamics of adhesion molecules in regulating 
leukocyte-endothelium interaction. Therefore extensive tuning on the surface density 
of functional groups is necessary, especially when more than one type of ligand is 
coupled, and it can become a tedious process if chemical conjugation is involved. In 
addition, the incorporation of mAbs generated in rodents will raise issues like 
immunogenicity when applied to humans, even though the materials of the particles 
are actually benign. 
 
1.5 Engineering active LFA-1 integrin – a physiological ligand during leukocyte 
adhesion 
Aforementioned concerns draw us to a different scenario: instead of engaging 
exogenous antibodies to particles, why not use a native ligand of leukocytes, such as 
integrin? First of all, it will eliminate the potential risk of immune response against 
‘foreign’ materials, because such particles directly tag them as ‘self’. What’s more, if 
we can somehow lock this ligand into its active state, it will reconstruct the same 
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allostery inflamed leukocyte utilized for specific adherence, therein becoming truly 
biomimetic.  
As the ligand of ICAM-1, β2 integrin exists as two distinct conformations 
(Figure 1.2), which have been well studied structurally and functionally [38]. The  
 
Figure 1.2: (a) Conformational change of β2 integrin from quiescent to active state. 
(b) Conversion of I domain from low-affinity conformation to high-affinity 
conformation that is ready for interaction with ICAM-1. Image adapted from Figure 
1A in [38] and Figure 12B in [24]. 
 
 
inserted domain (I domain), present in the α subunit of β2 integrin, contains the ligand-
binding site: metal ion-dependent adhesion site (MIDAS). Upon inflammatory signals, 
allosteric activation of β2 integrin (Figure 1.2a) results in a switch of the I domain 
from a closed conformation having low affinity with ICAM-1, to an open 
conformation having high affinity (Figure 1.2b). In our recent studies, one allosteric 
mutant of αLβ2 I domain adopting the active conformation with a 200,000-fold 
increase in affinity was engineered through directed evolution using a yeast display 
8 
system [39]. Clone F265S/F292G contains two mutations (Phe-265 and Phe-292) both 
residing in a hot spot termed the ‘switch-allostery region’ previously speculated by 
expert inspection [40-41]. The switch-allostery region is tightly coupled to the active 
site MIDAS, and the twisting/shearing motion of their extensive interface plays 
critical roles in balancing open and closed conformations. Our data showed that this 
activating mutant has even 20-fold higher binding affinity than another high affinity 
mutant of αMβ2 I domain discovered earlier [42], likely due to a lower free energy of 
its I-domain-ICAM-1 complex. 
 
1.6 Engineering iron oxide nanomicelles for facile coating of proteins – a platform 
for creating biomimetic nanoparticles in biomedical applications 
 Magnetite (Fe3O4) is a common magnetic iron oxide that offers attractive 
possibilities to biomedicine when it exists as nanocrystals [43]. Ever after the 
establishment of methodology 10 years ago [44], synthesis of magnetite nanoparticles 
in a size-controlled manner has been a routine practice in laboratories. Their 
dimensions are comparable to most biological molecules of interest, like a protein (5-
50 nm) or a gene (10-100 nm long), thereby providing a small enough entity for 
biological modification. Since they are magnetic, they can be easily manipulated by an 
external magnetic field gradient, enabling actions like separation [45] and transport to 
desired locations [46]. They can also be used as hyperthermia agents because magnetic 
particles will heat up when a time-varying magnetic field is applied and energy is 
transferred from the exciting field [47]. Most importantly, sufficiently small magnetite 
nanoparticles are superparamagnetic. In the presence of external magnetic field, they 
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can effectively increase local magnetic inhomogeneity and alter environmental 
magnetic relaxation, making them an exceedingly good contrast agent for MRI [48].   
 In order to use iron oxide nanocrystals as a biolabel, their colloidal stability 
needs to be maintained under aqueous biological conditions. Studies on fluorescent 
semiconductor nanocrystals (quantum dots) showed that encapsulating them into 
phospholipid micelles mixed with a certain ratio of polyethylene glycol (PEG) 
polymer is able to generate water soluble nanoparticles, yet minimize nonspecific 
absorption and aggregation in vivo [49]. PEG-grafted lipids are poorly immunogenic 
and largely comparable to naturally occurring carriers such as lipoproteins, therefore 
have been used for drug delivery [50] and diagnostic imaging [51]. Due to high 
similarity between the surface topology of magnetite nanocrystals and quantum dots, 
we believe micelle encapsulation can benefit the biological stability of iron oxide 
nanoparticles in the same fashion.  For ease of surface modification, it would also be 
 
Figure 1.3: Scheme of our conception of iron oxide nanomicelles for facile coating 
of proteins, which can later evolve into biomimetics for MRI-guided applications in 




sensible to incorporate additional lipid components with functional head groups, so 
that potential perplexity involved in the chemical conjugation process of biological 
molecules (e.g. loss of function, aggregation) could be alleviated. In such a scenario, 
we introduced dioleoyl-glycero-succinyl-nitrilotriacetic acid (DOGS-NTA) (Figure 
1.3). NTA nickel salt [52] has been widely used for the purification of proteins with 
His tag through high affinity (KD ~ 10
-13 
M) chelation. The presence of DOGS-NTA 
allows robust coupling of biological moieties to nanomicelles via non-covalent bonds, 
yet only requiring procedures as simple as mixing.  
 
1.7 Iron-sensing assays 
As a potential biosensor, magnetite nanomicelles are advantageous because the 
presence of their iron component can be detected by several methods including 
colorimetric assays, MRI and spectroscopy. We will briefly introduce them as follows:  
1.7.1 Perls’ Prussian blue 
The original formula of Perls’ Prussian blue staining technique was developed 
by German pathologist Max Perls (1843-1881). It is a chemical reaction between ferric 
iron and potassium ferrocyanide, which produces a highly water-insoluble and visible 
end product of ferric ferrocyanide (also known as Prussian blue). Ferrous iron does not 
produce a colored reaction product, thus is excluded from the visualization: 
 FeCl3 + K4Fe(CN)6 = KFeFe(CN)6 + 3KCl  
This assay utilizes hydrochloric acid to split off ferric irons from its biological 
complex with proteins, therefore it has been particularly useful in histological studies 
on conditions accompanied by varying degrees of iron excess [53] or hemosiderosis of 
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the bone marrow [54]. By the same token, it also becomes a routine method for 
demonstrating cellular or tissue retention of magnetite nanoparticles [55]. 
1.7.2 Ferrozine assay 
Ferrozine is acknowledged as an effective chelator of ferrous iron and has been 
used for determination of iron in biological samples [56-57]. Ferrozine binds ferrous 
iron, but not ferric iron, into a water soluble complex that absorbs strongly at 550 nm. 
Because of this, ferrozine can also be used for colorimetric quantification of iron, 
unlike Perls’ Prussian blue. An optimized ferrozine assay has been developed for total 
iron determination in cell samples, which involves releasement of iron content from 
biological entities using hydrochloric acid and KMnO4 as well as reduction of ferric 
iron into ferrous iron using ascorbic acid, prior to the application of ferrozine [58]. As 
a fast, cheap and reliable test, it is widely applied in recent studies of iron oxide 
nanoparticles administered into biological systems [59].   
1.7.3 Atomic absorption spectroscopy 
Atomic absorption spectroscopy (AAS) is a spectroanalytical procedure for the 
quantitative determination of chemical elements employing the absorption of optical 
radiation (light) by free atoms in the gaseous state [60]. This technique is commonly 
used in analytical chemistry for determining the concentration of a particular element 
in the sample to be analyzed. AAS can determine over 70 different elements in 
solution or directly in solid samples with high sensitivity (>0.1 ppm). It has been used 
for quantifying iron oxide nanoparticles at an analytical level [61]. However, access to 
AAS is usually expensive, and therefore less available for some laboratories.  
1.7.4 Quantitative susceptibility mapping (QSM) 
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In addition to intrinsic iron content, magnetite nanoparticles can also be 
characterized by their magnetic propertities, such as susceptibility, which modify the 
local magnetic field experienced by spins. It has been of long-standing interest to 
quantify the susceptibility of superparamagnetic nanomaterials in clinical MRI. 
Quantitative susceptibility mapping (QSM) is a technique recently developed for 
estimating magnetic field shifts based on magnetic resonance phase images, allowing 
noninvasive quantification of magnetic materials in vivo [62]. From magnitude images 
of MRI, regions of constant magnetic properties are segmented and the magnetic field 
for each region with unit susceptibility is computed to form the system matrix. Pseudo 
inversion is then used to determine the susceptibility from the measured field maps. 
Besides exogenous magnetite nanoparticles [63], QSM has also been successfully 
applied for the quantitation of pathological brain deposition of iron [64-65].  
 
1.8 Engineering molecules of interest using yeast surface display  
 The quality and controllability of biomimetics are tightly related with the 
design of functional molecules, namely how similar or superior they are compared to 
their physiological counterparts. This process can greatly benefit from protein 
engineering either through rational design or directed evolution. The yeast surface 
display (YSD) technique was first published by Dane Wittrup, where a protein of 
interest is displayed as a fusion to the Aga2p protein on the surface of yeast [66]. As 
such, high affinity protein ligands can be easily enriched through magnetic separation 
and quantified by flow cytometry. In addition to activating mutein of LFA-1 I domain 
[39], we have also discovered an activation-specific antibody against Mac-1 from 
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combinatorial libraries using YSD [67]. In most biological systems, regulation of one 
single response requires the coordination of multiple independent molecular 
interactions. Due to such complexity, it would be sensible to engineer more molecules 
specific to the allostery of interest, and equip biomimetics with more than one distinct 
receptor-ligand pair, so as to achieve higher specificity and efficacy of treatment. 
 
1.9 Organization of the dissertation 
The objective of the studies documented here is to establish a nanoparticle 
platform mimicking inflamed leukocytes using an engineered physiological ligand as 
the targeting moiety, translate it into clinical imaging modalities and provide 
quantitative diagnostic information about inflammatory diseases at the molecular 
level. An overview of the chapters and appendix are given below. 
Chapter 1: Introduction. This chapter provides the background on current 
studies of nanoparticle-based biomimetics (particularly biomimetics of leukocytes), 
their applications in biomedical imaging, and present knowledge that informs our 
work (especially our preliminary studies on protein engineering, nanoparticle design 
and analysis tools for biodistribution), as well as an introduction to the overall content 
of this dissertation. 
Chapter 2: Inflamed leukocyte-mimetic nanoparticles for molecular imaging of 
inflammation. In this chapter, we will first talk about the design of the inflamed 
leukocyte-mimetic nanoparticles (LMN). In order to incorporate inflammation-
sensitive molecular interactions, super paramagnetic iron oxide (SPIO) nanocrystals 
are conjugated with integrin lymphocyte function-associated antigen (LFA)-1 I 
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domain, engineered to mimic activated leukocytes in physiology. Then we will 
characterize its physical properties (size, stability, functionality and specificity) 
through a series of in vitro assays, confirming its preferential binding to unregulated 
levels of ICAM-1. Aided with whole-body fluorescence imaging and MRI, we will 
demonstrate LMN detecting inflammatory response in a spatial-temporal manner in 
vivo, using three different models of inflammatory diseases (tumor xenograft, 
subcutaneous acute inflammation, and systemic acute inflammation). 
Chapter 3: Visualizing and quantifying acute inflammation using ICAM-1 
specific nanoparticles and MRI quantitative susceptibility mapping. In this chapter, we 
will explore the translation of LMN into molecular diagnosis of systemic 
inflammatory response syndrome (SIRS) using mouse models. Specifically, we will 
verify the validity and accuracy of LMN-aided MRI with prudent examination, 
including extensive comparison of the quantitation of organ-specific distributions of 
nanoparticles through quantitative susceptibility mapping (QSM) and radioactivity 
measurement.  
 Chapter 4: Novel strategy for selection of monoclonal antibodies against 
highly conserved antigens: phage library panning against ephrin-B2 displayed on 
yeast. In this chapter, we will discuss how we can combine yeast surface display and 
phage display, so as to successfully select monoclonal antibodies against ephrin-B2, 
one highly conserved human antigen that plays important roles during tumor 
angiogenesis.  
Chapter 5: Conclusions and future directions. This chapter provides a summary 
for this thesis project. It also includes data and ideas supporting future work, such as 
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how we can improve LMN as a biomimetic; how we can extend it to diagnosing other 
inflammatory diseases such as strokes; how we can make LMN more versatile so that 
eventually it is able to target cancer where more implications besides inflammation 
exist. 
Appendix A: Yeast surface two-hybrid for quantitative in vivo detection of 
protein-protein interactions via the secretory pathway. This part describes one co-
author project in which we developed a yeast surface two-hybrid (YS2H) system 
based on the original YSD platform, enabling quantitative measurement of pairwise 
protein interactions via the secretory pathway by expressing one protein (bait) 
anchored to the cell wall and the other (prey) in soluble form. 
Appendix B: Cell surface assembly of HIV gp41 six helix bundles for facile, 
quantitative measurements of hetero-oligomeric interactions. This part describes one 
co-author project in which we reconstituted the six helix bundle (6HB) complex of 
HIV gp41 on the yeast surface, quantitatively measured the equilibrium and kinetic 
constants of soluble 6HB, and delineated the residues influencing homo-oligomeric 
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INFLAMED LEUKOCYTE-MIMETIC NANOPARTICLES FOR MOLECULAR 






Dysregulated host inflammatory response causes many diseases, including 
cardiovascular and neurodegenerative diseases, cancer, and sepsis. Sensitive detection 
of the site of inflammation will, therefore, produce a wide-ranging impact on disease 
diagnosis and treatment. We hypothesized that nanoprobes designed to mimic the 
molecular interactions occurring between inflamed leukocytes and endothelium may 
possess selectivity toward diverse host inflammatory responses. To incorporate 
inflammation-sensitive molecular interactions, super paramagnetic iron oxide 
nanoparticles were conjugated with integrin lymphocyte function-associated antigen 
(LFA)-1 I domain, engineered to mimic activated leukocytes in physiology. Whole 
body optical and magnetic resonance imaging in vivo revealed that leukocyte-mimetic 
nanoparticles localized preferentially to the vasculature within and in the invasive 
front of the tumor, as well as to the site of acute inflammation. This study explored in 
vivo detection of tumor-associated vasculature with systemically injected 
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inflammation-specific nanoparticles, presenting a possibility of tumor detection by 
inflamed tumor microenvironment. 
 
2.2 Introduction 
Dysregulated inflammatory responses of the host are implicated in the 
pathogenesis of many human diseases [1]. Acute inflammation from infection can 
cause sepsis [2], while chronic inflammation, and continual coexistence between acute 
and chronic inflammation are associated with various neurodegenerative [3] and 
cardiovascular diseases [4], metabolic disorders [5], and cancer [6, 7]. Accordingly, 
sensitive and early detection of inflammation and site-specific delivery of anti-
inflammatory agents will have a wide-ranging impact on the treatment of various 
inflammation-related diseases. Upon induction of inflammation, a set of adhesion 
molecules are upregulated in endothelium, with which immune cells interact using 
counter adhesion molecules such as integrins to adhere to endothelium and to initiate 
diapedesis. Many existing studies have investigated targeted nanoparticles for the 
detection and treatment of inflammation employing antibodies or peptides specific to 
adhesion molecules such as intercellular adhesion molecule (ICAM)-1 [8-10], vascular 
cell adhesion molecule (VCAM)-1 [11-13], selectins [14], and collagen [15], all of 
which display distinct spatiotemporal responses to inflammation. Among these 
molecules, ICAM-1 has caught a particular interest because of its highly inducible and 
localized expression upon inflammatory signals, serving as a marker for inflammation 
despite its constitutive low level expression [16, 17]. 
26 
In this study, we developed nanomicelle encapsulating superparamagnetic iron 
oxide (SPIO) nanoparticles, designed for facile and robust conjugation with targeting 
moieties and in vivo detection by optical imaging and magnetic resonance imaging 
(MRI). In order to design nanoparticles to mimic the behavior of inflamed leukocytes 
in their ability to locate to the inflamed site, SPIO nanoparticle was coated with an 
optimum number of high affinity inserted (I) domain of integrin called lymphocyte 
function-associated antigen (LFA)-1 [18], a physiological receptor for ICAM-1. 
Leukocyte-mimetic nanoparticles were examined for detection of ICAM-1 
overexpression in tumor cells, tumor vascular microenvironment, and acute 
inflammation in vivo. With our recently developed MRI technique for quantitative 
mapping of contrast agent [19, 20], we explored the possibility of quantitative 
spatiotemporal mapping of iron oxide distribution in vivo using a mouse model of 
acute inflammation. 
 
2.3 Materials and methods 
2.3.1 Preparation and characterization of protein coated SPIO nanomicelles 
Oleic acid-capped super paramagnetic iron oxide (SPIO) nanocrystals (Ocean 
Nanotech, LLC) in 5 mg were suspended in 1 ml chloroform with 12 mg 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)- 
2000] (DPPE-PEG) and 3 mg 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-
carboxypentyl)-iminodiacetic acid)succinyl] nickel salt (DOGS-NTA) (Avanti Polar 
Lipids, Inc.). For radiolabeled nanoparticles, 60 μCi of L-α-Dipalmitoyl-
Phosphatidylcholine, [Choline-Methyl-
3
H] (Perkin Elmer) was also added at this step. 
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After 10 min sonication and overnight desiccation, 1 ml of water was added to the 
residue to form a micelle layer on SPIO. After another 10 min sonication and filtration 
through 0.22 μm filters (Millipore), optically clear suspension containing SPIO 
micelles were obtained. Empty micelles without SPIO in the core were removed by 
ultracentrifugation. SPIO nanoparticles were purified and resuspended in pH 7.4 
phosphate-buffered saline (PBS) by size exclusion S200 column (GE Healthcare). The 
wild-type (wt), D137A, and F265S/F292G mutants of LFA-1 I domains fused to His 
tag (6 histidine residues) at the N-terminal were produced as previously described 
[17]. Conjugation of SPIO with His tagged I domains was obtained by incubation at 
4°C overnight. Free proteins were removed by size exclusion. All fluorescently 
labeled SPIO nanoparticles were prepared by covalently conjugating Alexa Fluor (AF) 
succinimidyl esters (Invitrogen) to the I domains. Conjugation of fluorescence dyes to 
the proteins rather than to phospholipid was chosen due to significant fluorescence 
quenching between iron oxide and AF-phospholipids. The coating density of proteins 
on SPIO was determined from the ratio of SPIO amount (OD600nm 1 = 0.42 mg/ml) 
and the concentration of the proteins bound to SPIO (by Lowry’s method). Specific 
activities of radiolabeled SPIO were measured by scintillation counter (Beckman 
Coulter LS6500). Dynamic light scattering (DLS, Malvern Instruments) was used to 
measure the average hydrodynamic size of SPIO after assembly and protein 
conjugation. Transmission electron microscopy (TEM; FEI Tecnai) images of SPIO 
were also taken before and after protein conjugation. 1% uranyl acetate was used for 
protein staining. 
2.3.2 Cell culture 
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All mammalian cells used in this study were cultured in Advanced Dulbecco’s 
modified Eagle’s medium containing 10% (v/v) fetal bovine serum and 2 mM L-
glutamine (Invitrogen) at 37°C in a 5% CO2 humidified incubator. For induction of 
inflammation, bEnd.3 (ATCC) cells were treated with 1 μg/ml of LPS (Escherichia 
coli 026:B6, Sigma) for 12 h. HeLa and 293T cells stably expressing GFP were 
established using pSMPUW-miR-GFP/Puro Lentiviral Expression Vector system 
(Cell Biolabs). 
2.3.3 Immunofluorescence flow cytometry 
Cells were trypsinized and washed once with the ice-chilled labeling buffer 
(pH 7.4 PBS, 1% (w/v) BSA, 1 mM MgCl2). 100,000 cells were incubated in 100 μl of 
the labeling buffer for 30 min on ice with 10 μg/ml of Alexa Fluor labeled proteins or 
SPIO conjugated with the same amount of proteins. For competition assay, 50 μg/ml 
of unlabeled proteins were included in the labeling buffer during incubation. Cells 
were washed twice and resuspended in 300 μl of the labeling buffer and subjected to 
flow cytometer (Beckman Coulter EPICS XL-MC). 
2.3.4 Microscopy visualization of cell labeling in vitro 
For immunofluorescence microscopy detection of protein labeling, cells were 
plated, washed in pH 7.4 PBS, and fixed with 4% paraformaldehyde for 15 min. After 
washing three times, cells were incubated with 10 μg/ml of Alexa Fluor labeled 
proteins in PBS/Triton (pH 7.4 PBS, 0.3% (v/v) Triton X-100, 1 mM MgCl2) at room 
temperature for 1 h. Cells were rinsed once with pH 7.4 PBS and twice with high salt 
PBS (pH 7.4 PBS, 0.4 M NaCl, 1 mM MgCl2). 300 nM DAPI (4’,6-diamidino-2-
phenylindole, Invitrogen) in PBS was then added and incubated for 10 min for nucleus 
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staining. Stained cells were washed and imaged with a confocal microscope (Zeiss 
LSM710). For detection of SPIO labeling, HeLa cells were plated and incubated with 
50 μg/ml of SPIO coated with Alexa Fluor 488 conjugated proteins in culture media 
for 2 h at 37°C. Cells were washed in pH 7.4 PBS, incubated for 1 h in serum-free 
medium for chasing, and imaged using confocal microscopy (Leica TCS SP2). After 
fluorescence imaging, cells were then prepared for Perls’ Prussian blue staining for 
iron detection. Labeled cells were fixed with 4% paraformaldehyde, followed by 
incubation in a freshly prepared solution of 2% potassium ferrocyanide in 2% HCl for 
20 min and counterstaining with 1% neutral red. 
2.3.5 Magnetic cell labeling and quantification 
Trypsinized cells were incubated for 4 h at 37°C in the labeling buffer (PBS, 
1mM MgCl2) under constant rotating with different concentrations of radiolabeled 
SPIO, washed and then fixed in 4% paraformaldehyde. Cells were divided into two 
conditions, half of which were used for radioactivity measurement using scintillation 
counter (Beckman Coulter LS6500), while the remaining half for MRI scanning and 
QSM measurement after imbedding in 100 μl 2% agarose block. MR imaging of the 
magnetically labeled cells were performed on a 3T MRI scanner (Signa, GE, 
Milwaukee, WI). A 3D multi-echo gradient sequence was used to sample multiple TEs 
in one TR. Imaging parameters were as follows: TEs 3.696 ms, 4.196 ms, 5.696 ms, 
11.696 ms, 35.696 ms; TR 40 ms; flip angle 30°; matrix size 256×64×64; voxel size 
500 μm3 isotropic. A 3D Fourier transform was applied to the raw k-space data to 
reconstruct T2* weighted images. QSM was obtained through Multiple Orientation 
Sampling (COSMOS) technique, as previously described [19]. 
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2.3.6 Subcutaneous tumor model 
3×10
6
 human cervical cancer HeLa cells and human embryonic kidney 293T 
cells stably expressing GFP mixed in Matrigel (BD) were injected bilaterally into the 
front lower flank areas of 8-wk-old female nude mice. Mice were used for 
experiments 16-20 days after injection when tumor size reached about 300 mm
3
. All 
animal experiments were conducted in compliance with the regulations defined by the 
Institutional Laboratory Animal Use and Care Committee of Cornell University. 
2.3.7 Acute LPS-inflammation model 
For subcutaneous LPS, 1 mg/ml LPS in 100 μl PBS and 100 ml PBS were 
injected bilaterally into the lower flank areas of 8-wk-old female BALB/c mice. For 
systemic LPS, 1 mg/ml LPS in 100 μl PBS were injected into 8-wk-old female 
BALB/c mice. Prior to imaging hair was removed to reduce background fluorescence. 
2.3.8 Near-IR optical imaging of mice 
Animals were anesthetized with isoflurane mixed with oxygen at 5% and 
maintained at 2% isoflurane during whole body imaging (Olympus, OV100). Mice 
were administered with SPIO coated with AF750-conjugated proteins in 150 μl PBS 
via retro-orbital injection. 500 and 100 μg of SPIO were used for tumor imaging and 
acute inflammation models, respectively. Near-IR images were taken at different time 
points post-injection of SPIO. Tumor growth was detected by imaging green 
fluorescence. Image analysis was performed with Matlab R2007a (MathWorks). 
2.3.9 MR imaging of mice with acute inflammation 
For subcutaneous LPS model, prior to nanoparticle injection mice were 
exposed to LPS/PBS for 12 h. At 4 h after injection of SPIO in 150 μl PBS, mice were 
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euthanized by intraperitoneal injection of 2.5% tribromoethanol (20 μl/g), 
transcardially perfused with PBS, and fixed in paraformaldehyde. Prepared mice were 
scanned on a 7T scanner (Bruker BioSpin, Biospec 70/30 USR) with 3D FLASH 
sequence. Imaging parameters were as follows: TEs (echo time) 5 ms, 6 ms, 30 ms, 35 
ms; TR (repetition time) 35 ms; excitation pulse angle 15°; matrix size 150×150×100; 
voxel size 200 μm3 isotropic; NEX 1. A 3D Fourier transform was applied to the raw 
k-space data to reconstruct the images [19]. For systemic LPS model, prior to 
nanoparticle injection mice were exposed to LPS for 12 h. At 1, 8, and 25 h post-
injection of SPIO coated with proteins in 150 μl PBS, mice were euthanized likewise. 
Prepared mice were scanned on a 3T scanner (GE Signa Excite) with 3D multi-echo 
EFGRE sequence [19]. Imaging parameters were as follows: TEs 3.696 ms, 4.196 ms, 
5.696 ms, 11.696 ms, 35.696 ms; TR 40 ms; flip angle 30°; matrix size 256×64×64; 
voxel size 500 μm3 isotropic. QSMs were reconstructed using the COSMOS 
technique, as previously described. 
2.3.10 Histology 
Tumor and normal tissues were collected from tumor bearing mice before or at 
the end of in vivo imaging experiments. 10 μm frozen tissue sections were sliced, 
fixed in paraformaldehyde, and stained with hematoxylin and eosin (H&E) or in Perls’ 
Prussian blue. Images of the tissue sections were acquired by scanscope (Aperio). For 
immunofluorescence, antibodies used include rat anti-mouse CD31 (BD, MEC13.3) 
and goat anti-rat IgG labeled with AF350 (Invitrogen). Six different fields of view 
containing CD31 staining for each sample were counted using 25 Chalkley’s random 
point method over an area of 0.16 mm
2
 for vascularity analysis (Figure 2.10b). To 
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quantify the level of staining, three different regions of interest (ROI) with 0.50 mm
2
 
area were sampled for each condition in immunofluorescence staining (Figure 2.10a) 
and four ROI with 0.04 mm
2
 area in each Prussian blue staining (Figure 2.14). 
Specific colors (blue for endothelium and Prussian blue, red for F265S/F292G) were 
extracted and intensities were measured using Image-Pro Plus 6.0 (Media Cybernetics) 
and ImageJ 1.41 (NIH). 
2.3.11 Statistical analysis 
Data were expressed as mean±standard deviation of no smaller than triplicates, 
and analyzed for statistical significance using GraphPad Prism 5 (Graphpad Software). 
Linear regression was used to examine the correlation between SPIO measurements by 
radioactivity and QSM (Figure 2.7). One-way ANOVA was used to compare the 
staining and vascularity levels between different tissues, followed by Tukey’s post-hoc 
test to determine statistical significance (Figure 2.10). Two-way ANOVA was used to 
compare the mean responses of different nanoparticles to different time points or to 
different tumors, followed by Bonferroni post-hoc test to determine statistical 
significance (Figure 2.13, 2.14, 2.16, 2.17 & 2.18). 
 
2.4 Results 
2.4.1 Synthesis and characterization of leukocyte-mimetic nanoparticles 
Selective binding of SPIO nanoparticles to overexpressed ICAM-1 was 
conferred by surface coating at an optimal density (~100 molecular/particle) with the I 
domain of LFA-1 integrin, engineered for high affinity by mutations of F265S/F292G 
(denoted as F265S/F292G, KD = 6 nM) [18]. Among physiological ligands for LFA-1 
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such as ICAMs and junctional adhesion molecule (JAM)-1 [21], ICAM-1 is most 
important in the setting of leukocyte adhesion to inflamed endothelium due to its 
highest affinity to LFA-1 [22], being highly inducible over basal low level expression, 
and localized expression upon inflammatory signals [16, 23]. In order to fine-tune 
coating density of F265S/F292G and present targeting moiety in a most functional 
orientation, oleic acid capped SPIO nanocrystals (Ocean Nanotech) were encapsulated 
with a layer of phospholipid consisting of 80% n-poly(ethylene glycol) 
phosphatidylethanolamine (DPPE-PEG) and 20% dioleoyl-glycero-succinyl-
nitrilotriacetic acid (DOGS-NTA) (Figure 2.1). DOGS-NTA was used for non-
covalent conjugation of targeting moieties with His tag in a robust and reproducible 
manner via high affinity binding to nickel ions chelated by NTA (Ni-NTA) [17, 24]. 
DPPE-PEG was included to maintain solubility, stability, and for its low 
immunogenicity and non-specific binding to cells and tissues in vivo [25]. 
Transmission electron microscope (TEM) images revealed monodispersed SPIO 
nanocyrstals with an outer layer of micelle-like structure (Figure 2.2; dark ring density 
corresponds to uniformly distributed nickel ions (the black arrow in top right) and 
diffuse dark density to His-tagged proteins attached to Ni-NTA (the white arrow in 
bottom right)). Hydrodynamic size of SPIO with or without protein conjugation was 
measured to be 60±10 nm by dynamic light scattering (DLS), an increase from 15 nm 
diameter SPIO core mainly due to the addition of phospholipid and PEG. 
Prior to detecting ICAM-1 with nanoparticles, we first examined by 
immunofluorescence flow cytometry and fluorescence microscopy (Figure 2.3) 

























































































































































Figure 2.2: Uniformly sized, monodispersed SPIO with 15 nm core revealed by 
TEM. A close up view on top demonstrates a dark halo corresponding to nickel ions 
(black arrow) chelated by NTA groups surrounding SPIO. On the bottom is the 
negative staining of protein-conjugated SPIO with proteins and PEG groups darkly 
stained (white arrow), in contrast to a brighter phospholipid layer.   
 
 
ICAM-1 expressed in monolayer culture of cervical cancer cells (HeLa). Specific 
binding to ICAM-1 was detected with the F265S/F292G, which was inhibited by 
unlabeled F265S/F292G. In contrast, no significant binding was observed with the wt 
I domain (KD = 1.7 mM) [22] and the I domain containing a mutation of D137A [17], 
which disrupts the metal-ion dependent adhesion site (MIDAS) and abolishes ICAM-1  
binding. The level of nanoparticle binding coated with the I domain variants was 
overall in good agreement with the soluble I domain binding, which varied in order 
from highest to lowest, F265S/F292G, wt, and D137A (Figure 2.4a). Markedly,  
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Figure 2.3: (a) Flow cytometry measurements of HeLa cells stained with different I 
domains (10 μg/ml) labeled with AF488. Non-stained HeLa cells are shown in grey 
shaded histograms. In a competition assay, non-labeled I domains were used at 50 
μg/ml. (b) Shown in green is immunofluorescence staining of ICAM-1 in HeLa cells 
using F265S/F292G labeled with AF488. Nuclei staining by DAPI is shown in blue. 
 
   
specific binding of SPIO conjugated with F265S/F292G (abbreviated as Leukocyte-
Mimetic Nanoparticle or ‘LMN’) was not inhibited by competition with soluble I 
domain, presumably due to multivalent interaction between nanoparticles and HeLa 
cells. Enhanced binding due to avidity effect was also observed in the binding of 
nanoparticle coated with the wt I domain to HeLa, which resulted in greater binding 
than with the free wt I domain. ICAM-1-mediated binding of LMN but not with the 
nanoparticles coated with D137A (abbreviated as Non-Targeted Nanoparticle or 
‘NTN’) led to significant cell surface labeling and internalization into the cells, 










Figure 2.4: (a) Flow cytometry measurements of HeLa cells stained with nanoparticles 
(25 μg/ml of SPIO and 10 μg/ml of I domains) conjugated with different I domains. 
Non-labeled I domains as a competitor were used at 50 μg/ml. (b) ICAM-1 dependent 
internalization of SPIO into HeLa cells was confirmed with confocal fluorescence 
microscopy (nanoparticles labeled with AF488) and Perls’ Prussian blue staining. 
 
 
2.4.2 Quantitative measurement of selective binding of LMN by MRI 
SPIO nanoparticles are being used in clinics as T2* negative contrast agent for 
MRI. In order to validate SPIO as MRI contrast agent as well as to test the accuracy of 
our MRI technique for quantitative mapping of SPIO [19], 
3
H-labeled phospholipid 
was additionally incorporated into the outer phospholipid layer of SPIO. When HeLa 
cells were incubated with LMN for 4 h at 37°C, an increase in concentration led to an 
increase in cellular uptake of nanoparticles, reaching a plateau at 450 ng/10
6
 cells 
(Figure 2.5). LMN delivery was specific to ICAM-1 expression, evidenced by little 
accumulation into HeLa with NTN and much lower delivery with LMN into 293T, a 
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cell line with no or little expression of ICAM-1. HeLa cells with known amount of 
internalized LMN by 
3
H-radioisotope decay were then embedded into agarose and 
scanned with a MRI scanner. As expected, T2* showed a decrease in magnitudes with 
an increase in the amount of SPIO (Figure 2.6). With quantitative susceptibility 
mapping (QSM) algorithm was observed a close agreement with ~30% standard 
deviation from direct radioactivity measurements of free or intracellular SPIO, 
highlighting the ability of QSM in detecting as low as 1 μg accumulation into 100 μl 









Figure 2.5: The amount of SPIO internalized into HeLa or 293T was measured by 
radioisotope measurement of 
3
H-phospholipid incorporated into SPIO nanoparticles. 
SPIO nanoparticles were coated with either F265S/F292G (LMN) for ICAM-1 





Figure 2.6: T2* and susceptibility images of agarose-embedded HeLa cells that were 




Figure 2.7: A comparison of iron mass estimated by QSM technique and 
radioisotope measurement. Shown are the measurements of agarose-embedded free 
LMN (closed circles) and LMN internalized into HeLa cells (closed circles). 
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2.4.3 Ex vivo detection of ICAM-1 induction in human tumor xenograft and in 
inflamed stroma 
Not only is ICAM-1 upregulated in several carcinomas compared to respective 
normal epithelium, implicating active involvement of ICAM-1 in cancer development, 
its induction has also been observed in tumor vasculature caused by an inflamed 
network encompassing tumor and tumor microenvironment [26-28]. Previously, we 
have found that human LFA-1 I domain cross-reacted with murine ICAM-1 [17], 
which was recapitulated by the staining of ICAM-1 induced in murine brain 
endothelium (b.End3) after lipopolysaccharide (LPS) treatment (Figure 2.8). When  
 
Figure 2.8: Confocal fluorescence images of murine b.End3 cells before and after 
LPS treatment and HeLa cells stained with murine (top) and human (bottom) I 





tissue sections of GFP-expressing HeLa xenograft were analyzed for ICAM-1 
detection by soluble F265S/F292G labeled with AF594 (Invitrogen), most of the GFP 
signal was overlapped with red fluorescence (Figure 2.9). Notably, we found that the  
 
Figure 2.9: Immunofluorescence images of GFP-expressing HeLa xenograft tumor 
tissue costained with F265S/F292G-AF594 and anti-murine CD31 antibodies. Skin 




majority of endothelial cells (PECAM-1 (CD31) positive) within the tumor were also 
stained by F265S/F292G. In contrast, the level of ICAM-1 induction and 
colocalization with CD31 staining in the vasculature away from the tumor, such as 
those in the skin, was far lower, amounting to ~15% compared to 70% and 35% of the 
vasculature within the tumor and its periphery (defined as a region within 300 μm 
distance from the edge of tumor), respectively (Figure 2.9 & 2.10). 
 
Figure 2.10: (a) The percentages of endothelium costained with CD31 and 
F265S/F292G within the tumor, in the periphery (300 μm from the tumor), and in 
the skin were determined from immunohistology (n = 6). (b) Vascularity within the 
tumor, in the periphery (300 μm from the tumor), and in the skin was quantified 




 2.4.4 In vivo detection of ICAM-1 induction in human tumor xenograft and in 
inflamed stroma 
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After confirming specific detection of ICAM-1 in ex vivo tumor slice by free 
F265S/F292G, we then examined if systemically delivered nanoparticles would 
accumulate to the tumor and inflamed stroma by ICAM-1 targeting. To validate that 
nanoparticle localization is ICAM-1 specific and not due to an increased permeability 
of the tumor vasculature, NTN and ICAM-1 negative 293T cell xenograft were used 
as controls. The growth of HeLa and 293T xenograft in mice was confirmed by whole 
body imaging of GFP (Figure 2.11a). At 50 h after intravenous injection of  
 
Figure 2.11: In vivo near-IR imaging of mice at 50 h after intravenous injection of 
NTN vs. LMN. GFP indicates the growth of HeLa (‘1’) and 293T (‘2’) tumors.  
 
 
nanoparticles, whole body imaging of near-infrared (near-IR) fluorescence (AF750 
attached to the I domains) indicated accumulation of LMN into HeLa but much less 
into 293T xenograft (Figure 2.11). Subsequent ex vivo imaging of the tumor and the   
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Figure 2.12: Ex vivo near-IR imaging of mice at 50 h after intravenous injection of 
NTN vs. LMN. GFP indicates the growth of HeLa (‘1’) and 293T (‘2’) tumors. The 
distribution of nanoparticles into the major organs (‘3’-‘8’) were also examined. 
 
 
major organs harvested from the mice further confirmed a greater level of delivery 
into HeLa xenograft with LMN (Figure 2.12). The signal from the kidney was by far 
greater than those from other organs both for LMN and NTN, indicating ICAM-1 
independent clearance through the kidney (Figure 2.12). Interestingly, higher 
fluorescence was also detected in the liver with LMN, presumably caused by 
persistent, low-level inflammation in the liver. Whole body imaging of nanoparticles 
localized to HeLa and 293T xenograft over the time course of 30 min to 50 h post-
injection showed that the peak accumulation occurred at 1-3 h post-injection, followed 
by a gradual decrease over 3 days and a complete clearance by 7 days (Figure 2.13). 
The presence of LMN into HeLa was also confirmed by direct staining of iron with  
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Figure 2.13: Near-IR fluorescence intensities of HeLa and 293T tumors at different 




Prussian blue (Figure 2.14). To map the distribution of LMN by fluorescence 
microscopy, SPIO nanoparticles conjugated with AF594-labeled I domains were 
intravenously injected into the mice with HeLa/293T xenograft. When the xenograft 
tissue was examined 4 h after nanoparticle injection, specific accumulation of LMN 
into HeLa tumor was observed, judging from colocalization between GFP expression 
in HeLa and AF594 fluorescence (Figure 2.15). Importantly, consistent with the 
detection of ICAM-1 in the tumor vasculature by direct staining of the tissue (Figure  
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Figure 2.14: (a) Perls’ Prussian blue staining of tumor sections collected at 50 h after 
the injection of LMN vs. NTN. Stained iron is marked with black arrows. (b) 
Percentage of cells stained in Prussian blue (top) and the intensity of Prussian blue 
in the field of view (bottom) within tumor sections (n = 3; ***p < 0.001 between 
LMN vs. NTN in Hela tumor. 
†††




2.9), a high percentage of CD31 positive cells in HeLa as well as in 293T xenografts 
were also targeted by LMN. The localization of ICAM-1 specific nanoparticles within 
the tumor-associated vasculature, therefore, was likely responsible for higher signals 
detected within 293T xenograft at earlier time points (Figure 2.13), despite the fact 
that 293T itself exhibited almost no binding of LMN (Figure 2.14). This finding 
highlights a potential use of LMN for detection of tumor growth by their accumulation 




































































































































































































2.4.5 In vivo detection of temporal dynamics of inflammation by optical imaging 
and MRI 
In order to further confirm that our leukocyte-mimetic nanoparticles sensitively 
detect the induction of ICAM-1 not only due to an inflammatory milieu in the tumor 
but also by acutely induced inflammation, we imaged mice after subcutaneous (Figure 
2.16) or intravenous injection of LPS (Figure 2.17 & 2.18). Temporal mapping of 
nanoparticle distribution demonstrated a greater localization of LMN into the LPS 
injection site over PBS injection site as a control, peaking at 12 h post-injection of 
LPS and gradually decaying over 72 h (Figure 2.16a & 2.16b). Higher accumulation 
into the liver was also observed with LMN, attributed to the inflammatory response 
induced by the leakage of locally injected LPS into circulation. We also observed a 
rapid increase in fluorescence in the bladder, irrespective of targeting moieties, 
attributed to renal clearance of some fraction of proteins dissociated from 
nanoparticles. Interestingly, NTN accumulated more into the LPS site than into the 
PBS site, presumably due to non-specific phagocytosis of nanoparticles by immune 
cells. Selected mice treated with systemic delivery of 100 μg LMN were then 
subjected to MRI after whole body optical imaging to demonstrate that our 
nanoparticles could be used for quantitative detection of inflammation by a clinically 
relevant imaging technique (Figure 2.16c). T2* magnitude images identified the 
presence of LMN in the LPS injection site as darkness, which could be confused with 
other dark regions. QSM revealed the accumulation of ~0.3 μg of iron oxide 
(corresponding to detection of less than 1% of injected dose) into the LPS injection 



















































































































































































































































































































































































































































































In response to systemic inflammation caused by intravenous injection of LPS 
for 12 h prior to nanoparticle (~200 μg) injection, optical mapping of nanoparticle 
distribution demonstrated greater localization of LMN in the liver compared to that of 
NTN in mice (Figure 2.17), peaking at 1 h post-injection of nanoparticles and 
subsequently diminishing at later time points. The level of delivery overall was higher 
with LPS even with NTN, indicating some of nanoparticles accumulated into the liver 
was caused by ICAM-1 independent phagocytosis. After optical imaging, mice were 
transcardially perfused with PBS for MRI, which would have removed nanoparticles 
retained in the blood pool in the liver. Temporal mapping of SPIO distribution using 
MRI QSM measured about 20% of the total dose of LMN was specifically uptaken by 
the liver 1 h post injection due to LPS-induced inflammation (Figure 2.18). QSM 
quantification also demonstrated a similarly greater localization of LMN into the liver 
under acute inflammation at different time points, exhibiting qualitative agreement 
with the temporal mapping using optical imaging (Figure 2.18). Discrepancy between 
optical intensity and QSM was unavoidable as MRI was performed after perfusion of 
the mice as well as due to the different kinetics of degradation for fluorescence dye 
(AF750) and SPIO.  
 
2.5 Discussion 
Sensitive detection of inflammation will be of high significance for diagnosis 
of diseases caused directly by host inflammatory response such as sepsis, allograft 



























































































































































































































































































































































































































































cardiovascular disease and cancer. In this study, we designed MRI-compatible SPIO 
nanoparticles, and demonstrated a successful detection of constitutive expression of 
ICAM-1 in tumor, as well as ICAM-1 induction in tumor-associated vasculature, 
where tumor growth and angiogenesis are active. Prior approaches to inflammation 
detection have been largely based on antibodies that are against cell adhesion 
molecules such as ICAM-1 and VCAM-1 [8-13, 29], lacking in the ability to fine tune 
affinity and avidity of targeting moieties on nanoparticles that are critical to 
inflammation-specific targeting. From our previous in vitro studies [17, 24], we have 
demonstrated specific localization into inflamed but not to resting endothelium and 
immune cells of nanoparticle (50-100 nm in diameter) coated with integrin LFA-1 I 
domain engineered for high affinity to ICAM-1. Furthermore, combining recently 
developed quantitative susceptibility mapping technique, we quantified sub-
microgram quantity of iron oxide accumulated in both ICAM-1-expressing cell 
phantom in vitro and acute inflammation induced by LPS in vivo, corresponding to 
less than 1% of injected dose.  
Despite the fact that ICAM-1 is basally expressed in all endothelium [16, 23] 
and therefore the notion that ICAM-1 may not be a suitable target for inflammation, 
our studies emphasize selective delivery by targeting molecules that are induced 
greatly under inflammation [30, 31]. Nanoparticles of ~100 nm will experience 
hydrodynamic force generated by the blood flow [32, 33], such that there should be 
sufficient simultaneous molecular interactions with the cells for nanoparticles to 
remain on cell surface. The number of minimum molecular interactions required for 
stable adhesion of nanoparticles will also depend on the adhesion strength of each 
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interaction. Therefore, specificity toward high ICAM-1 site will be influenced by the 
affinity of molecular interaction and the valency between nanoparticles and target 
cells, where the design of nanoparticles to permit tunable affinity and avidity of 
physiological interaction is of significant advantage. Our nanoparticles to a great 
extent mimic the behavior of activated leukocytes, which would adhere much better to 
inflamed endothelium.  
Increasing number of studies have begun to focus on the crosstalk between the 
immune activation of vascular niche, angiogenesis, and tumor progression [34, 35]. 
Upregulated levels of ICAM-1 in tumor have been linked to two different contexts, 
one serving as a marker for the recruitment of effector immune cells and tumor killing 
[36], while it was also observed in malignant and metastatic tumors with poor 
prognosis [37]. Seemingly contradicting roles of ICAM-1 may be due to the 
complexity of inflammation in various phases of tumor development, which can be 
better examined by in vivo imaging tools. Our nanoparticles did indeed show the 
localization into the tumor vasculature, while their localization into the vasculature 
elsewhere was non-detectable. With human tumor xenograft model, we observed that 
the majority of tumor mass was comprised of tumor cells with poor vascularity present 
therein. Higher vascularity was found in the periphery of the tumor, often called the 
invasive tumor front, where ICAM-1 overexpression associated with higher immune 
activity has also been reported in many carcinoma cases [27, 38-41]. Notably, we have 
demonstrated that intravenously injected nanoparticles targeting ICAM-1 specifically 
localized into the vasculature associated with the tumor progression. With further 
improvement of detection sensitivity in addition to more native tumor models 
55 
containing not only tumor cells themselves but also fully-developed vasculatures and 
other stroma cells such as macrophages, our nanoparticles may provide a universal 
tumor imaging strategy not by tumor surface markers limited to specific cancer types 
but by the inflamed microenvironment which is associated with almost all cancer 
development.  
Besides sensitive detection of chronic inflammation implicated in cancer, 
prompt and accurate detection of acute inflammation induced by bacterial or viral 
infection such as sepsis is also of clinical importance. Acute inflammation 
dramatically induces ICAM-1 induction not only in endothelium but also in immune 
cells, such that both cellular components become the targets by I domain-coated 
nanoparticle. Using LPS-induced acute inflammation model, we demonstrated optical 
imaging of the temporal dynamics of inflammation. Specific localization of LMN was 
also confirmed by QSM technique using MRI. The degree of localization of ICAM-1 
targeting nanoparticles into an inflamed site will closely reflect different phases of 
inflammation, from the onset of inflammation to resolution phase. Therefore, 
quantitative prediction of spatiotemporal distribution of nanoparticles may provide 
critical information on diagnosis and the choice of therapy regimen in clinics. 
In summary, our ICAM-1 targeting strategy by mimicking the behavior of 
leukocytes in their ability to localize to the inflamed endothelium was able to detect 
ICAM-1 overexpression in tumor cells, tumor vascular microenvironment, and acute 
inflammation. In the design of ICAM-1 targeting nanoparticles by conjugation with 
LFA-1 I domain, we employed His-tag binding to nickel-NTA, which we previously 
found [17] to be critical in order to fine-tune the coating density of targeting moieties 
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to be specific to ICAM-1 overexpression but not to basally present ICAM-1. The idea 
of optimizing molecular interactions by tuning the avidity between ligands and 
receptors could provide a useful strategy to molecular targeting of some important 
targets that are basally expressed elsewhere. Inflammation-targeting nanoparticles 
with the lipid layer shell can also be used to carry small, hydrophobic drugs, achieving 
simultaneous imaging and targeted drug delivery. 
 
2.6 Conclusion 
This study presents physiology-inspired design of SPIO nanoparticles for in 
vivo detection by optical imaging and MRI, mimicking activated leukocyte in its 
ability to recognize inflamed endothelium. Nanoparticles in vivo will experience 
hydrodynamic force induced by the blood flow, requiring simultaneous molecular 
interactions with sufficient adhesion strength with the cells for nanoparticles to remain 
on cell surface. Therefore, the design of nanoparticles with tunable affinity and avidity 
of physiological interactions would be critical to selectivity and efficiency of 
leukocyte-mimetic nanoparticles in targeting inflammation. Notably, we observed 
specific accumulation of systemically-delivered nanoparticles into the vasculature 
within the tumor and invasive tumor front where the tumor growth and angiogenesis 
were active, while their localization into the vasculature elsewhere was much lower. 
The use of two different nanoparticles differed only by the type of I domains (active 
vs. inactive) as targeting moieties against ICAM-1 enabled us to discriminate 
inflammation-driven accumulation into the tumor microenvironment from passive 
distribution, which may result from the leakiness of the vasculature within the tumor. 
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Inflammation-targeting nanoparticles such as SPIO with the layer of phospholipid are 
also suitable for carrying small molecule drugs, achieving simultaneous imaging and 




[1]   Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140:871-82. 
[2]   Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885-91. 
[3]   Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying 
inflammation in neurodegeneration. Cell. 2010;140:918-34. 
[4]   Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74. 
[5]   Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-7. 
[6]   Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7. 
[7]   Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. 
Nature. 2008;454:436-44. 
[8]   Sipkins DA, Gijbels K, Tropper FD, Bednarski M, Li KC, Steinman L. ICAM-1 
expression in autoimmune encephalitis visualized using magnetic resonance imaging. 
J Neuroimmunol. 2000;104:1-9. 
[9]   Weller GE, Lu E, Csikari MM, Klibanov AL, Fischer D, Wagner WR, et al. 
Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to 
intercellular adhesion molecule-1. Circulation. 2003;108:218-24. 
[10]  Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. PLGA 
nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion 
molecule-1. Bioconjug Chem. 2008;19:145-52. 
[11]   Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder 
R. Detection of vascular adhesion molecule-1 expression using a novel multimodal 
nanoparticle. Circ Res. 2005;96:327-36. 
59 
[12]   Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M. 
Immunoliposomes directed toward VCAM-1 interact specifically with activated 
endothelial cells--a potential tool for specific drug delivery. Pharm Res. 
2005;22:1906-17. 
[13]   Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, Figueiredo JL, et 
al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC 
Cardiovasc Imaging. 2009;2:1213-22. 
[14]   Ehrhardt C, Kneuer C, Bakowsky U. Selectins-an emerging target for drug 
delivery. Adv Drug Deliv Rev. 2004;56:527-49. 
[15]   Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, et al. Spatiotemporal 
controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A. 
2010;107:2213-8. 
[16]   Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 
1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural 
adherence molecule (ICAM-1). J Immunol. 1986;137:245-54. 
[17]   Kang S, Park T, Chen X, Dickens G, Lee B, Lu K, et al. Tunable physiologic 
interactions of adhesion molecules for inflamed cell-selective drug delivery. 
Biomaterials. 2011;32:3487-3498. 
[18]   Jin M, Song G, Carman CV, Kim YS, Astrof NS, Shimaoka M, et al. Directed 
evolution to probe protein allostery and integrin I domains of 200,000-fold higher 
affinity. Proc Natl Acad Sci U S A. 2006;103:5758-63. 
[19]   Liu T, Spincemaille P, de Rochefort L, Kressler B, Wang Y. Calculation of 
susceptibility through multiple orientation sampling (COSMOS): a method for 
conditioning the inverse problem from measured magnetic field map to susceptibility 
source image in MRI. Magn Reson Med. 2009;61:196-204. 
60 
[20]   Wharton S, Schafer A, Bowtell R. Susceptibility mapping in the human brain 
using threshold-based k-space division. Magn Reson Med. 2010;63:1292-304. 
[21]   Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in 
vascular inflammation. Nat Rev Immunol. 2007;7:467-77. 
[22]   Shimaoka M, Lu C, Palframan RT, von Andrian UH, McCormack A, Takagi J, 
et al. Reversibly locking a protein fold in an active conformation with a disulfide 
bond: integrin alphaL I domains with high affinity and antagonist activity in vivo. 
Proc Natl Acad Sci U S A. 2001;98:6009-14. 
[23]   Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) 
is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987;51:813-
9. 
[24]   Park S, Kang S, Veach AJ, Vedvyas Y, Zarnegar R, Kim JY, et al. Self-
assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-
regulated molecular interactions. Biomaterials. 2010;31:7766-75. 
[25]   Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. 
In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 
2002;298:1759-62. 
[26]   Kelly CP, O'Keane JC, Orellana J, Schroy PC, 3rd, Yang S, LaMont JT, et al. 
Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent 
lymphocyte adhesion in vitro. Am J Physiol. 1992;263:G864-70. 
[27]   Maurer CA, Friess H, Kretschmann B, Wildi S, Muller C, Graber H, et al. Over-
expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in 
colorectal cancer. Int J Cancer. 1998;79:76-81. 
[28]   Hayes SH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, 
metastases and normal tissues. Int J Clin Exp Pathol. 2009;2:553-60. 
61 
[29]   Reinhardt M, Hauff P, Linker RA, Briel A, Gold R, Rieckmann P, et al. 
Ultrasound derived imaging and quantification of cell adhesion molecules in 
experimental autoimmune encephalomyelitis (EAE) by Sensitive Particle Acoustic 
Quantification (SPAQ). Neuroimage. 2005;27:267-78. 
[30]   Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell. 1990;62:3-
6. 
[31]   Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-
34. 
[32]   Shi W, Wang J, Fan X, Gao H. Size and shape effects on diffusion and 
absorption of colloidal particles near a partially absorbing sphere: implications for 
uptake of nanoparticles in animal cells. Phys Rev E Stat Nonlin Soft Matter Phys. 
2008;78:061914. 
[33]   Mailander V, Landfester K. Interaction of nanoparticles with cells. 
Biomacromolecules. 2009;10:2379-400. 
[34]   Rajashekhar G, Willuweit A, Patterson CE, Sun P, Hilbig A, Breier G, et al. 
Continuous endothelial cell activation increases angiogenesis: evidence for the direct 
role of endothelium linking angiogenesis and inflammation. J Vasc Res. 2006;43:193-
204. 
[35]   Franses JW, Baker AB, Chitalia VC, Edelman ER. Stromal endothelial cells 
directly influence cancer progression. Sci Transl Med. 2011;3:66ra5. 
[36]   Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB, et al. 
Expression of cell adhesion molecules in human melanoma cell lines and their role in 
cytotoxicity mediated by tumor-infiltrating lymphocytes. Cancer. 1992;69:1165-73. 
[37]   Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and 
cancer progression. Curr Med Chem. 2007;14:377-86. 
62 
[38]   Nelson H, Ramsey PS, Donohue JH, Wold LE. Cell adhesion molecule 
expression within the microvasculature of human colorectal malignancies. Clin 
Immunol Immunopathol. 1994;72:129-36. 
[39]   Fox SB, Turner GD, Leek RD, Whitehouse RM, Gatter KC, Harris AL. The 
prognostic value of quantitative angiogenesis in breast cancer and role of adhesion 
molecule expression in tumor endothelium. Breast Cancer Res Treat. 1995;36:219-26. 
[40]   Suzuki Y, Ohtani H, Mizoi T, Takeha S, Shiiba K, Matsuno S, et al. Cell 
adhesion molecule expression by vascular endothelial cells as an 
immune/inflammatory reaction in human colon carcinoma. Jpn J Cancer Res. 
1995;86:585-93. 
[41]   Cianchi F, Cuzzocrea S, Vinci MC, Messerini L, Comin CE, Navarra G, et al. 
Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase 





VISUALIZING AND QUANTIFYING ACUTE INFLAMMATION USING ICAM-1 
SPECIFIC NANOPARTICLES AND MRI QUANTITATIVE SUSCEPTIBILITY 
MAPPING 





As intense and prolonged inflammation correlates with the progression of 
various inflammatory diseases, locating specific regions of the body with dysregulated 
levels of inflammation could provide crucial information for effective medical 
diagnosis and treatment. In this study, we demonstrate high resolution spatiotemporal 
imaging of inflammation in mice treated with systemic injection of 
lipopolysaccharides (LPS) to mimic systemic inflammatory response or sepsis. 
Diagnosis of organ-level inflammation was achieved by magnetic resonance imaging 
(MRI) of inflammation-sensitive superparamagnetic iron oxide (SPIO)-based 
nanomicelle termed leukocyte-mimetic nanoparticle (LMN), designed to preferentially 
localize to cells with inflammation-induced overexpression of intercellular adhesion 
molecule (ICAM)-1. Using a novel MRI quantitative susceptibility mapping (QSM) 
technique for non-invasive quantification of SPIO nanoparticles, we observed greater 
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accumulation of LMN in the liver, specific to ICAM-1 induction due to LPS-induced 
inflammation. However, the accumulation of nanoparticles into the spleen appeared to 
be due to an ICAM-1 independent, phagocytic activity, resulting in higher levels of 
both LMN and control nanoparticles in the spleen of LPS-treated than untreated mice. 
Overall, the amounts of nanoparticles in liver and spleen estimated by QSM were in a 
good agreement with the values directly measured by radioactivity, presenting an idea 
that spatiotemporal mapping of LMN by MRI QSM may provide a reliable, rapid, 
non-invasive method for identifying organ-specific inflammation not offered by 
existing diagnostic techniques. 
 
3.2 Introduction 
Nonresolving inflammation contributes significantly to the pathogenesis of a 
variety of human diseases and represents one of the most significant factors of medical 
burden worldwide [1]. While inflammation is typically initiated in response to harmful 
stimuli, dysregulation of the inflammation pathways can result in prolonged and 
excessive inflammation, leading to host damage that can surpass the harm inflicted by 
the original pathogen [2]. Indeed, unresolving chronic inflammation has been linked to 
atherosclerosis [3], obesity [4], and cancer [5], prolonged acute inflammation has been 
closely associated with sepsis [6] and local infections [7], and the cyclic coexistence 
of acute and chronic inflammation has been implicated in rheumatoid arthritis [8], 
asthma [9], multiple sclerosis, Crohn’s disease, and ulcerative colitis [1]. Of particular 
concern of inflammatory dysregulation is the intense localized recruitment of 
macrophages, lymphocytes, and neutrophils to otherwise healthy tissue, resulting in 
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necrosis of vital tissues and organs, contributing greatly to increased patient morbidity 
and mortality [10]. Thus, identifying localized inflammation in the context of broader 
inflammation-driven diseases can aid in isolating regions at risk of host-response 
necrosis and can provide a valuable insight into the progression and severity of the 
condition.  
Current approaches to inflammation detection employ various markers as 
targets for biospecificity, including soluble extracellular molecules, such as fibrinogen 
[11], factor XIII [12], and collagen [13], as well as cell surface molecules such as 
tissue factor [14], chondroitin sulfate proteoglycans [15], vascular adhesion molecule 
(VCAM-1) [16], and ICAM-1 [17-19]. Of particular interest is ICAM-1, a 
transmembrane molecule that displays a distinct spatiotemporal response to 
inflammation. While basally expressed at low levels throughout the body under 
normal conditions, ICAM-1 is highly inducible under inflammatory stimuli [20] and 
exhibits highly localized cell surface expression on immune and non-immune cells, 
such as endothelial cells, fibroblasts, lymphocytes, and myeloid cells [21]. 
Furthermore, cell surface ICAM-1 overexpression has been linked to various diseases 
and conditions, and correlates well with inflammation-related tissue and organ damage 
resulting from hepatic ischemia [22-23], intestinal and colon ischemias [24], hepatitis, 
cirrhosis, Wilson’s disease, transplantation rejection [25], pancreatitis [26], type 1 
diabetes [27], and multiple organ dysfunction syndrome in sepsis [6]. To target cell 
surface ICAM-1, we previously employed a high affinity variant of the domain called 
inserted (I) domain [28], present in the α subunit of the integrin lymphocyte function-
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associated antigen (LFA)-1 and solely responsible for LFA-1 interaction with ICAM-1 
[29].  
 One potential application for specific inflammation imaging is for the detection 
of sepsis. Sepsis is the leading cause of death in critically ill patients admitted to the 
medical intensive care unit (ICU) in the United States [30], defined as a systemic 
inflammatory response to infection manifested by two or more systemic inflammatory 
response syndrome (SIRS) criteria (such as changes in body temperature, tachycardia, 
and changes in the number and/or immaturity of white blood cells) [6]. Under sepsis, 
the endothelium experiences sustained and generalized activation, resulting in 
procoagulant phenotype, increased endothelial cell apoptosis, increased expression of 
adhesion molecules, and ultimately organ-specific coagulation and dysfunction [6]. As 
ICAM-1 plays a significant role in mediating leukocyte adhesion as a part of 
inflammatory response and has been linked to organ-specific inflammation-driven 
necrosis, identifying sites of high ICAM-1 expression may offer detection or even 
additional insight into the progression of sepsis or other systemic inflammatory 
response not offered by existing diagnostic techniques.  
In this study, we demonstrate that high resolution spatiotemporal imaging of 
LPS-induced systemic inflammation through the use of inflammation-specific 
nanoparticles termed leukocyte-mimetic nanoparticles (LMN) [31], a fluorescently 
tagged ICAM-1 specific nanomicelle encapsulating superparamagnetic iron oxide 
nanoparticle as a targeted bimodal near-infrared (NIR) optical/magnetic resonance 
imaging (MRI) contrast agent. Using optical imaging and a novel MRI quantitative 
susceptibility mapping (QSM) technique [32], and directly corroborated by 
 67 
radiolabeled isotope measurement, we utilize LMN to quantitatively observe the 
degree of localized acute inflammation as an indicator of sepsis progression. By 
tracking the biodistribution of nanoparticles using whole body imaging techniques, we 
have found greater accumulation of LMN than that of non-ICAM-1 specific controls 
in the liver of septic mice, while this difference in accumulation was absent in the liver 
of non-septic mice. In contrast, greater accumulation of nanoparticles irrespective of 
ICAM-1 targeting was observed in the spleen of septic mice than that of non-septic 
control, suggesting that localization into the spleen was mainly a result of ICAM-1 
independent phagocytic activity. Our study demonstrates the utility of quantitative 
MRI-based detection of ICAM-1 specific nanoparticles in the major organs including 
the liver and spleen, organs closely associated with systemic inflammatory response, 
as a diagnosis method for systemic inflammation through the imaging and 
quantification of localized inflammation. 
 
3.3 Materials and methods 
3.3.1 Preparation of ICAM-1 specific nanoparticles (Leukocyte-mimetic 
nanoparticles (LMN))  
Details in the synthesis of LMN were described previously [31] . Briefly, oleic 
acid-capped superparamagnetic iron oxide (SPIO) nanocrystals (15 nm in diameter, 
Ocean Nanotech, LLC) were additionally coated with an outer layer of phospholipid, 
consisting of 1,2-dipalmitoyl-snglycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DPPE-PEG) and 1,2-dioleoyl-sn-glycero-3-
[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] nickel salt (DOGS-NTA) 
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(Avanti Polar Lipids, Inc.). Radiolabeled lipid-coated SPIO nanoparticles were 
synthesized by addition of 
3
H-DPPC (L-α-Dipalmitoyl-Phosphatidylcholine) (Perkin 
Elmer) at less than 5% of the total phospholipid to the mixture of DPPE-PEG and 
DOGS-NTA. The lipid layer on SPIO nanoparticles was formed by hydration of the 
mixture of lipid-film and SPIO, and lipid-coated SPIO were then purified by density 
centrifugation, followed by a gel filtration technique. LFA-1 I domains containing 
mutations of Asp137→Ala (D137A; non-ICAM-1 specific) and 
Phe265→Ser/Phe292→Gly (F265S/F292G; ICAM-1 specific) fused to His tag (6 
histidine residues) at the N-terminal were produced as previously described [31]. 
Conjugation of lipid-SPIO with His-tagged I domains was obtained by incubation of 
nanoparticles with I domains at 4°C overnight, forming LMN (with F265S/F292G) 
and non-targeting nanoparticle (NTN) (with D137A). All fluorescently labeled 
nanoparticles were prepared by covalently conjugating Alexa Fluor 750 (AF750) 
(succinimidyl esters (Invitrogen) to the I domains.  
3.3.2 Animal model of acute inflammation 
All animal experiments were conducted in compliance with the regulations 
defined by the Institutional Laboratory Animal Use and Care Committee of Cornell 
University. 1 mg/ml LPS in 100 μl PBS were injected intravenously through 
retroorbital vein into 8-wk-old female BALB/c mice 12 h before nanoparticle 
administration. Prior to imaging hair was removed to reduce background fluorescence. 
Mice with no treatment were used as negative control. Three mice per group were 
used for each treatment and imaging regimen. 
3.3.3 Near-IR optical and MR imaging of mice 
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Animals were anesthetized with isoflurane mixed with oxygen at 5% and 
maintained at 2% isoflurane during whole body imaging (Olympus, OV100). After 12 
hour treatment with LPS or no-treatment control, mice were administered with 100 μg 
of nanoparticles coated with AF750-conjugated I domains in 150 μl pH 7.4 PBS via 
retro-orbital injection. Near-IR images of the same mice were taken three times at 1, 8, 
and 25 hours after nanoparticle injection. Image analysis was performed with Matlab 
R2007a (MathWorks). Mice were euthanized at 1, 8, or 25 hours after injection of 
nanoparticles for MRI by intraperitoneal injection of 2.5% tribromoethanol (20 μl/g), 
transcardially perfused with pH 7.4 PBS, and fixed in 4% paraformaldehyde. Prepared 
mice were scanned on a 3T scanner (GE Signa Excite) with 3D multi-echo enhanced 
fast gradient echo (EFGRE) sequence. Imaging parameters were as follows: TEs 3.696 
ms, 4.196 ms, 5.696 ms, 11.696 ms, 35.696 ms; TR 40 ms; flip angle 30°; matrix size 
256×64×64; voxel size 500 μm isotropic. A 3D Fourier transform was applied to the 
raw k-space data to reconstruct the images. QSMs were reconstructed using the 
COSMOS technique, as previously described [31]. Regions of interest were 
segmented for the liver, spleen, and kidneys, and SPIO localization was estimated 
using QSM, normalized to a calibration standard. 
3.3.4 Histological sections 
At 1 hour post nanoparticle injections, mice were euthanized and perfused with 
PBS transcardially. Liver tissues were then collected from animals. Part of the tissues 
were fixed in 4% paraformaldehyde, embedded in paraffin, sliced into 4 μm slides, 
and stained with hematoxylin and eosin (H&E) or with Perls’ Prussian blue. The rest 
of the tissues were frozen in OCT compounds (Sakura Finetek), sectioned to 10 μm 
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slides, and immunostained with rat anti-mouse CD68 (BioLegend) for detection of 
macrophages. 
3.3.5 Quantification of radiolabeled LMN 
Animals were anesthetized with isoflurane and each was administered with 
100 μg 3H-labeled SPIO (600 nCi per mouse) in 100 μl PBS via retro-orbital injection. 
At 1 hour post injection, blood samples were first collected and mice were perfused 
with PBS and sacrificed. Major organs were harvested, homogenized, lysed in tissue 
solubilizer (Fisher), and then mixed with scintillation counter fluid for radioactivity 
measurement (Beckman Coulter). Percent distribution into the major organs was 
obtained after normalization to the total counts of radioisotope decay per animal. 
3.3.6 Surface plasmon resonance (SPR) analysis 
The affinity of human LFA-1 I domains, F265S/F292G and D137A, to murine 
ICAM-1 was determined by SPR using BIAcore (BIA2000), as previously described 
[28]. In brief, a CM5 sensor chip was prepared using an amine coupling kit (BIAcore) 
to immobilize recombinant murine ICAM-1fusion with human IgG1 Fc (R&D 
Systems). Then F265S/F292G and D137A were injected over the chip in injection 
buffer (20 mM Tris HCl, pH 8.0, 150 mM NaCl, 10 mM MgCl2) at a flow rate of 10 
µl/min at RT. In order to examine the specificity of nanoparticle to the level of ICAM-
1 expression, CM5 sensor chip was immobilized with three different concentrations of 
ICAM-1, representing basal to highly induced cell surface density (200, 1000 and 
3,250 molecules/μm2) [33]. Nanoparticles were then flowed over the chip at a flow 
rate of 15 μl/min to approximate the shear force on nanoparticles in vivo. 
3.3.7 Statistical analysis 
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Statistical analysis was performed using two-way analysis of variance and one-
way analysis of variance with Tukey’s HSD post-hoc test at 95% confidence interval 
(GraphPad Prism). 
 
Figure 3.1: (a) Structural model of the complex of ICAM-1 domain 1 and LFA-1 I 
domain. White spheres depict allosteric activation sites along the peptide backbone. 
Metal ion and two oxygen atoms of water molecules are depicted as colored spheres. 
Residues that coordinate to the metal ion are shown as sticks. Mutations of 
Phe265→Ser (F265S), Phe292→Gly (F292G), and Asp137→Ala (D137A), and N 
and C termini are indicated. Figure adapted from Hu et al [44]. (b) SPR 
measurement of the binding kinetics of I domain variants F265S/F292G and D137A 
to immobilized murine ICAM-1. F265S/F292G exhibits high ICAM-1 binding 






Previously, we validated the suitability of I domain as a targeting moiety for 
selective binding of nanoparticles to ICAM-1 overexpression [17, 19, 31]. In order to 
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design control nanoparticles, termed non-targeted nanoparticle (NTN), we used the 
same LFA-1 I domain but containing a mutation of D137A, which abolished a ligand-
binding site called a metal-ion adhesion site (MIDAS) and subsequently its binding to 
ICAM-1 (Figure 3.1a). SPR measurement confirmed our previous observation with 
cell staining [31]  that human I domain cross-reacted with murine ICAM-1 with 
comparable affinity to human ICAM-1 (KD = 2 nM to murine ICAM-1 vs. 6 nM to 
human ICAM-1 [28]; Figure 3.1b). Subsequent conjugation of F265S/F292G and 
D137A to prepared lipid-coated SPIO nanoparticles produced LMN and NTN, 
respectively, through spontaneous assembly from binding of His tag (6 histidine 
residues) to Nickel-NTA (Figure 3.2).  
 
Figure 3.2: Schematic diagram of LMN and NTN. LMN (ICAM-1 specific) and 
NTN (non-ICAM-1 specific) differ only in surface-conjugated targeting moiety. 
 
 
Prior studies demonstrated that the number of targeting moieties on 
nanoparticles affected selectivity and targeting efficiency of nanoparticles in binding 
 73 
to cells [31, 34]. In order to preferentially target ICAM-1 induced under inflammation 
but not basally expressed ICAM-1, an optimal ratio of I domain to nanoparticle was 
empirically determined (~100 molecules per nanoparticle [17]). When an SPR chip 
was prepared with varying ICAM-1 densities representing basal to high levels of 
ICAM-1 expression (200, 1000 and 3,250 molecules/μm3), LMN binding was limited 
to the surface coating with higher than normal ICAM-1 site density, while LMN 
binding to the basal ICAM-1 surface was the same as the background levels seen with 
NTN (Figure 3.3). 
 
Figure 3.3: SPR measurement of the binding kinetics of LMN and NTN to varying 
concentrations of immobilized ICAM-1 (low, intermediate, and high correspond to 
approximately 200, 1000 and 3,250 molecules/μm2, respectively). LMN binding was 
limited to the surface coating with higher than normal ICAM-1 site density, while 
LMN binding to the basal ICAM-1 surface was the same as the background levels 




To obtain qualitative assessment of nanoparticle biodistribution, we first 
imaged each mouse using near-IR optical fluorescence camera. Near-IR optical 
temporal mapping of the nanoparticle distribution demonstrated greater localization of 
LMN into the liver in mice treated with LPS (Figure 3.4 & 3.6). Control nanoparticles 
(NTN) also exhibited slightly higher accumulation into the liver of LPS-treated mice, 
which might be attributed to increased ICAM-1 independent phagocytic activity of 
immune cells or increased blood pool retention due to the inflammation in the liver. 
Higher fluorescence in the bladder was found to be due to some degree of shedding of 
 
Figure 3.4: Fluorescent heat maps (color) are superimposed over brightfield images 
(grey scale), indicating greater nanoparticle localization in the liver in LPS/LMN-
treated mice compared to that of negative controls, with observable localization 





Figure 3.5: MRI-QSM reconstructions of the (a) liver and (b) spleen. QSM 
technique reveals greater nanoparticle localization in the liver of LMN/LPS-treated 
mice compared to that of negative controls, while greater nanoparticle localization is 
observed in the spleen in LPS-treated mice, regardless of injected nanoparticle. 
Portions of these results were previously described in Chen et al [31], and 
reproduced here. Representative QSM maps at each time point post-injection (p.i.) 
of nanoparticles are shown: organ-specific QSM heat maps (color) are superimposed 
over MRI T2* weighted EFGRE scans used for navigational reference (gray). 
 
 
the I domains from the nanoparticles, which would be small enough to pass through 
glomerular capillaries in the kidney and collected into the bladder. After optical 
imaging, mice were sacrificed, transcardially perfused with PBS to remove 
nanoparticles in the blood, and subjected to MRI to quantitatively map nanoparticle 
distribution by QSM. Full body temporal mapping of the SPIO distribution was  
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Figure 3.6: Fluorescence detected in the liver region of mice analyzed using near-IR 
optical imaging at 1, 8, and 25 hours post nanoparticle injection. 
 
 
conducted and individual organs were segmented for analysis (Figure 3.5). Specific 
SPIO quantification of each organ revealed a greater localization of LMN in the liver 
compared to that of NTN in mice with LPS treatments (Figure 3.5a), peaking at one 
hour and progressively diminishing at each subsequent time point. In contrast to 
higher accumulation of NTN by optical imaging in the liver of LPS-treated mice 
(Figure 3.4), QSM quantification (Figure 3.5a & 3.7) and radioisotope measurement 
(Figure 3.8) performed after perfusion revealed that NTN accumulation in the liver 
was not augmented by LPS treatment, indicating that the higher fluorescence with LPS 
treatment is due to the increase in the blood pool retention of NTN. While the 
presence of LPS or the type of nanoparticles administered each independently 
influenced the magnitude of observable nanoparticle accumulation in the liver, the 
simultaneous interaction of LMN and LPS had a statistically significant effect in all 
measured time points (Table 3.1). In the spleen, higher amounts of nanoparticle 








































































of the type of nanoparticles used (Figure 3.5b & 3.7). Therefore, LPS treatment was 
the predominant differentiating factor in observable nanoparticle accumulation in the 
spleen, independent of the targeting moiety or the interaction between LPS treatment 
and type of nanoparticle injected (Table 3.1). Negligible amounts of SPIO were 
detected in the kidneys, supporting the speculation that nanoparticles of ~ 60 nm in 
size [31] would be too large for renal filtration.  
 
Figure 3.8: Radioactivity measurement of 
3
H labeled nanoparticles from the liver, 
kidney, spleen, and blood 1 hour post-nanoparticle injection, normalized to the total 
counts of radioisotope decay per mouse. All modalities measured high liver-specific 
nanoparticle localization in LPS/LMN-treated mice 1 hour post nanoparticle 
injection over controls. QSM measured high spleen-specific nanoparticle 
localization in LPS-treated mice, regardless of nanoparticle injected. Trends persist 
through 25 hours post nanoparticle injection. Portions of these results were 
previously described in Chen et al [31], and reproduced here. One-way analysis of 
variance with Tukey HSD post-test at 95% confidence interval are summarized in 
each figure (*** p < 0.001, ** 0.001 < p < 0.01, * 0.01 < p < 0.05). 
 
 
To further validate MRI quantification of nanoparticles, the values obtained 
with QSM technique were directly compared to those quantified by measuring 
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radioisotope decay of 
3
H-labeled nanoparticles. Mice were treated with LPS for 12 
hours and subsequently injected with 
3
H-labeled LMN or NTN. At 1 hour post 
nanoparticle injection, blood was collected and after perfusion and sacrifice of the 
mice, organs were harvested. Radioactivities of the blood and major organs such as 
liver, kidney, and spleen were measured and normalized to the total radioactivity of 
each mouse in order to quantify percent nanoparticle biodistribution in the major 
organs (Figure 3.8). Highest radioactivity, irrespective of LMN vs. NTN and LPS vs. 
no treatment, was observed in the blood with a mean radioactivity of ~40%, followed 
by the levels in the liver with significantly higher radioactivity detected in LPS/LMN-
treated mice (31.3 ± 6.7%) than those in non-LPS/LMN-treated (14.8 ± 9.9%),  
 
Figure 3.9: Measurements of nanoparticles in the spleen and liver obtained from by 
radioisotope measurement and by QSM are linearly related. Error bars indicate 95% 
confidence interval. Dotted line indicates 95% confidence interval for linear 




Table 3.1: Two-way analysis of variance of organ-specific nanoparticle accumulation 
resulting from the treatment of LPS, the type of nanoparticle administered, or due to 
the interaction between both factors, quantified by QSM technique.  
Factors 
Liver Spleen Right Kidney Left Kidney 
1 hr 8 hr 25 hr 1 hr 8 hr 25 hr 1 hr 8 hr 25 hr 1 hr 8 hr 25 hr 
LPS *** ** ns *** *** ** ns ns * ns ns * 
Nanoparticle *** ** *** ** ** ns ns ns ns * * ns 
Interaction *** ** * ns ns ns ns ns ns ns * ns 
*** p < 0.001, ** 0.001 < p < 0.01, * 0.01 < p < 0.05, n.s. no significance. 
 
 
LPS/NTN-treated (13.6 ± 6.6%), or non-LPS/NTN-treated controls (17.2 ± 5.7%). 
Significantly lower amounts (less than 10% of the total) were detected in the lung, 
kidney, and spleen (Figure 3.8 and not shown). Consistent with the QSM 
measurement of nanoparticle distribution in the spleen, slightly higher amounts of 
radioactivity were observed in the spleen of LPS-treated (2.7 ± 0.7%) than non-treated 
(1.5 ± 0.5%) mice. Values obtained by radioisotope measurement and by QSM 
showed overall an excellent linear relationship (sy.x = 1.60%), with QSM 
overestimating radioisotope measurements by approximately 25% (Figure 3.9). 
In order to examine cellular basis for the increase in LMN accumulation into 
the liver in LPS-treated mice, selected liver tissues were stained for identification of 
different types of cells (hepatocyte, endothelium, and Kupffer cells) and localization 
of nanoparticles (Figure 3.10, 3.11 & 3.12). Vasculature dilatation was apparent in 
LPS-treated liver tissue (Figure 3.10) with LMN deposited primarily on endothelial 
cells and Kupffer cells (Figure 3.11). Simultaneous detection of Kupffer cells (CD68) 
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and nanoparticles by Prussian Blue staining revealed that most large deposits of LMN 
were accumulated into Kupffer cells (Figure 3.12), implying that higher accumulation 
of LMN over NTN in the liver of LPS-treated mice is mainly due to ICAM-1 
induction and uptake by Kupffer cells. 
 
Figure 3.10: H&E stain of liver tissue sections show distinct dilation of liver tissue, 





With developments in quantitative MRI techniques, this study presents a 
clinically adaptable method for organ-level mapping of inflammation by quantifying 
the susceptibility of SPIO-based contrast agents, a measure directly proportional to 
SPIO concentration. While existing methods for detecting inflammation exist in the 
context of sepsis diagnosis, such detection methods typically rely on bulk 
measurements of the presence of pathogens, blood-borne cytokines, and other  
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Figure 3.11: Prussian Blue staining of liver tissue sections shows SPIO 
accumulation primarily in the endothelial cells and Kupffer cells, with markedly 
more staining in LPS treated subjects with injected LMN. 
 
 
inflammatory markers, lacking in the spatiotemporal progression and detection of 
inflammation locally in the body. Central to inflammation is the adhesion of 
leukocytes to vascular endothelium, a process mediated by molecular interactions 
between cell adhesion molecules such as integrins and ICAM-1. Toward a sensitive 
molecular imaging of inflammation, we designed nanoparticles to mimic the ability of 
leukocyte to preferentially adhere to inflamed vasculature, which was achieved by 
attaching the high affinity I domain of LFA-1 to nanoparticles. Despite the fact that 
ICAM-1 is basally expressed in many different types of cells including endothelium 
and immune cells, our nanoparticles were shown to be selective to vasculature under 
inflammation with upregulated ICAM-1 expression [31]. Capable of in vivo detection  
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Figure 3.12: CD68 (brown) and Prussian Blue (blue) staining indicates primary 
localization of iron deposition in Kupffer cells. Examples of hepatocytes (arrow), 
endothelium (double headed arrow), and Kupffer cells (arrowhead) are marked. 
 
 
by optical imaging and MRI techniques, leukocyte-mimetic nanoparticle has 
previously been shown to specifically localize to the areas of acutely induced local 
inflammation and to the vasculature within and in the vicinity of the tumor growth, 
providing spatial and temporal insight into various inflammation-related diseases and 
conditions. In this study, we demonstrated the potential use of LMN as a bimodal 
diagnostic agent for the early detection of sepsis or systemic inflammatory response 
using quantitative MRI techniques. 
Previously, we have described a tunable approach to creating nanoparticles that 
mimic an intrinsic behavior of leukocytes that bind selectively to inflammatory sites 
[17]. By modulating the affinity and avidity of surface-bound I domains for targeting 
inflammation, we were able to construct nanoparticles that can resist thermal diffusion 
and detachment forces exerted by fluid-induced shear stress, while allowing little 
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binding to cells with only basal levels of ICAM-1 expression. Approximately 100 I 
domains were conjugated to the surface of each LMN, roughly comparable to that of a 
surface density-optimized approach to ICAM-1 specific nanoparticle design [17, 34]. 
While prior approaches have demonstrated the appeal of employing both selectin 
ligands and anti-ICAM-1 antibodies to more accurately mimic the rolling and 
adhesion characteristics of leukocytes [35-36], we chose to utilize as the targeting 
moiety for LMN the I domain of LFA-1 integrin, which has been engineered to engage 
with ICAM-1 with high affinity without prior dependence on interaction with 
selectins. We found that a targeting moiety derived from physiological molecules, 
optimized for affinity and avidity, gave superior selectivity and targeting efficiency to 
inflamed cells in in vitro and in vivo settings [17, 31]. 
In treating mice with ICAM-1-specific LMN, we were able to readily 
differentiate between mice, either pre-treated with LPS or left untreated, by 
quantitatively measuring nanoparticle localization in various abdominal organs in each 
of the subjects. This differential effect is most apparent when measuring nanoparticle 
localization in the liver; a temporal mapping of nanoparticle distribution through MRI 
QSM demonstrated significantly greater localization of LMN into the liver of sepsis-
induced mice compared to that of non-septic subjects, or of those treated with ICAM-1 
independent NTN. The observed differences by QSM, corroborated qualitatively by 
near-IR optometry, were most pronounced one hour after the treatment of 
nanoparticles, gradually decaying over time while persisting through at least 24 hours 
after nanoparticle injection. While particles of ~100 nm in diameter in systemic 
circulation may accumulate in the liver regardless of targeting moiety due to 
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phagocytic activity of immune cells within the liver, the ICAM-1 specificity conferred 
by the surface conjugation of high affinity I domain (F265S/F292G) of LFA-1 on 
LMN led to a close to a 2-fold increase in the accumulation in the liver to enable 
quantitative differentiation. NTN nanoparticles, conjugated with the same LFA-1 I 
domain but with an inactivating mutation, D137A, did not exhibit higher accumulation 
into the inflamed liver. This observation was corroborated through histology using 
iron stating of tissue sections of the liver, revealing a greater degree of nanoparticle 
accumulation in LPS-treated LMN cases with specific staining observed in both 
endothelial cells and Kupffer cells with the most significant nanoparticle 
accumulations co-localized in the Kupffer cells. Thus, while ICAM-1 is basally 
expressed in all endothelium and utilizing it as a molecular target for inflammation 
and sepsis imaging techniques may lead to a background signal, it was found that this 
background binding was negligible, judging from no difference between LMN and 
NTN accumulations into the liver by radioactivity measurement and QSM. The 
relationship between LMN biodistribution independent of ICAM-1 expression can be 
further characterized through the use of ICAM-1 knockout mice or through the use of 
blocking antibodies to systemically eliminate available ICAM-1 binding sites.   
A high degree of nanoparticle localization was also observed in the spleen of 
LPS-treated mice through optical imaging and QSM. However, unlike the 
observations in the liver, increases in nanoparticle accumulations to the spleen were 
observed in all LPS-treated subjects, regardless of the targeting moiety employed, 
suggesting that localization is a result of phagocytic activity rather than ICAM-1 
biospecificity. Severe and pervasive inflammation, such as that prompted by LPS-
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induced systemic endotoxic shock, may result in increased phagocytic uptake of 
nanoparticles in areas in the immediate proximity of major monocyte sources in the 
spleen, an organ that functions as a major reservoir for undifferentiated monocytes 
before inflammation-initiated recruitment [37], and is responsible for the release of 
splenic lymphokines necessary for the increase of phagocytic activity of macrophages 
cells in response to inflammatory stimuli [38-40]. While studies have indicated high 
ICAM-1 expression in the epithelial cells of the lungs due to endotoxin-induced 
inflammation [41-42], MRI-based techniques such as QSM cannot quantitatively 
differentiate between signal voids resulting from SPIO-based spin dephasing and 
signal voids created by air. This difficulty with reliably differentiating QSM-based 
quantification of SPIO deposits and air may be overcome by multiple data acquisition 
at differing magnetic field strengths [43]. 
Using radiolabeled SPIO nanoparticles, we were able to provide a quantitative 
mapping of nanoparticle distribution by the measurement of radioactivity  and at the 
same time clinically relevant QSM technique based on MRI. At one hour post 
nanoparticle injection, QSM determined that ~39% of injected nanoparticles were 
localized into the liver of LPS/LMN mice, a value 70% greater than that of negative 
controls. In comparison, radioisotope quantification found ~31% of the total body 
radioactivity was located in the liver of LPS/LMN treated mice, a value 81% greater 
than that of negative controls. However, some difference in QSM quantification vs. 
radioactivity measurement of nanoparticles was unavoidable as it was found that the 
lipid layer outside of SPIO was subject to some degree of shedding during circulation. 
This may explain, in the course of optical imaging, varying degrees of fluorescence 
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(conjugated to the I domains) observed in the bladder of each subject, regardless of the 
nanoparticle targeting moiety. The decoupling of the fluorescence or protein from 
nanoparticles was found to be caused by shedding of the phospholipid lipid layer from 
SPIO or lipid degradation by phospholipase activity in the plasma, but not due to 
dissociation between His tag and Ni-NTA, judging from a dramatic decrease in 
decoupling when crosslinkable fatty acids were used to cage SPIO (data not shown).  
Sepsis represents a continuum in clinical-pathologic severity with definable 
phases that characterize patients at risk for increased mortality. Current diagnosis 
techniques have limited windows of detection and may rely on transient biology and 
physiological conditions that may not persist across all phases of sepsis progression. 
Moreover, the onset of sepsis can be linked to a widely heterogeneous set of initial 
risk factors, further complicating diagnosis and delaying treatment. In particular, the 
endothelium is crucial in regulating a local balance between pro-inflammatory and 
anti-inflammatory mediators; under sepsis, endothelium undergoes excessive, 
sustained, and generalized activation, resulting in unregulated expression of 
inflammation-associated products. Among these, adhesion molecule ICAM-1 has been 
implicated as a highly localized biomarker for inflammation induced under organ 
damage [23-25], one of the most significant mortality risks in septic patients [6]. By 
specifically targeting ICAM-1 using bimodal LMN, we were able to readily 
differentiate septic and non-septic mice using optical imaging and quantitative MRI 
techniques, both non-invasive modalities. Most significantly, the observed differences 
were pronounced as soon as one hour after the treatment of the nanoparticle, and 
persist through at least 25 hours after injection. In this study, our temporal mapping of 
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inflammation was focused on following nanoparticle distribution over 25 hours in 
mice exposed to LPS for 12 hours. However, as surface-expressed ICAM-1 is induced 
rapidly under inflammation, with some studies observing peak expression as quickly 
as 1-2 hours after the introduction of stimuli [20], additional information on 
spatiotemporal dynamics of inflammation can be obtained by subjecting mice to 
different durations of LPS while maintaining similar post-treatment imaging protocols. 
Such information on spatiotemporal dynamics of inflammation would be necessary to 
better understand the distinct yet common processes of inflammation in 
reticuloendothelial systems such as the liver and spleen. 
This study also reveals the strength of MRI QSM in quantitatively measuring 
contrast agent localization into specific structures within the body. While optical 
imaging provides a gross view of the overall biodistribution of a fluorescent marker, 
the results are coarse, qualitative in nature, and prone to confounding effects due to the 
relatively shallow penetration depth of common fluorescent wavelengths, and the 
technique is not ideal for most clinical applications. Alternatively, traditional MRI 
techniques, such as typical T2* weighted imaging, provide significantly greater spatial 
resolution, but visualization is hindered by large obscuring signal voids resulting from 
SPIO use, and the resulting images are largely qualitative in nature, making it difficult 
to precisely estimate SPIO localization. In contrast, QSM technique offers a 
quantitative, high resolution method of tracking the biodistribution of paramagnetic 
contrast agents to specific organs and structures through mapping of magnetic 
susceptibility, a physical property of paramagnetic materials that relates linearly to its 
concentration, allowing for direct determination of the amount and spatial location of 
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contrast agent accumulation. Moreover, while SPIO-based contrast agents may result 
in signal voids in traditional T2* imaging and obscured underlying structure, QSM 
reconstruction techniques enable unimpeded analysis of the distribution of contrast 
agent and spatiotemporal mapping of inflammation. Given the speed and robustness 
by which these differences can be observed after administration of LMN, this 
technique offers temporal flexibility ideal for clinical applications, while granting 
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NOVEL STRATEGY FOR SELECTION OF MONOCLONAL ANTIBODIES 
AGAINST HIGHLY CONSERVED ANTIGENS: PHAGE LIBRARY 
PANNING AGAINST EPHRIN-B2 DISPLAYED ON YEAST 





Ephrin-B2 is predominately expressed in endothelium of arterial origin, 
involved in developmental angiogenesis and neovasculature formation through its 
interaction with EphB4. Despite its importance in physiology and pathological 
conditions, it has been challenging to produce monoclonal antibodies against ephrin-
B2 due to its high conservation in sequence throughout human and rodents. Using a 
novel approach for antibody selection by panning a phage library of human antibody 
against antigens displayed in yeast, we have isolated high affinity antibodies against 
ephrin-B2. The function of one high affinity binder (named as ‘EC8’) was manifested 
in its ability to inhibit ephrin-B2 interaction with EphB4, to cross-react with murine 
ephrin-B2, and to induce internalization into ephrin-B2 expressing cells. EC8 was also 
compatible with immunoprecipitation and detection of ephrin-B2 expression in the 
tissue after standard chemical fixation procedure. Consistent with previous reports on 
                                                 
3
 This chapter is modified with the permission of the publisher from Gu X, Vedvyas Y, Chen 
X, Kaushik T, Hwang CI, Hu X, Nikitin AY, Jin MM. Novel strategy for selection of 
monoclonal antibodies against highly conserved antigens: phage library panning against 
ephrin-B2 displayed on yeast. Plos One. 2012. Gu X, Vedvyas Y and Chen X contribute 
equally. Xiaoyue Chen conducted the experiments, analyzed the data and wrote the paper with 
regard to the following figures: 4.1b, 4.2b, 4.7a, 4.8 & 4.9. 
 96 
ephrin-B2 induction in some epithelial tumors and tumor-associated vasculatures, EC8 
specifically detected ephrin-B2 in tumors as well as the vasculature within and outside 
of the tumors. We envision that monoclonal antibody developed in this study may be 
used as a reagent to probe ephrin-B2 distribution in normal as well as in pathological 




The erythropoietin-producing hepatocellular (Eph) receptors and their ligands, 
ephrins comprise the largest subfamily of receptor tyrosine kinases (RTK), playing an 
important role in physiology such as embryogenesis, organ development, and 
angiogenesis as well as implicated in several types of cancers [1]. Among different 
classes of ephrins, ephrin-B2 is primarily expressed in arterial endothelial cells and 
neovasculature, forming a bidirectional signal with its cognate receptor EphB4, which 
is mainly expressed in venous endothelial cell [2-3]. The importance of such 
interaction in a developmental process has been demonstrated by impaired 
angiogenesis and ultimately embryonic lethality in mice due to homozygous mutation 
of ephrin-B2 or EphB4 [3-6]. The role of EphB4 and ephrin-B2 also extends to tumor 
growth and angiogenesis [1, 7]. Inhibition of their interaction by EphB4 antibody or 
extracellular fragment of EphB4 can inhibit tumor angiogenesis and tumor growth [8-
10]. Ephrin-B2 is involved in vascular endothelial growth factor (VEGF) signaling, 
through the internalization of VEGF receptor in all endothelial cell types during 
physiological and pathological angiogenesis [11-13], and could be upregulated in 
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VEGF-treated endothelial cells [5-6]. Expression of ephrin-B2 along with EphB4 was 
found to be higher in many tumors including colorectal, breast, ovarian, and lung, 
serving as a poor prognostic marker [14-18].  
Despite the importance of ephrin-B2 in physiology and pathological 
conditions, there are no widely available monoclonal antibodies against ephrin-B2, 
likely attributed to the fact that immume system in rodents prevents responses to self 
antigen or to highly conserved human antigens. To overcome the problem with 
generating antibodies against highly conserved antigens, mice with impaired immune 
tolerance (e.g. NZB/W) have been exploited [19-20]; however, concerns remain on 
this alternative approach due to the observations of multi-specificity and low-affinity 
on auto-antibodies developed from autoimmune mice [20]. In order to generate 
antibodies against highly conserved ephrin-B2, we used phage display of single chain 
human antibody and screened them against ephrin-B2 expressed in yeast. From our 
previous work [21], we found that phage panning against antigens displayed in yeast is 
highly efficient in rapid enrichment of specific phage clones, obviating the need to 
produce soluble antigens as well as ensuring native conformation. With newly 
developed monoclonal antibody, we found that tumors of colon, breast, ovary, and 
lung upregulated ephrin-B2 compared to respective normal tissues. Antibody staining 
was also observed in the neovasculature within the tumor, corresponding to new vessel 
sprouts. Our antibody also exhibited properties such as its ability to cross-react with 
murine ephrin-B2, to inhibit EphB4 binding, and to be internalized into cells after 
binding to ephrin-B2. We anticipate that antibodies developed in this study will be 
useful in probing ephrin-B2 distribution in normal and disease processes, and in 
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antagonizing the interaction between ephrin-B2 and EphB4 for scientific and 
therapeutic applications.  
 
4.3 Materials and methods 
4.3.1 Selection and expression of ephrin-B2-specific scFvs 
A part of human ephrin-B2 ectodomain (Thr-22 to Gly-165) was cloned into 
yeast surface display vector, CAga2 (a modified version of PCTCON [30]), and 
transformed into yeast strain EBY100 by EZ-transformation kit (Zymo Research). 
Yeast culture and protein induction were performed as previously described [30]. 
Proteins displayed on yeast contain ephrin-B2 ectodomain, Myc tag, and Aga2 from 
N- to C-terminal. Surface expression of ephrin-B2 in yeast was measured by 
immunofluorescence flow cytometry using mouse anti-Myc antibody (9E10, Santa 
Cruz Biotechnology) followed by goat phycoerythrin-conjugated anti-mouse antibody 
(Santa Cruz Biotechnology), as well as by recombinant human EphB4-Fc chimera 
(Biomiga) followed by goat phycoerythrin-conjugated anti-human antibody (Santa 
Cruz Biotechnology). A phage library of human single chain variable fragment (scFv) 
antibody with 10
8
 diversity (Tomlinson I + J, Source BioScience) was panned against 
ephrin-B2 expressing-yeast cells, following a procedure previously described [21]. 
Briefly, 2×10
13
 phage clones were first incubated with phosphate buffered saline 
(PBS) containing 2% nonfat dry milk (Carnation) for 30 min at room temperature 
(RT), to which 2×10
7 
yeast cells expressing unrelated protein (Zif268) was added for 
depletion of non-specific phage binders. The mixture of phage and yeast cells were 
then incubated for 1 h at RT with agitation. Non-binding phage clones in the 
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supernatant were removed after centrifugation to pellet yeast cells, which were 
subsequently washed five times with PBS/0.05% Tween 20. Then phage particles were 
eluted from yeast cells with trypsin and used to infect Escherichia coli (TG1) to 
amplify enriched phage library for the next round of selection. After three rounds of 
selection, ~200 TG1 clones were picked to produce individual phage clones. The 
binding of phage clones to ephrin-B2 expressing yeast cells was measured by 
immunofluorescence flow cytometry using anti-His tag antibody (Sigma-Aldrich) 
followed by goat phycoerythrin-conjugated anti-mouse antibody (Santa Cruz 
Biotechnology). 
4.3.2 Expression of scFv 
Individual phage clones with high affinity binding to ephrin-B2 were 
sequenced, and selected scFv antibodies were solubly expressed from bacteria 
HB2151 (Clontech). Transformed HB2151 cells were grown at OD600 = 0.4, to which 
1 mM isopropyl β-D-1-thiogalactopyranoside was added. Cells were induced to 
express protein at 25
°
C by culturing for 16 h with shaking at 250 rpm. After induction, 
cells were spun down, resuspended in binding buffer (50 mM sodium phosphate, pH 
8.0, 300 mM sodium chloride, and 10 mM imidazole), sonicated to break the cell wall, 
and were spun at 10,000 g for 15 min to remove cell debris. Proteins in the supernatant 
were purified with Ni-NTA column followed by gel filtration chromatography using 
Superdex 75 column connected to AKTA Purifier (GE Healthcare). The purity and the 
size of proteins were confirmed by sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE). 
4.3.3 Cell culture 
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Chinese hamster ovary (CHO) cells [30] were maintained in Ham’s F12 
medium (Invitrogen) supplemented with 2 mM L-glutamine and 5% fetal bovine 
serum (FBS). Colorectal adenocarcinoma COLO205 [31] were cultured in RPMI 1640 
medium supplemented with 2 mM L-glutamine, 10% FBS and 1% Penicillin-
Streptomycin. HCT116 colon cancer cell line [32] was grown in McCoy's 5A Medium 
(Invitrogen) supplemented with 10% FBS. Human embryonic kidney (HEK) 293T 
cells [30] were maintained in advanced DMEM supplemented with 10% FBS, 2 mM 
L-glutamine, 20 μg/mL hygromycin and 1% Penicillin-Streptomycin. All cell cultures 
were maintained at 37°C in a humidified 5% CO2 atmosphere. 293T cells stably 
expressing ephrin-B2 were established by transfection of cells with pcDNA3.1 
(Invitrogen) containing full-length ephrin-B2 with 200 μg/ml of hygromycin for 
selection. 
4.3.4 Immunofluorescence flow cytometry 
Protein expression on yeast cell surface was analyzed by flow cytometry as 
described [33]. Briefly, yeast cells were incubated with primary antibodies (10 μg/ml) 
in 200 μl of labeling buffer (PBS/0.5% bovine serum albumin) for 1 h with shaking at 
30°C. Cells were then washed and incubated with secondary antibodies in 200 μl of 
labeling buffer for 1 h at RT. After washing, cells were resuspended in 200 μl of 
labeling buffer and subjected to flow cytometry. The expression of ephrin-B2 in 
mammalian cells was detected by incubating cells with ephrin-B2 antibody for 1 h at 
4°C, followed by Alexa Fluor 488 (AF488)-conjugated goat anti-human secondary 
antibody (Invitrogen). Flow cytometry was performed on a FACSCalibur (BD 
Biosciences) and analyzed with CellQuest software (BD Biosciences). 
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4.3.5 Conversion of scFv into scFv-Fc 
In order to fuse scFv into immunoglobulin G (IgG) constant region (Fc) 
including a hinge sequence, scFv sequence followed by IgG1 Fc was cloned into 
pcDNA3.1. scFv-Fc fusion protein was expressed in 293T cells and purified with 
Protein A beads (Thermo Scientific).  
4.3.6 Conformation specificity and selectivity of EC8 against ephrin-B2 
Yeast cells expressing ephrin-B2 were incubated either in 50 mM Tris buffer 
(pH 8.0) containing 6 M guanidine hydrochloride for 20 min at room temperature, or 
in labeling buffer (PBS/0.5% bovine serum albumin) heated to 80°C for 10 min, to 
denature ephrin-B2. EC8 or EphB4-Fc binding to yeast cells after denaturation of 
ephrin-B2 was then measured by flow cytometry. To examine crossreactivity of EC8 
to other ephrins, human ephrin-B1 (Leu-24 to Gly-165) and ephrin-A5 (Pro-22 to 
Gly-169) ectodomains were cloned and displayed on yeast surface. 
Immunofluorescence flow cytometry was conducted with mouse anti-Myc antibody 
(9E10, Santa Cruz Biotechnology), recombinant human EphB2/Fc chimera (R&D 
Systems), and EC8 followed by respective secondary antibodies as previously 
described. 
4.3.7 Competition assay 
Yeast cells expressing ephrin-B2 were incubated with varying concentrations 
of mAb EC8 or affinity (protein A column, Pierce) purified human IgG for 20 min at 
30°C, to which recombinant human EphB4 containing His-tag at C-terminal (R&D 
Systems) was added at 100 nM and incubated for 20 min at 30°C. The binding of 
EphB4 to yeast was detected by flow cytometry using anti-His tag antibody, followed 
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by phycoerythrin-conjugated goat anti-mouse antibody. 
4.3.8 Immunoprecipitation of ephrin-B2 by mAb EC8 
293T cells with stable expression of ephrin-B2 were incubated in lysis buffer 
(20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM 
ethylenediaminetetraacetic acid (EDTA), protease inhibitor cocktail (Sigma)) for 30 
min on ice. Cell debris were removed by centrifugation for 20 min at 14,000 g. Total 
protein lysate was precleared by Protein A beads for 1 h at 4°C. After centrifugation, 
supernatants were collected and incubated with 10 μg/ml EC8 for 2 h at 4°C, followed 
by incubation with Protein A beads overnight at 4°C. Immunoprecipitated proteins 
were run on SDS-polyacrylamide gel and transferred to polyvinyl difluoride 
membranes (Bio-Rad) for western blot analysis. The membrane was first blocked with 
5% non-fat milk in TBS/0.05% Tween 20 for 1 h at RT, incubated with rabbit 
polyclonal anti-ephrin-B2 antibody (Genscript) overnight at 4°C, and detected by 
horseradish peroxidase (HRP)-conjugated anti-rabbit antibody (Santa Cruz). ECL 
substrate (Pierce) was added to the membrane for 1 min at RT, which was exposed to 
X-ray film. 
4.3.9 Immunofluorescence microscopy for ephrin-B2 labeling and internalization by 
EC8 
Antibody labeling of ephrin-B2 was examined separately for cell-surface vs. 
internalized pool of ephrin-B2. 293T cells were grown on culture slides (BD 
Biosciences) to 50% confluence, to which 10 μg/ml of anti-ephrin-B2 antibody (EC8) 
was added. Cells were then incubated for 1 h at 37°C to allow antibody binding and 
endocytosis to occur. To detect EC8 bound to cell surface ephrin-B2, cells were fixed 
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with 4% formaldehyde in PBS for 20 min at RT and incubated with blocking solution 
(PBS with 5% goat serum) for 1 h, followed by incubation with fluorescein-
conjugated goat anti-human antibody (Invitrogen). Then to label internalized EC8, 
cells were permeabilized by 100% ice-cold methanol for 15 min on ice and incubated 
with blocking solution for 30 min at RT, followed by incubation with rhodamine-
conjugated anti-human antibody (Invitrogen). Cell surface vs. internalized antibodies 
were imaged by confocal microscope (Zeiss LSM 710). 
4.3.10 RT-PCR 
Total RNA was isolated from cultured cells with RNAeasy kit (Qiagen, Valencia, CA) 
according to the manufacturer’s protocol. 1 μg of total RNA was used for reverse 
transcription. The expression of GAPDH and ephrin-B2 was analyzed with the 
following primers: GAPDH: 5’-TTGAGGTCAATGAAGGGGTC/5’-
GAAGGTGAAGGTCGGAGTCA; Ephrin-B2: 5’-
GTGTGGAAGTACTGCTGGGGTGTT/5’-GGCACAGTTGAGGAGAGGGGTATT. 
4.3.11 Immunohistology of tumor xenograft 
10
6
 human colon cancer cells (COLO205 and HCT116; a kind gift from Dr. 
Michael King, Cornell University) were mixed in 0.1 ml 50% Matrigel (BD) and 
xenografted into nude mice (Jackson Laboratory). 14 days after injection when 
xenograft tumor size reached ~80 mm
3
, mice were euthanized and tumors were 
harvested. All animal experiments were conducted in compliance with the regulations 
defined by the Institutional Laboratory Animal Use and Care Committee of Cornell 
University (Protocol number 2009-0071). Harvested tumors were fixed in 4% 
paraformaldehyde overnight at RT, rinsed 3 times for 10 min at RT each in 30% 
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ethanol and then 50% ethanol, and then kept in 70% ethanol for several hours before 
embedding into a paraffin block for sectioning. In order to detect ephrin-B2 in the 
xenograft sections, tissues sections were deparaffinized in xylene 3 times for 4 min 
each at RT, rehydrated with graded ethanol, and then boiled in 10 mM citrate buffer 
(pH 6.0) for 10 min for antigen retrieval. The tissue sections were blocked with 
blocking solution (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM KCl, 0.3% Triton 
X-100, 1% goat serum) for 1 h at RT. Sections were incubated with the primary 
antibodies at 1 μg/ml overnight at 4°C, followed by incubation with secondary biotin-
conjugated goat anti-human antibody (Invitrogen). Endogenous peroxidase activity 
was quenched with 0.3% hydrogen peroxide in methanol for 10 minutes at RT. 
Peroxidase-conjugated streptavidin (Vectastain Elite ABC stain, Vector Laboratories) 
was added to the sections. After each incubation, sections were washed 3 times with 
TBS buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 2 mM KCl). Sections were then 
exposed to chromogen diaminobenzidine peroxidase substrate (Invitrogen) for 5 min, 
rinsed with water, and counterstained with Mayer’s hematoxylin, dehydrated in graded 
ethanol, and cleared in xylene. Slides were sealed in mounting medium and a 
coverslip. Negative control slides were treated same way except for the use of primary 
antibody. 
4.3.12 Immunohistology of human tissue array 
Human tumor tissue array (TP484, US Biomax) was deparaffinized and 
subjected to the same procedures as used for the immunostaining of tumor xenograft 
with EC8. Selected tumor tissue array slides were also used for immunofluorescence. 
After antigen retrieval and blocking, sections were incubated with primary antibodies 
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(EC8, mouse anti-human CD31 antibody (Invitrogen)) at 1 μg/ml overnight at 4°C. 
After washing, tissue sections were incubated with AF488-conjugated goat anti-mouse 
secondary antibody, biotin-conjugated goat anti-human antibody, and were 
subsequently labeled with rhodamine-conjugated streptavidin. After each incubation, 
sections were washed 3 times with TBS buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 2 
mM KCl). Immunofluorescent images were acquired with a fluorescent microscope 
(MetaMorph, Molecular Devices). 
4.3.13 Statistical analysis 
 Data were expressed as mean ± standard deviation of no smaller than 
triplicates, and analyzed for statistical significance using GraphPad Prism 5 (Graphpad 
Software). Student's t-test was used to compare the binding levels and to determine 
statistical significance (Figure 4.7a). 
 
4.4 Results 
4.4.1 Novel strategy of selecting antibodies against ephrin-B2 
We have previously shown that phage library of human antibody can be 
directly panned against antigens expressed in yeast (Figure 4.1a) with great efficiency 
in selection of high affinity monoclonal antibodies [21]. Surface expression of 
ectodomain of ephrin-B2 on yeast cell surface was first validated by antibody binding 
to Myc tag, which was placed at the C-terminal of ephrin-B2, as well as the binding of 
EphB4, a physiological receptor of ephrin-B2 (Figure 4.1). Subtractive panning of a 
phage library of human single chain fragment variable fragment (scFv), consisting of 
depletion against yeast expressing irrelevant antigens followed by positive selection  
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Figure 4.1: (a) A schematic diagram of phage panning against antigens expressed in 
yeast display system [34]. (b) Immunofluorescence flow cytometry measurements of 
protein and phage binding to yeast cells. Surface-displayed ephrin-B2 was detected 
by the binding of anti-Myc antibody (‘Myc’) as well as recombinant human EphB4-
Fc (‘EphB4’) to yeast cells (top panel). Progressive enrichment of phage clones 
from first three rounds of panning (denoted as ‘1 st’, ‘2 nd’ and ‘3 rd’) was detected 
by antibody against His tag (bottom panel). Histograms drawn in shaded area and 
solid lines indicate antibody binding to uninduced and induced yeast cells, 
respectively. The percentage of phage clones with positive binding is indicated. 
 
 
against ephrin-B2, resulted in a progressive increase in the percentage of phage clones 
bound to ephrin-B2 (Figure 4.1b). A total of 96 phage clones were selected from the 
third round pool and tested individually for binding to ephrin-B2 using flow 
cytometry. This resulted in 85 clones with positive binding (data not shown). Out of 
these 85 clones, 10 high-affinity phage clones were then sequenced, which identified 
three unique clones (designated as scFv-EA6, scFv-EB1 and scFv-EC8). Two best 
binders, scFv-EB1 and scFv-EC8 were chosen for production in bacteria and purified 
by nickel-nitrilotriacetic acid (Ni-NTA) column, followed by gel filtration 
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chromatography, which resulted in one distinct band around 35 kDa in SDS-PAGE 
(Figure 4.2a). Soluble scFv-EB1 and scFv-EC8 not only retained binding to yeast but 
also showed specific binding to ephrin-B2 expressed in mammalian cells, judging 
from the detection of basal expression in 293T and enhanced binding after transient 
expression of full-length ephrin-B2 in 293T (Figure 4.2b). scFv-EA6, scFv-EB1 and 
scFv-EC8 differed mainly within the complementarity determining regions (Figure 
4.3). Overall, scFv-EC8 showed highest binding affinity to ephrin-B2, and was chosen 
for further studies. 
 
Figure 4.2: (a) SDS-PAGE of scFv-EB1 (lane ‘1’) and scFv-EC8 (lane ‘2’). (b) 
Ephrin-B2 specific scFv binding to irrelevant yeast cells, yeast cells with expression 
of ephrin-B2 ectodomain, 293T cells, and 293T cells with transient expression of 
full-length ephrin-B2. Shown are the histograms of cells labeled with secondary 








































































































































































































Although scFv-EC8 was fully functional in binding to ephrin-B2, for future in 
vivo applications and many standard assays relying on the presence of 
immunoglobulin Fc region, scFv fusion to Fc was constructed in pcDNA3.1 and 
produced in mammalian cells (Figure 4.4). Under the reducing condition, the Fc fusion 
of scFV-EC8 migrated around 64 kDa, consistent with its nominal molecular weight. 
scFv-EC8 fusion to Fc (designated as EC8) was fully functional, retaining specific 
binding to ephrin-B2 expressed in yeast and in 293T (Figure 4.5) with higher level of 
binding compared with the levels seen with scFv-EC8 (Figure 4.2b). EC8 also 
exhibited comparable binding to murine ephrin-B2 expressed in transformed murine 
ovarian cells [22] (Figure 4.5), an anticipated result due to the fact that murine ephrin-
B2 differed by only three residues from human ephrin-B2 expressed in yeast (Thr-22 
to Gly-165) for phage screening. The binding affinity (equilibrium dissociation 
constant, KD) of EC8 to ephrin-B2 was around 3.2 nM, based on the fluorescence 
measurement using ephrin-B2-expressing 293T cells labeled in serial dilutions of EC8 
(Figure 4.6). The increase in affinity of EC8 to ephrin-B2 was due to the dimerization 
 
Figure 4.4: SDS-PAGE images of EC8 resolved under reducing (R) and non-




effect of scFv, commonly noted as bivalency or avidity effect.  
 
Figure 4.5: EC8 (solid line) binding to yeast cells, 293T with stable expression of 
ephrin-B2, and murine ovarian epithelium. The binding of isotype control is shown 
in shaded area. 
 
 
EC8 was conformation-specific against ephrin-B2, indicated from significant 
loss of binding to ephrin-B2 expressing yeast cells when ephrin-B2 was partially 
denatured by incubating cells either in guanidine hydrochloride at 6 M or in elevated 
temperature (Figure 4.7a). The reduction in the level of EC8 binding to ephrin-B2 was 
not due to a change in surface expression as antibody binding to Myc tag was 
invariant. The property of EC8 to recognize conformation-specific epitope was also 
corroborated by its inability to stain ephrin-B2 in western blot (data not shown). We 
then tested if EC8 would specifically pull down ephrin-B2 from detergent-solubilized 
293T cell lysates. Conformation-specificity of monoclonal antibody (mAb) EC8 was 
also confirmed with the detection of one distinct band of ~45 kDa in size from the 
lysates only after precipitation with EC8, stained by polyclonal antibody against 
ephrin-B2 (Figure 4.7b). Due to high sequence homology among some members of 
ephrin family, polyclonal antibodies against ephrin-B2 often crossreact with other 
ephrins like ephrin-B1 and ephrin-A5, which share sequence identity at 43% and 41% 
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Figure 4.6: Flow cytometry measurements of EC8 binding to 293T cells are shown 
in filled squares. First order Langmuir adsorption model was used to fit the data to 
estimate equilibrium dissociation constant (KD). 
 
 
with ephrin-B2, respectively. While EphB2 showed comparable binding to all three 
ephrins tested, EC8 was found specific to ephrin-B2 with little binding to ephrin-B1 
and ephrin-A5 (Figure 4.8).  
 
Figure 4.7: (a) Conformation specificity of EC8 against eprhin-B2 was examined by 
flow cytometry with (‘+’) or without (‘-’) incubating cells either in 6 M guanidine 
hydrocholoride (‘GnHCl’) for 20 min or in elevated temperature at 80°C (‘Heat’) for 
10 min. (b) Western blot image of immunoprecipitated ephrin-B2 from 293T cells 






Figure 4.8: Flow cytometry measurements of EC8 binding to ephrin-B1 and ephrin-




4.4.3 mAb EC8 blocked ephrin-B2 interaction with EphB4 and was internalized by 
ephrin-B2 ligation 
 After confirming specific binding of EC8 to ephrin-B2, we examined if EC8 
was able to block ephrin-B2 interaction with its cognate receptor, EphB4. This would 
potentially be useful in blocking bidirectional signals triggered by ephrin-B2 and 
EphB4 interaction, which is important for normal physiology as well as in disease 
progression. In comparison to human immunoglobulin G (IgG) as isotype control, 
increasing concentration of EC8 added to yeast cells expressing eprhin-B2 led to a 
gradual decrease in the binding of EphB4 (used at 100 nM) to ephrin-B2, close to 
complete inhibition seen at 250 nM of EC8 (Figure 4.9). We detected the distribution 
of EC8 in 293T after labeling under fluorescence microscope, and observed that 
ephrin-B2 ligation by EC8 triggered cells to internalize the antibody. In order to 
differentiate surface-bound vs. intracellular pool of EC8, confocal microscopy was 
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used to image cells prior to and after membrane permeabilization, which visualized 
distinct intracellular staining of EC8 (Figure 4.10).  
 
Figure 4.9: Competition assay. Relative binding of EphB4 (100 nM) to yeast cells 
expressing ephrin-B2, preincubated with varying concentrations of EC8, was 
measured by flow cytometry. Affinity purified human IgG was included as isotype 
control. n = 3 independent measurements. 
 
 
4.4.4 EC8 detection of ephrin-B2 expression in tumor tissues and tumor-associated 
vasculature 
Upregulation of ephrin-B2/EphB4 has been observed in many tumors, 
including ovary, colon, breast, and glioma, with a strong correlation with poor 
prognosis [14-18, 23-24]. With two widely used colon cancer cell lines, COLO205 
and HCT116, we found upregulation of ephrin-B2 by flow cytometry using EC8 
(Figure 4.11a). Chinese hamster ovarian (CHO) cells with no ephrin-B2 expression  
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Figure 4.10: Confocal microscopic images of surface-bound EC8 and internalized 
ones before and after membrane permeabilization of 293T cells. Scale bar = 10 m. 
 
 
were included as a negative control. The relative levels of eprhin-B2 between 
different cell lines were further confirmed by RT-PCR, with 293T cells stably 
expressing ephrin-B2 as a positive control (Figure 4.11b). Since not all conformation- 
 
Figure 4.11: (a) Flow cytometry measurements of EC8 binding to COLO205 and 
HCT116 cells (solid line) in comparison to the isotype control (shaded area). CHO 
cells with no ephrin-B2 expression were also included for comparison. (b) RT-PCR 




specific antibodies are compatible with immunohistology after a standard procedure 
for tissue fixation, we examined if EC8 can be used to probe eprhin-B2 expression in 
the tissue. When colon tumor tissues were immunostained after tumor growth in mice 
and harvest, EC8 not only delineated human tumor xenograft with high ephrin-B2 
expression, but also identified the vasculature within the tumor due to the cross-
reactivity of EC8 with both human and murine ephrin-B2 (Figure 4.12). EC8 staining 
of ephrin-B2 clearly differentiated tumor cells (marked with arrowhead) from the 
murine stroma (marked with arrow) (Figure 4.12). 
 
Figure 4.12: Immunostaining of ephrin-B2 on human colon cancer xenografted in 
mice. Control denotes immunostaining without EC8 as a primary antibody. Tumor 
and stromal cells were indicated with arrowhead and arrow, respectively. Circle 
indicates murine endothelium stained with EC8. Scale bar = 20 m. 
 
 
4.4.5 EC8 detection of the upregulation of ephrin-B2 in diverse human tumors of 
epithelial origin 
We further examined if EC8 could be applied to detect ephrin-B2 expression 
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in other types of tumor directly collected from human patients. Among several 
epithelium-originated cancers, ranging from ovarian, lung, prostate, breast to colon, 
high level expression of ephrin-B2 was all found by immunostaining (Figure 4.13a & 
4.13b). In comparison to normal tissues or tumor stroma showing no or only baseline 
ephrin-B2 staining, malignant tumor cells characterized by their irregular cell shape 
(e.g. colon and lung) and aberrantly enlarged (e.g. colon, lung and prostate) or dense 
(e.g. breast) nucleoli had distinctively higher ephrin-B2 staining. Dual staining on 
human colon cancer sample with both anti-CD31 antibody and EC8 revealed some of 
the vasculatures that were co-stained, indicative of EC8 detecting tumor-associated 
vasculature (Figure 4.13c). 
 
4.5 Discussion 
Ephrin-B2 is preferentially expressed in arterial endothelium and smooth 
muscle cells, as well as neovasculature within the tumor. Expression of ephrin-B2 is 
modulated by VEGF, smooth muscle cell contact, and stress [25-27]. Ephrin-B2 has 
also shown to be upregulated in many cancers, including colon [15], uterine [16], 
ovarian [17] and esophageal cancers [18]. Despite the importance of the role of 
ephrin-B2 in physiology and disease, up until now monoclonal antibody specific to 
ephrin-B2 has not been widely available. This may be attributed to the fact that human 
ephrin-B2 is highly homologous to those of other mammals including rodents, 
presenting a challenge to isolating high affinity antibody from immunization and 
hybridoma technique. Limited in vivo alternatives for making antibodies against 































































































































































































































































































































































































































































































20], have been reported, yet the concerns remain on the multi-specificity and low-
affinity of auto-antibodies [20].  
Here we report the isolation of monoclonal antibody against ephrin-B2, which 
was selected from a phage library of human single chain antibody. Rather than 
panning phage clones against soluble antigens, we used yeast cells expressing antigens 
to pull down reactive phage clones, which was found to be highly efficient in rapidly 
enriching specific phage library. Given the library diversity (10
8





 per each round of our screening strategy [21], we were able to 
observe specific phage clones reactive to ephrin-B2 as early as after two rounds of 
sorting. As antibody selection is based on monomeric interaction between antigen-
antibody, after conversion into a dimer by fusion to IgG Fc, the affinity (KD = 3.2 nM) 
of ephrin-B2 antibody (EC8) was comparable to those of high affinity monoclonal 
antibodies produced from hybridoma. Compared to many polyclonal antibodies 
generated from peptide fragments by immunization, EC8 selected against ephrin-B2 
displayed in native conformation on yeast surface was found to be conformation-
specific and discriminate ephrin-B2 from other ephrins with high homology.  
Antibodies against EphB4 were found to inhibit tumor growth and 
angiogenesis, some of which are being investigated for anti-cancer therapy in 
preclinical studies [9-10]. Eph receptor antibodies that were conjugated to small 
molecule drugs caused internalization of drugs and inhibition of tumor growth in vivo 
[28-19]. Soluble extracellular domain of EphB4 targeting ephrin-B2 has been used in 
inhibiting angiogenesis and tumor growth in vivo [8]. We have found that mAb EC8 
potently antagonized ephrin-B2 binding to EphB4, which would block forward and 
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reverse signaling by EphB4 and ephrin-B2 interaction. Similar to the observation of 
EphB4 upregulation in some tumors, when human tissue array was probed with mAb 
EC8, ephrin-B2 was found to be also overexpressed in tumors in lung, breast, ovary, 
colon, and prostate over respective normal tissue. Consistent with the previous 
observation of ephrin-B2 expression in tumor-associated vasculature, EC8 delineated 
ephrin-B2 expression in newly formed vessels within the tumor. Upregulation of 
ephrin-B2 was also found in colorectal cancer cell lines, COLO205 and HT108 both in 
cell culture and as a tumor xenograft in mice. Notably, due to the cross-reactive nature 
of antibody with murine ephrin-B2, mAb EC8 also identified tumor-associated 
vasculature, simultaneously detecting ephrin-B2 in human tumor as well as ephrin-B2 
in murine host.   
Neovasculatures in adults sprouting from arterial vessels and capillaries, 
whether caused by VEGF-signaling, tissue injury, or tumor growth, were found to 
express ephrin-B2. It is unknown how ephrin-B2 upregulation in some of the tumors 
of epithelium origin would perturb the balance between ephrin-B2 and Eph4 expressed 
in arterial and venous vessels, respectively, and contribute to the tumor growth and 
metastasis. Given the observation that overexpression of ephrin-B2 in some tumors is 
correlated with poor prognosis [1, 16], it will be an interesting question if the role of 
ephrin-B2 together with EphB receptors in some tumor is associated with the 
promotion of the vasculature growth and the adenoma-carcinoma transition, 
facilitating tumor metastasis. We propose that high affinity and antagonist antibodies 
such as EC8 would provide a valuable tool for examining the role of ephrin-B2 
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CONCLUSIONS AND FUTURE DIRECTIONS 
  
5.1 Summary  
In this study, we first present a physiology-inspired design of magnetite 
nanoparticles compatible with molecular detection by both optical imaging and MRI. 
Generally, nanoparticles will experience a hydrodynamic force induced by the blood 
flow in vivo, requiring simultaneous molecular interactions with sufficient adhesion 
strength with the cells for nanoparticles to remain on the cell surface. Therein the 
design of nanoparticles with tunable affinity and avidity of physiological interactions 
would be critical to their selectivity and efficiency of targeting. Through a surface 
coating of activating mutant of LFA-1 integrin, our SPIO nanomicelle mimics an 
inflamed leukocyte in its ability to recognize inflamed endothelium expressing a high 
level of ICAM-1. Despite the fact that ICAM-1 is basally expressed in many different 
types of cells including endothelium and immune cells, we observed specific 
accumulation of systemically-delivered nanoparticles into several inflammatory 
microenvironments, such as vasculature within the tumor and the invasive tumor front 
where tumor growth and angiogenesis were active, as well as the subcutaneous space 
where acute inflammation was induced by LPS, while their localization elsewhere was 
much lower as indicated by optical imaging.  
With developments in quantitative MRI techniques, this study also explores a 
clinically adaptable method for organ-level mapping of inflammation by quantifying 
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the susceptibility of leukocyte-mimetic nanoparticles (LMN). We examined 
quantitative susceptibility mapping (QSM) in the context of sepsis diagnosis and 
demonstrated the potential use of LMN as a bimodal diagnostic agent for the early 
detection of sepsis or systemic inflammatory response. In treating mice with LMN, we 
were able to readily differentiate between mice, either pre-treated with systemic LPS 
or left untreated, by quantitatively measuring nanoparticle localization in various 
abdominal organs in each of the subjects. This differential effect is most apparent 
when measuring nanoparticle localization in the liver; a temporal mapping of 
nanoparticle distribution through MRI QSM demonstrated twice the amount of LMN 
localized into the livers of sepsis-induced mice compared to that of non-septic 
subjects, or of those treated with ICAM-1 independent nanoparticles. The observed 
differences by QSM were corroborated qualitatively by near-IR optometry and 
quantitatively by radioactivity measurement. Histological stating of the tissue sections 
of liver also revealed a larger degree of nanoparticle accumulation in LPS-treated 
LMN cases, with specific iron staining observed in both endothelial cells and Kupffer 
cells, while greater amount of LMN localized into Kupffer cells. 
 
5.2 LMN as a biomimetic: potential caveats and improvements 
 Biocompatibility is the priority concern of engineering nanoparticles, which 
determines the risk of exposure during animal studies and clinical trials. In the case of 
LMN, we chose magnetite, phospholipid/fatty acid, and engineered human protein as 
the main building blocks. Magnetite is the major component of Feridex, an 
intravenously injectable colloidal superparamagnetic iron oxide (SPIO) associated 
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with dextran and FDA approved contrast agent for MRI [1]. Known to be taken up by 
the reticuloendothelial system (RES), iron oxide enters the usual iron metabolism 
cycle after administration. Lipid complexes composed of phospholipids and fatty acids 
have also been widely applied in drug delivery. For example, Doxil is the 
chemotherapy drug doxorubicin (DOX) encapsulated in a closed lipid sphere, and is 
used primarily for the treatment of ovarian cancer or AIDS-related Kaposi's sarcoma 
[2]. Even though no obvious cytotoxicity is currently associated with the materials of 
LMN, including iron oxide, lipid and protein; potential immunogenicity of 
nanoparticles could exist when a large density of proteins are laid out in a regular 
manner on the particle surface, which are highly similar to other naturally occurring 
immunogens such as viruses. Consistent with present documentation on the RES 
uptake of iron oxide nanoparticles, we have observed distinguishable retention of 
SPIO in normal mouse liver, probably due to the phagocytic activity of resident 
immune cells (Figure 3.7 & 3.8).  Is this part of the normal excretion pathway of 
magnetite nanoparticles or a sign of immunogenicity? To scrutinize these possibilities, 
we examined the mRNA level of two inflammation markers (ICAM-1 and VCAM-1), 
after exposing HMEC-1 cells (human microvascular endothelial cell) to nanoparticles 
with or without surface protein coating. As one important sentinel for immune system, 
if the endothelial cell senses nanoparticles as ‘alien’ and sets off the alarm of 
inflammation, subsequent immune response to nanoparticles will subsequently follow. 
Quantitative PCR showed no noticeable upregulation of ICAM-1 and VCAM-1 in 
HMEC-1 cells after incubation with nanoparticles, unlike LPS treatments that trigger 
significant inflammatory signals (Figure 5.1). This observation indicates that 
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nonspecific interaction between nanoparticles and endothelial cells, or baseline 
binding of LMN to quiescent endothelium, will not cause the activation of immune 
system. Therefore the overall design of LMN is largely benign to biological systems 
based on our current knowledge. 
 
Figure 5.1: Quantitative PCR of HMEC-1 cells on the mRNA level of inflammatory 
markers (ICAM-1 & VCAM-1), in comparison to housekeeping gene PECAM-1. 
Cells were treated with 50 μg/mL nanoparticles (coated with no protein: mSPIO; 
coated with inactive I domain mutant D137A: NTN; coated with active I domain 
mutant F265S/F292G: LMN.) or 10 μg/mL LPS at 37°C for 3 h. Inset shows the 
result when cells were incubated with 20 μg/mL of I domain. Refer to Table 5.1 for 
specific versions of nanoparticles. 
 
   
In addition to biocompatibility, in vivo stability is also an important factor that 
should be taken into account for nanomicelle-based biomimetics. Natural 
biomembranes are primarily composed of lipids, proteins and a relatively small 
amount (less than 10%) of carbohydrates which are covalently bound to either lipids 
or proteins [3]. A variety of molecular motions exist within the membrane matrix. 
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Lipids undergo rotation and segmental motions, kink formation, and traverse from one 
interface to the other (flip-flop). Because of this, phospholipid membranes are 
mechanically weak and unstable by nature. In most artificially prepared phospholipid 
complexes, fewer types of phospholipids and non-covalent interactions are present, 
making it even more difficult to maintain their stability for practical applications in 
vivo [4]. In one of our studies, subjecting LMN to vigorous shaking at 37°C overnight 
resulted in significant increase of its hydrodynamic size, indicating our current design 
nanomicelle is prone to aggregation under shear force (Table 5.1). It is not a surprising 
discovery, as great amount of effort has been previously put into obtaining a stable 
biomembrane model for artificial cells. These attempts include synthesizing 
phospholipid analogues, particularly polymerizable ones [5]. Among all polymerizable 
lipids, lipid diacetylene [6] caught our particular attention because it can easily initiate 
polymerization under the exposure to ultraviolet light (254 nm), and this reaction can 
be visually monitored by a highly colored product [7] (Figure 5.2a). Replacing DPPE-
PEG with an amphiphilic diacetylene 10,12-pentacosadiynoic acid (PCDA) and 
PCDA-PEG, we obtained a polymerized version of LMN, which we termed as LMN 
v2.0, in order to differentiate it from the original design, which we termed as LMN 
v1.0 (Table 5.1). Due to the covalent crosslink between fatty acid molecules, the 
micelle structure of LMN v2.0 can be well maintained in the presence of chloroform, a 
strong organic solvent, unlike LMN v1.0, which released its iron content into 
chloroform soon after incubation, leaving lipids on the interface of water and 
chloroform (Figure 5.2b).  Polymerizing the micelle layer also improved the stability 
of v2.0 against shear stress as its size did not alter after overnight shaking (Table 5.1).  
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Table 5.1: Summary of LMN evolution of their property changes 
 
















































Nanoparticle sizes were measured by DLS before and after overnight shaking in PBS at 37°C. 
b 
Nanoparticles coating with fluorescent proteins were dialyzed in 50% normal goat serum using 50 
kDa MWCO dialysis tubing at RT. Percentage of proteins retained on nanoparticles was quantified 





Figure 5.2: (a) Exposure of PCDA vesicle to a UV lamp resulted in the relaxation of 
photoproduct which was initially blue to a purple polymer. (b) Exposure of LMN 




Another caveat of our nanoparticle may be the circulation half-life of His-
tagged protein coupled with NTA lipid in vivo. Though Ni-NTA-6×His complex 
offers outstanding convenience in terms of ligand conjugation, Ni-NTA also interacts 
with some plasma proteins, such as histidine-rich ones [8], resulting in the fast 
dissociation of ligand proteins off nanoparticles in serum environment (Table 5.1). 
This is consistent with our previous observation of a high fluorescence signal 
appearing in the bladder at very early time points (less than 1 h) post nanoparticle 
injection (Figure 2.16a). Intact LMN has a hydrodynamic diameter of 60 nm, much 
bigger than the threshold of renal excretion (5.5 nm). However free intergrin I domain 
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is about 5 nm in diameter, and can be rapidly excreted into urine once dissociated. In 
order to ameliorate this situation, we further replaced DOGS-NTA in LMN v2.0 with 
23:2 Diyne-PE, to whose primary amine group I domain can be covalently linked 
through N terminal cysteine. We termed this new version LMN v3.0, and found it 
indeed retains more proteins on the surface in the presence of serum (Table 5.1).  
 
5.3 Application of LMN in cancer diagnosis: implications and challenges 
It is now well accepted that inflammation actively participates in cancer 
development [9-11]. As a matter of fact, tumor-promoting inflammation within 
neoplasia is one critical characteristic enabling the acquisition of canonical cancer 
hallmarks [12]. There is a plethora of signs showing endothelial cells directly regulate 
tumor growth through a proinflammatory network consisting of immune cells [11], 
‘angiocrine factors’ (FGF2 [13], PDGFβ [14], TGFβ [15], VEGFA [16], LAMA4 
[17], G-CSF [18], NO [19], etc), adhesion molecules (ICAM-1 [20], VCAM-1 [20], E-
selectin [20], P-selectin [21], etc), cytokines (TNF [13], IL-1 [14], IL-6 [14], IL-17 
[22], etc) and chemokines (IL-8 [14], MCP-1 [23], SDF1 [24], etc). For example, it 
has been postulated that the binding between ICAM-1 on endothelial cells with apical 
MUC-1 on circulating tumor cells may represent the first crucial step in metastasis 
[25]. This binding is known to induce intracellular calcium signaling that instigates 
two important effects: the release of chemoattractant cytokines for leukocytes, and 
upregulation of tumor expression of ICAM-1 by the adherent tumor cells [26]. 
Macrophages then aggregate around the now-adherent tumor cells via formation of 
tight bonds with the tumor-expressed ICAM-1 and this specific binding elicits the 
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release of macrophage-derived cytokines and chemokines that attract 
polymorphonuclear leukocytes  (PMNs) [27]. Further, PMN-binding to ICAM-1 on 
the surface of the tumor cells causes degranulation of the PMNs, [28] releasing 
proteases that breakdown the endothelial barrier to promote extraluminal migration of 
tumor cells, subsequent binding of tumor cells to matrix proteins (including ICAM-1), 
and establishment of metastases [29]. Consistent with such scenarios, several 
examples of neoplasms expressing high levels of ICAM-1 and their potential for 
invasion/metastasis have been recognized [20, 30-32]. In this study, we also observed 
ICAM-1 induction in tumor-associated vasculature, where tumor growth and 
angiogenesis are active (Figure 2.9). All of this knowledge suggests neoplastic 
vascular microenvironments undergoing active inflammatory remodeling could be an 
alternative strategy for tumor targeting [33].  
In accordance with current literature on the inflammatory niche of the tumor 
microenvironment, our preliminary data demonstrated that intravenously injected 
LMN specifically localized into the vasculature associated with the tumor progression, 
independent of tumor surface antigen (Figure 2.15). Even though the tumor is known 
to have the enhanced permeability and retention (EPR) effect [34] in terms of the 
accumulation of macromolecules, due to a combination of the increased permeability 
of tumor blood vessels caused by their abnormal structure and the decreased rate of 
clearance caused by the lack of functional lymphatic vessels in the tumor; a number of 
implications woven into the architecture of tumor may have perplexed effective 
penetration of LMN as well as its similars throughout the overall mass of the tumor, as 
the majority of LMN is distributed at the peripheral region of the tumor xenografts 
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(Figure 2.15). Three-dimensional penetration studies in solid tumor have shown that 
increasing the molecular weight of the macromolecule significantly reduces its tumor 
vascular permeability [35]. With passive distribution, 2-MDa dextrans could only 
penetrate 5 μm into tumor tissue from the vessel wall (molecular weight of LMN is 
about 5 MDa) [35]. On the other hand, the vascular hyperpermeability and the lack of 
functional lymphatic vessels inside tumors also cause interstitial hypertension [36]. 
While this uniformly elevated interstitial fluid pressure (iFP) reduces convective 
transport, the dense extracellular matrix hinders the diffusion of nanoparticles [37]. In 
the case of tumor xenografts, permeable vasculature is more abundant at the invasive 
front and scarcer in the necrotic core where high iFP builds up (Figure 2.10), leading 
to heterogeneous accumulation of nanoparticles as seen in our studies (Figure 2.15). In 
order to overcome these barriers and render LMN an effective targeting agent for 
tumors, pertinent considerations need to be combined into our future design of the 
targeting strategy. 
While it could be difficult to further decrease the size of LMN for higher 
vascular permeability due to the minimal amount of payload (SPIO) required for 
sensitive detection, nanoparticles with positive surface charge exhibit higher 
permeability and preferentially target tumor vessels compared with their negative or 
neutral counterparts [38-41]. However cautions should be paid to cationic 
nanoparticles at the same time, because it has been shown that hemolytic tendency 
increases in proportion to the positive surface charge [42] and cationic particles are 
more attractive to phagocytes than neutral particles of the same size [43].  
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Regarding the characteristic of iFP that greatly hinders the transport of 
nanoparticles across vessel walls and compromises the benefits of the EPR effect, 
auxiliary stratagems should be taken to normalize the tumor vasculature and tumor 
interstitial matrix, so that the efficiency of the vascular network increases, allowing 
nanoparticles to penetrate faster and deeper inside the tumor [44]. The balance 
between proangiogenic and antiangiogenic factors is crucial for maintaining the 
normal architecture of the vascular network in tissue. In tumors, proangiogenic 
molecules (for example, VEGF, FGF and PDGF) are usually overexpressed, which 
tips the balance towards the proangiogenic side and causes the formation of chaotic 
blood vessels. Therefore, judicious application of antiangiogenic agents can restore the 
balance and revert the vasculature to a more ‘normal’ phenotype [45-46]. To improve 
particle penetration through the tumor interstitial matrix, there have been some 
attempts (for example, collagenase [47] and matrix metalloproteinase (MMP) [48]) to 
degrade these components and thus increase the accessible volume of tissue. Besides 
that, the hormone relaxin [49-50], which modifies the structure of collagen fibers, as 
well as tumor penetrating peptide [51] also showed potential to improve the interstitial 
transport of particles inside tumor. Coadministration of such agents with LMN may 
help ameliorate tumor structure and accessibility, and thereby increase the targeting 
efficiency.   
 
5.4 Application of LMN in assessing cerebral inflammation and ischemic 
reperfusion injury post stroke 
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 As the number one cause for mortality worldwide, cardiovascular disease leads 
to a fatal outcome mainly through stroke. Thrombolysis can be an effective treatment 
for acute ischemic stroke, but the resulting reperfusion of the ischemic brain comes 
with a price - destruction of the microvasculature and extension of infarct volume 
often occur thereafter [52].  
Much evidence suggests that inflammation plays an important role in the 
pathobiology of ischemic stroke [53-54]. An inflammatory response following the 
restoration of circulation largely contributes to the ischemic reperfusion injury [55]: 
the recruitment of leukocytes to the ischemic area leads to the reocclusion of blood 
vessels, posing a “no-reflow” phenomenon [56] after clot lysis; the same leukocytes 
also produce proteolytic enzymes, oxygen free radicals and other inflammatory 
effectors which directly cause endothelial injury in addition to neuronal damage [57-
58]. Animal data supporting this contention comes from three lines: notable 
correlation exists between the time course of leukocyte accumulation and the 
expansion of brain damage [59-61]; neutropenia ameliorates reperfusion injury [62]; 
treatments preventing leukocyte adhesion, including neutralization and knockout of 
ICAM-1, have a cerebral protective effect [63-69]. Even though the combined use of 
anti-ICAM-1 antibodies with tissue plasminogen activator (tPA) has been shown in 
many rodent experiments to improve the neurological outcome (suggesting anti-
inflammation therapy can extend the therapeutic window for thrombolysis) [70], most 
biologics for adhesion blockade have been designated as negative in clinical trials 
[71]. One essential reason for this is that the current regime for applying thrombolysis 
is within 3 hours of symptom onset [72], while interindividual variability of 
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hospitalization time and the upregulation of adhesion molecules can be large among 
stroke patients, compared to experiment animals with guaranteed early reperfusion and 
close genetic background; however at this time there are no useful implications for 
measuring these molecules in clinical practice and the limited knowledge we have 
comes sparsely from postmortem examination. Therefore in vivo platforms allowing 
quantitative examination of the cerebral pattern of ICAM-1, one of the most NF-kB 
responsive adhesion molecules, would be significant for post-stroke treatment.  
 
Figure 5.3: Two-photon laser scanning microscopy (TPLSM) imaging of ICAM-1 
(FITC-labeled mAb) upregulation in mouse cortical vessels (Texas-red dextran) 
under systemic LPS-treatment (right panel), which mimics artificially induced acute 
neuroinflammation. Animal treated with the same volume of PBS (left) was shown 
as a negative control. 
 
 
As one crucial ligand for leukocyte adhesion to damaged endothelial tissue, 
ICAM-1 is upregulated soon after the onset of ischemic stroke [73] (Figure 5.3). LMN 
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is designed to mimic the behavior of leukocytes in their ability to interact with the 
high density of ICAM-1 on the inflamed endothelium and macrophages, and is 
potentially a good imaging contrast agent for both fluorescence imaging and MRI. 
With our recently developed MRI technique, QSM, the amount of LMN distribution 
can be measured with sufficient accuracy to allow comprehensive evaluation of 
inflammation progression and/or regression, thereby enabling real-time assessment of 
neuroinflammation post stroke. Based on our current observation of LMN in sensing 
local and systemic acute inflammation, we anticipate a future application of LMN in 
providing a spatial-temporal map of post-ictus neuroinflammation with the assistance 
of molecular imaging methodologies, which has not been possible in almost all other 
imaging studies to date.  
 
5.5 Developing theranostic LMN 
Theranostic nanomedicine [74] is emerging as a promising paradigm for 
therapeutics. One convenience in constructing such function-integrated agents is that 
many nanoplatforms are already themselves imaging agents. Besides, their well-
developed surface chemistry makes it easy to load pharmaceutics. In such scenario, 
magnetite nanoparticles, an MRI contrast agent and hyperthermia agent, becomes also 
an intriguing drug carrier. Furthermore, the combined therapy of high temperature and 
pharmaceutics facilitated by theranostic iron oxide nanoparticles can give rise to a 
synergistic therapeutic effect. In some recent studies, Jain et al. [75] loaded 
doxorubicin (DOX) and paclitaxel (PTX), along with oleic acid coated magnetite 
nanoparticles, into pluronic-stabilized nanoparticles. Similarly, Yu et al. [76] loaded 
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DOX into anti-biofouling polymer coated iron oxide nanoparticles. When applied in a 
Lewis lung carcinoma xenograft model, such DOX loaded nanoconjugates showed 
better pharmacokinetics and therapeutic effects than DOX alone, presumably due to 
the anti-biofouling feature of the particles.   
 
Figure 5.4: Absorbance spectrum of LMN loaded with (right) and without (left) 
celastrol. Wavelength where celastrol has maximal absorption is marked in black.  
 
 
In the case of LMN, small molecule anti-inflammation drugs (e.g., celastrol) 
can be co-loaded with SPIO into the matrix of the nanomicelle during fabrication, 
rendering it a theranostic agent for inflammatory diseases. As a potent antioxidant and 
anti-inflammatory drug [77-78], celastrol is poorly water-soluble by itself, and thus 
exists as aggregates in aqueous solutions. After mixing it with SPIO and lipids in 
organic solvent, desiccation and rehydration, celastrol will disperse into the 
hydrophobic space between lipid tails which then protects it from aggregation. Our 
preliminary data showed that purified LMN loaded with celastrol produced a 
distinctive absorbance peak at 430 nm, the same wavelength celastrol has maximal 
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absorption (Figure 5.4). Following the validation of successful drug encapsulation, we 
estimated the drug loading capacity of LMN to be about 1 μg celastrol per 100 μg 
SPIO. Using HeLa cell culture, we further confirmed the dose-dependent cytotoxicity 
of LMN-celastrol (Figure 5.5), supporting our future plan in applying for 
inflammation-guided cancer therapy.  
 
Figure 5.5: Crystal violet staining of HeLa cells after incubation with different 
amounts of LMN-celastrol for 24 h at 37°C. Dead cells would no longer attach to the 
surface of flask, thus not appear in the field of view. The concentration of LMN and 
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YEAST SURFACE TWO-HYBRID FOR QUANTITATIVE IN VIVO DETECTION 
OF PROTEIN-PROTEIN INTERACTIONS VIA THE SECRETORY PATHWAY 





A quantitative in vivo method for detecting protein-protein interactions will 
enhance our understanding of protein interaction networks and facilitate affinity 
maturation as well as designing new interaction pairs. We have developed a novel 
platform, dubbed "yeast surface two-hybrid (YS2H)," to enable a quantitative 
measurement of pairwise protein interactions via the secretory pathway by expressing 
one protein (bait) anchored to the cell wall and the other (prey) in soluble form. In 
YS2H, the prey is released either outside of the cells or remains on the cell surface by 
virtue of its binding to the bait. The strength of their interaction is measured by 
antibody binding to the epitope tag appended to the prey or direct readout of split 
green fluorescence protein (GFP) complementation. When two alpha-helices forming 
coiled coils were expressed as a pair of prey and bait, the amount of the prey in 
complex with the bait progressively decreased as the affinity changes from 100 pM to 
10 microM. With GFP complementation assay, we were able to discriminate a 6-log 
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difference in binding affinities in the range of 100 pM to 100 microM. The affinity 
estimated from the level of antibody binding to fusion tags was in good agreement 
with that measured in solution using a surface plasmon resonance technique. In 
contrast, the level of GFP complementation linearly increased with the on-rate of 
coiled coil interactions, likely because of the irreversible nature of GFP reconstitution. 
Furthermore, we demonstrate the use of YS2H in exploring the nature of antigen 
recognition by antibodies and activation allostery in integrins and in isolating heavy 
chain-only antibodies against botulinum neurotoxin.  
 
A.2 Introduction 
A quantitative in vivo method for detecting protein-protein interactions will 
enhance our understanding of protein interaction networks and facilitate affinity 
maturation as well as designing new interaction pairs. We have developed a novel 
platform, dubbed “yeast surface two-hybrid (YS2H),” to enable a quantitative 
measurement of pairwise protein interactions via the secretory pathway by expressing 
one protein (bait) anchored to the cell wall and the other (prey) in soluble form. In 
YS2H, the prey is released either outside of the cells or remains on the cell surface by 
virtue of its binding to the bait. The strength of their interaction is measured by 
antibody binding to the epitope tag appended to the prey or direct readout of split 
green fluorescence protein (GFP) complementation. When two α-helices forming 
coiled coils were expressed as a pair of prey and bait, the amount of the prey in 
complex with the bait progressively decreased as the affinity changes from 100 pM to 
10 μM. With GFP complementation assay, we were able to discriminate a 6-log 
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difference in binding affinities in the range of 100 pM to 100 μM. The affinity 
estimated from the level of antibody binding to fusion tags was in good agreement 
with that measured in solution using a surface plasmon resonance technique. In 
contrast, the level of GFP complementation linearly increased with the on-rate of 
coiled coil interactions, likely because of the irreversible nature of GFP reconstitution. 
Furthermore, we demonstrate the use of YS2H in exploring the nature of antigen 
recognition by antibodies and activation allostery in integrins and in isolating heavy 
chain-only antibodies against botulinum neurotoxin.  
Protein-protein interactions are essential to virtually every cellular process, and 
their understanding is of great interest in basic science as well as in the development 
of effective therapeutics. Existing techniques to detect and screen pairs of interacting 
proteins in vivo include the yeast two-hybrid system [1] and protein-fragment 
complementation assay (PCA) [2-6], where the association of two interacting proteins 
either turns on a target gene that is necessary for cell survival or leads to the 
reconstitution of enzymes or green fluorescence protein (GFP) or its variants. The 
application of protein-protein interactions that are probed with yeast two-hybrid and 
PCA has been focused mainly on the interactions occurring in the nucleus or cytosol. 
To study interactions among secretory proteins and membrane-associated proteins, a 
variant of yeast two-hybrid has been developed for detecting protein-protein 
interactions occurring in the secretory pathway [7-8]. However, most existing methods 
are designed to map connectivity information for pairwise interactions and are not 
suitable for measuring the affinity between two interacting proteins, comparing 
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interaction strength of different pairs, or ranking multiple binders to the interaction 
“hub” according to their binding affinity.  
Quantitative estimation of protein-protein interactions in vivo will require the 
amount of the complex to be directly measured or the level of reconstituted reporters 
to be directly proportional to the strength of the interactions. To achieve quantitative 
analysis of protein interactions in eukaryotic expression system, we have designed a 
yeast surface two-hybrid (YS2H) system that can express a pair of proteins, one 
protein as a fusion to a yeast cell wall protein, agglutinin, and the other in a secretory 
form. When two proteins interact in this system, they associate in the secretory 
pathway, and the prey that would otherwise be released into the media is captured on 
the surface by the bait. We have devised two different schemes to quantitatively 
estimate the affinity of two interacting molecules: flow cytometric detection of 
antibody binding to the epitope tags fused to the prey and the bait, and the GFP 
readout from the complementation of split GFP fragments fused to the prey and the 
bait. They are induced under a bi-directional promoter to promote a synchronized and 
comparable level of expression.  
Herein we demonstrate the quantitative nature of YS2H in predicting the 
affinity between two interacting proteins, particularly in the range of 100 pM to 10 
μM. This feature allowed us to examine specific interactions between antigen and 
antibody, to identify hot spots of allosteric activation in integrins, and to isolate 
camelid heavy chain-only antibodies against botulinum neurotoxin as components of 
therapeutic agents to treat botulism [9]. With the incorporation of PCA technique into 
the YS2H, our system may be developed into an in vivo tool to measure the kinetics of 
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protein-protein interactions. Potential applications of YS2H include affinity 
maturation of antibodies, differentiation of weak to high affinity binders to the hub 
protein in interaction networks, and confirmation of hypothetical interacting pairs of 
proteins in a high throughput manner.  
 
A.3 Experimental procedures 
A.3.1 YS2H vector design 
Plasmid pCTCON was used as a backbone for constructing the YS2H vector 
(Figure A.1). A PCR fragment containing GAL10 promoter, AGA2, eGFP gene, 
FLAG tag, and terminator was inserted into the pCTCON by AgeI/KpnI sites. To 
express prey proteins as secretory forms, AGA2 sequence under the GAL1 promoter 
was removed by replacing an EcoRI/BamHI fragment with the fragment consisting of 
a signal sequence, either that of Aga2 or α-1 mating factor, and prey. The cDNA 
coding for the variable domains of AL-57 was obtained from the expression plasmid 
(a kind gift from Dr. Shimaoka at Harvard Medical School). The variable domains of 
TS1/22 were cloned from the hybridoma (ATCC). VH and VL cDNAs were 
connected with four repeats of a Gly-Gly-Gly-Gly-Ser linker sequence to produce 
scFv. 
A.3.2 Yeast transformation, magnetic affinity cell sorting, and library construction 
The plasmid encoding a specific pair of prey and bait proteins was introduced 
into yeast cells using a commercial reagent (Frozen-EZ Yeast Transformation II Kit, 
Zymo Research). Transformed yeast cells were grown in a solid medium plate for 48 
h. A mutagenesis library of LFA-1 I domain was constructed by electroporation of a 
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mixture of a MluI/NcoI linearized vector and error-prone PCR products of the I 
domain (Asn-129-Thr-318) into yeast, as described previously [10]. After 
transformation, the yeast libraries were grown in selective dextrose liquid medium at 
30°C with shaking for 24 h and induced in selective galactose media for 24–48 h at 
room temperature with shaking. To construct the variable domain of heavy chain from 
heavy chain-only antibody (VHH) yeast library, cDNA encoding VHH library was 
amplified by PCR using primers designed based on the primers used by Maass et al. 
[11]. VHH cDNA PCR product was first ligated into the YS2H vector using 
NheI/BamHI sites and then was transformed into XL1-Blue (Stratagene) by 
electroporation. The plasmids extracted from ∼5×106 colonies were transformed into 
EBY100 by a lithium acetate method [12]. A single colony of EBY100 from fresh 
plate was inoculated into 10 ml of YPDA medium and cultured at 30°C with shaking 
at 225 rpm for 16 h. The cells were then inoculated into 100 ml of YPDA at 0.5 OD600 
and cultured for another 4 h until A600 reaches 2. The cells were washed twice in water 
and resuspended in 10.8 ml of transformation mix buffer (7.2 ml of 50% polyethylene 
glycol, 1.1 ml of 1 M LiAc, 1.5 ml of 2 mg/ml single strand carrier DNA, and 150 μg 
of library plasmid in 1.0 ml water). The mixture was then incubated at 42 °C for 50 
min. After incubation, the cells were cultured into 100 ml of selective dextrose liquid 
medium for 24 h and induced in selective galactose medium for 24–48 h. Library 
construction by homologous recombination or the lithium acetate method produced a 
library size of 10
6–107. The libraries of LFA-1 I domain and VHH were sorted with 
anti-Myc antibody using magnetic affinity cell sorting as described previously [10]. 
A.3.3 Immunofluorescence flow cytometry 
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Antibodies used in this study were the anti-c-Myc antibody 9E10 (ATCC), 
anti-FLAG, and phycoerythrin-labeled goat polyclonal anti-murine antibodies (Santa 
Cruz Biotechnology, Santa Cruz, CA). To measure the surface expression of specific 
prey and bait proteins using flow cytometry, one to five colonies from solid medium 
plate were inoculated together to obtain averaged values. After induction, the cells 
were harvested, washed in 100 μl of the labeling buffer (phosphate-buffered saline 
with 0.5% bovine serum albumin), and then incubated with ligands at 10 μg/ml in 50 
μl of the labeling buffer for 20 min with shaking at 30°C. The cells were then washed 
and incubated with secondary antibodies at 5 μg/ml in 50 μl of the labeling buffer for 
20 min at 4°C. Finally, the cells were washed once in 100 μl and suspended in 100 μl 
of the labeling buffer for flow cytometry (FACScan, BD Biosciences). For detecting 
TS1/22 binding (Figure A.5b), goat polyclonal anti-murine antibody was used as a 
primary antibody. 
A.3.4 Protein expression 
The I domains were expressed in Escherichia coli BL21 DE3 (Invitrogen) as 
inclusion bodies and refolded and purified by an S75 size exclusion column connected 
to fast protein liquid chromatography (GE Healthcare) [10]. AL-57 as a single-chain 
format (scFv AL-57) was expressed using the protocol for I domain production, except 
that 3 mM cystamine and 6 mM cysteamine were added to the refolding buffer. Full-
length BoNT/A and BoNT/B-LC encoding DNA (amino acids 1–448 of A-LC and 1–
440 of B-LC) were synthesized employing codons optimal for expression in E. coli. 
A-LC and B-LC containing hexahistidine tags at both termini were produced using a 
pET14b vector. To express VHHs in soluble forms, we inserted VHH cDNA into the 
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pET20b expression vector (Novagen). Soluble VHH was expressed in E. coli BL21 
DE3, extracted by sonication, and purified using a nickel nitrilotriacetic acid column. 
Eluted VHHs were then injected into an S75 size exclusion column for further 
purification. 
A.3.5 SPR analysis 
A protein-coupled or a control mock-coupled CM5 sensor chip was prepared 
using an amine coupling kit (BIAcore, Piscataway, NJ), as described previously [10]. 
SPR was measured using a Biacore (BIA2000). I domains were injected over the chip 
in 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 mM MgCl2 at a flow rate of 10 μl/min 
at room temperature. VHHs were injected over the chip in 20 mM Tris-HCl, pH 8.0, 
150 mM NaCl at a flow rate of 10 μl/min at room temperature. The chip surface was 
regenerated by flowing 20 μl of 10 mM Tris-glycine, pH 1.5 buffer. 
 
A.4 Results 
A.4.1 The design of the YS2H 
YS2H is built on a yeast display system [13-14], which expresses, under the 
control of the GAL1 promoter, a protein of interest as a fusion to Aga2. Aga2 connects 
to the β-glucan linked Aga1 to form a cell wall protein called agglutinin. To extend 
this methodology to the expression of a pair of proteins, we have inserted into the 
yeast display vector, pCTCON [13], an additional expression cassette under the 
GAL10 promoter [15]. We observed comparable expression of eGFP by GAL1 and 
GAL10 promoters using two different plasmids that were constructed to express eGFP 
under either GAL1 or GAL10 promoters (data not shown). The final YS2H vector 
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(Figure A.1a) was designed to express the bait protein under the GAL10 promoter as a 
fusion to Aga2 and the prey protein under the GAL1 promoter without Aga2 fusion.  
 
Figure A.1: (a) A map of the YS2H vector is drawn with restriction enzyme sites 
and genes labeled. The bait protein is expressed as a fusion to Aga2 on cell surface, 
whereas the prey protein is expressed as a secretory form. (b) Schematic diagram of 
the expression cassette and protein-protein interactions (acid base coiled coils) via 
the secretory pathway is depicted. The prey bound to the bait is detected by antibody 
binding to the Myc tag. FLAG (DYKDDDDK) and Myc (EQKLISEEDL) epitope 
tags are fused to the C-terminal of the bait and prey proteins, respectively, and are 
used to measure the surface expression of the bait and the amount of the prey that is 
bound to the bait. 
 
 
The signal sequence used is either that of Aga2 or the α-1 mating factor [16]. The 
expression level of prey proteins with α-1 mating factor was comparable with those 
containing Aga2 signal sequence (data not shown). FLAG and Myc tags are fused to 
the C-terminal of the bait and prey proteins, respectively, and are used to examine the 
surface expression of the bait and the amount of the prey that is bound to the bait 
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(Figure A.1b). To incorporate the PCA technique into the YS2H system, we inserted 
the sequence encoding enhanced eGFP fragments [3] downstream of the bait (NeGFP 
contains residues Val-2 to Ala-155) and the prey (CeGFP with Asp-156 to Lys-239) to 
monitor their interaction by GFP readout (Figure A.2a). The deletion of the secretory 
signal sequence of the prey and bait proteins causes this pair to express in the cytosol 
(Figure A.2b), which can be used to compare protein-protein interactions occurring in 
the secretory pathway versus cytosol. 
 
Figure A.2: (a) Schematic diagram of the expression cassette and protein-protein 
interactions (acid base coiled coils) via the secretory pathway is depicted. The prey 
bound to the bait is detected by direct GFP readout from split GFP 
complementation. (b) The deletion of signal sequence for the prey and bait proteins 
leads to their expression in the cytosol.  
 
 
A.4.2 The validation of the yeast surface two-hybrid system using coiled coil 
interaction 
To validate that antibody binding to the Myc tag or GFP readout correlates 
with the strength of molecular interactions in YS2H, we expressed five pairs of acid 
(En) and base (Kn) α-helices of varying heptad repeats (n) that associate into coiled 
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coils (Figure A.3). These coiled coils have been designed de novo to have affinities 
(KD) in the range of 100 pM (E5/K5) to 100 μM (E3/K3) with higher affinity for 
longer helices through hydrophobic interactions at the interface and electrostatic 
attraction between the oppositely charged residues from each helix [17]. Myc 
expression (mean fluorescence intensity (MFI), measured by antibody binding to Myc 
tag) exhibited a strong correlation with the interaction affinity within the range of 100 
pM to 10 μM KD for E5-K5 to E5-K3 (Figure A.3b & A.4a). With GFP 
complementation, this correlation extended beyond 10 μM KD, and the difference 
between E5-K3 and E3-K3, corresponding to the affinity range of 10 μM to 100 μM, 
was clearly discernible (Figure A.3c & A.4b). The Myc expression and GFP 
complementation were close to the level of background when the acid coil (K3 in 
Figure A.3b & A.3c) was deleted, indicating a lack of spontaneous complementation 
of the two split GFP. The level of surface expression of the bait protein measured by 
antibody binding to the FLAG tag was relatively invariant (Figure A.3b & A.3c), 
supporting the idea that the difference in the amount of the prey protein is solely due 
to the difference in its affinity to the bait. In contrast to a quantitative correlation 
between the strength of protein-protein interactions and GFP complementation, the 
acid and base coil interactions occurring in the cytosol (expression of the coils without 
secretory signal sequence) led to the complementation of split GFP that lacks 
correlation with the strength of coiled coil interactions (Figure A.3d & A.4c). 
However, GFP complementation for these pairs was still due to specific interaction 
between acid and base coils, evidenced by the absence of fluorescence when the base 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.4.3 YS2H detects specific interactions of antibodies and antigens 
To investigate a potential use of YS2H for antibody discovery, we first 
examined whether YS2H can detect specific interactions of known pairs of antigen 
and antibody. As a model system, we chose a ligand-binding domain of the integrin 
LFA-1, known as the Inserted or I domain, and monoclonal antibodies specific to 
LFA-1 I domain (Figure A.5). The I domain exists in two distinct conformations that 
correspond to low and high affinity states to its ligand, intercellular adhesion 
molecule-1 (ICAM-1) (Figure A.6). Although the I domain in isolation is 
predominantly in an inactive, low affinity conformation, the mutations that would 
 
Figure A.5: Detection of specific interactions between antibodies and antigens in 
YS2H. (a) Schematic diagram of the expression cassette used to study antigen (bait) 
and antibody (prey) interactions. (b-c) Shown are the histograms of the interactions 
of the wild-type and the high affinity (HA) I domains as baits and activation-
insensitive antibody, TS1/22 (b) activation-specific antibody, AL-57 (c) as preys. 
Filled histograms are of antibody binding to Myc and FLAG tags to the induced 
clones. Thin black lines represent antibody binding to uninduced clones as controls. 
The numbers in each plot indicate the means ± SE of the MFI of the filled 




favor the active conformation were found to induce high affinity binding of the I 
domain to the ICAM-1. For example, the mutations of K287C and K294C (high 
affinity or HA I domain) designed to stabilize by disulfide bond the position of the α7-
helix into active conformation led to an increase in the affinity to ICAM-1 by 10,000-
fold over the wild-type I domain [18]. 
 
Figure A.6: (a) Cartoon diagrams of low (inactive) and high affinity (active) 
conformations of the LFA-1 I domains. The regions that are structurally conserved 
between two states are colored gray. The regions that differ structurally are colored 
in magenta and yellow for the inactive and the active conformations, respectively. 
The metal ions in the metal ion-dependent adhesion site are shown as spheres. The 
N and C termini and α7-helix are labeled. (b) The structure of the I domain is shown 
in complex with the first domain of ICAM-1 (D1). Gray spheres with a white center 
display the positions for the hot spots for allosteric activation found in our previous 
study [10]. The metal ion and three oxygen atoms of water molecules are depicted as 
spheres. The residues that coordinate to the metal ion are shown in stick models. 
The structures of the I domains and the complex of I domain with the ICAM-1 were 




The antibodies that were expressed as scFv formats include the activation-
insensitive antibody (TS1/22) [19], binding to both inactive and active I domains, and 
the activation-dependent antibody (AL-57) [10, 20], which binds only to the active I 
domain. The interaction between antigen and antibody was measured by the detection 
of Myc tag fused to the antibody at the C terminus (Figure A.5). A tag-based assay 
was chosen instead of GFP complementation because it was found that the I domain 
fused to NeGFP did not express (no antibody binding to FLAG tag), presumably 
because of the quality control machinery in protein secretion [21] that prohibits 
misfolded proteins to be secreted (data not shown). This is in contrast to the 
expression of split GFP with a fusion of short coils, e.g. K3-NeGFP in Figure A.3c. 
Therefore, it appears that when NeGFP is fused to the I domain that by itself requires 
proper folding for secretion, the I domain fusion to NeGFP becomes completely 
misfolded and does not pass the quality control for secretion. 
Myc tag expression in YS2H was in agreement with the specificities of 
monoclonal antibody AL-57 and TS1/22 against the LFA I domain; although the 
clones expressing TS1/22 displayed Myc expression either with the wild-type or with 
the HA I domains as antigens (Figure A.5b), the AL-57 clones exhibited Myc 
expression only with the HA I domain (Figure A.5c). 
A.4.4 Discovery of activating mutations in the LFA-1 I domain 
Next, we examined the ability of our system in isolating activating mutations 
in antigens that exhibit two different activation states. With the expression of AL-57 
scFv and the error-prone PCR products of the wild-type I domain in YS2H, yeast 
library was constructed and sorted with anti-Myc antibody using a magnetic affinity 
 165 
cell sorter. With successive sorting, there was a gradual increase in the percentage of 
the population of cells that showed Myc expression above the background level 
(Figure A.7a). After two rounds of sorting, the cells were plated to yield individual 
clones, from which four clones were sequenced and tested for Myc expression. Of the 
four, three contained a mutation of F265S, and one contained L295P (Figure A.7b). 
These two mutations belonged to a long list of activation hot spots that were identified 
in our previous study [10], where a large number of yeast cells were sorted and 
 
Figure A.7: (a) Myc expression of the I domain library before sort and after first and 
second sort are shown. The numbers indicate the percentage of the clones within the 
gated region. Antibody binding was measured with 10 mM MgCl2 or no metal ions 
with 10 mM EDTA. (b) Two activating mutations from the second sort were of 
F265S and L295P. The numbers in each plot indicate means ± SE of the MFI of the 
filled histograms from three independent measurements. (c-d) SPR measurements of 
L295P (c) and F265S (d) binding to scFv AL-57. I domains were injected over the 




analyzed for their binding to exogenous AL-57 or ICAM-1-Fcγ.  
The mutations of L295P and F265S were previously found to contribute to an 
increase in the binding of the I domain to ICAM-1 at 6 and 152%, respectively, of the 
HA I domain binding to ICAM-1 [10]. To directly measure the affinity of scFv AL-57 
to I domain variants, we used a SPR technique (Figure A.7c & A.7d). A first order 
Langmuir adsorption equation was fitted to the sensograms to obtain the kinetic and 
equilibrium binding constants. The equilibrium dissociation constants (KD) of L295P 
and F265S to scFv AL-57 were 243 and 15.7 nM, respectively, in agreement with 
higher Myc expression with F265S in our system. AL-57 binding to the LFA-1 I 
domain depends on the presence of metal ions at the top of the I domain, known as the 
metal ion-dependent adhesion site (Figure A.6b) [22]. This was also confirmed by the 
decrease in the Myc tag expression when EDTA was added at 10 mM to the cells 
during labeling (Figure A.7a & Figure A.7b).  
A.4.5 Antibody discovery: VHH against Botulinum neurotoxin protease 
Approximately half of the IgGs in camelid sera are heavy chain-only 
antibodies devoid of light chains [11, 23]. Because of the lack of light chains, 
antigenic specificity of the heavy chain-only antibodies is limited to a variable domain 
of the heavy chain. We are seeking VHH agents that bind and inhibit the LC protease 
domains of Botulinum neurotoxins (BoNTs) as components in therapeutic agents for 
the treatment of botulism. In prior work (Maass et al. [11], we immunized alpacas 
with BoNT LCs of serotype A (A-LC) followed by serotype B (B-LC). We then used 
phage display techniques to identify VHHs from these alpacas with affinity for the 
BoNT LC proteases. We selected two A-LC binding VHHs (B8 and G6) and two B-
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LC binding VHHs (B10 and C3) for testing with the YS2H system (Figure A.8a). Myc 
tag expression was found to be highest in the clone expressing VHH-B8 and BoNT/A-
LC, whereas the binding level of the other VHHs was lower with MFI ranges from 14 
to 29. 
 
Figure A.8: (a) Specific binding of the VHHs against A-LC and B-LC was 
confirmed in YS2H by Myc expression. (b) New VHHs against B-LC protease were 
isolated by YS2H. The numbers in each plot indicate means ± SE of the MFI of the 
filled histograms from three independent measurements. 
 
 
To confirm that the level of Myc expression correlates with the solution 
affinity of VHH to LC, we used a SPR technique (Figure A.9). A series of 2-fold 
dilutions of A-LC was injected into a chip coated with B8 and G6. The KD values of 
B8 and G6 to BoNT/A-LC were estimated to be 2.3 and 230 nM, respectively. The 
100-fold difference in the affinity was mainly due to the 34-fold difference in the 
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 for G6).  
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Figure A.9: SPR measurements of B8 (a) and G6 (b) binding to BoNT/A-LC. A-LC 
was injected at a series of 2-fold dilutions beginning at 160 nM to the B8-coated and 
400 nM to the G6-coated chip.  
 
 
To validate the use of YS2H for antibody discovery, a yeast antibody library 
was constructed by transforming cells with the alpaca immune cDNA library as prey 
and the BoNT/B-LC gene as bait. Yeast cells enriched after two rounds of magnetic 
affinity cell sorting with anti-Myc antibody began to show an increase in Myc tag 
expression (data not shown). Of 30 clones that were tested individually, 14 clones 
displayed positive expression of Myc tag. Eleven of these 14 clones were found to be 
unique clones, including B10 and C3, which were originally isolated by phage display. 
Anti-Myc antibody binding of the newly isolated nine clones was in the range of 21–
33 MFI units, which is lower than that of B8 binding to A-LC (Myc expression of four 
selected clones are shown in Figure A.8b). Overall, anti-B-LC VHHs isolated by both 
the phage display and YS2H were low affinity binders (KD = 100 nM to 1 μM), 
suggesting a lack of the high affinity binders to B-LC protease in alpaca immune 
library.  
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Sequence analysis of the VHHs identified by phage or YS2H revealed that 
VHHs contain two, four, or six cysteines, which would result in up to two extra 
disulfide bonds in addition to the one that is conserved in all immunoglobulin fold 
domains (Figure A.10). We found that of the nine VHHs newly isolated by our YS2H 
system, three VHHs contain six cysteines, and the other six VHHs contain four 
cysteines. In contrast, either two or four cysteines were dominant in VHHs that were 
isolated by phage display. The VHHs identified by a phage display system may be 
limited to those that fold properly in a bacterial expression system. VHHs containing 
extra disulfides may fold improperly in bacteria, whereas the formation of correct 
disulfide bonds is much less problematic in yeast.  
 
Figure A.10: Sequence analysis of VHHs. Cysteines are highlighted in yellow for 
the pair that forms a conserved disulfide bond or in orange that forms extra disulfide 
bonds. The framework region (FR) and complementarity determining regions 






Here we demonstrate that our novel system, YS2H, is highly efficient in the 
detection and discovery of protein-protein interactions. The quantitative nature of 
YS2H is from the fact that protein-protein interactions occur via a secretory pathway, 
and the amount of the prey protein in complex with the bait is determined by the 
equilibrium affinity between the two. With the use of a PCA technique, our system 
may be designed to discriminate different pairs of protein-protein interactions 
according to their kinetics of binding.  
The utility of in vivo methods for quantitative estimation of binding affinity 
extends to the cases where one aims to increase the affinity of weak interactions 
between antigen and antibody and to engineer high affinity ligands and receptors that 
can potentially serve as agonists or antagonists. As an example, a prokaryotic system 
capable of co-expression of antigens anchored on the inner membrane of bacteria and 
single chain variable fragments (scFv) as soluble form was efficient in affinity 
screening and maturation [24]. Therefore, co-expression of antigen and antibody 
through eukaryotic secretory system will further enable screening of antibody libraries 
against the proteins that require eukaryotic folding machinery or that undergo post-
translational modifications.  
The amount of the prey bound to the bait in our system follows the Langmuir 
binding isotherm model. With the expression system used in this study, the 
concentration of prey proteins released into the media is far larger than that of the bait 
proteins, which is fused to Aga2. Under the mating conditions, the number of 
agglutinin goes up to 10,000 copies/cell [25], which approximates the concentration of 
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the bait proteins to be 1.7 nM at 10
8
 cells/1 ml of culture medium. The Langmuir 
equation is then given by [bait:prey]/[bait] = [prey]/([prey] + KD) where [bait:prey], 
[bait], and [prey] denote the concentrations of the bait in complex with the prey, the 
bait, and the prey, respectively. By replacing [bait:prey] and [bait] with antibody 
binding to Myc (MFI_Myc) and FLAG tag (MFI_FLAG), respectively, and taking 
into consideration of the MFI ratio (α) of anti-Myc to anti-FLAG antibody binding to 
equal copies of Myc and FLAG tags, the Langmuir equation rearranges into 
1/MFI_Myc = α−1(1+KD/[prey])/MFI_FLAG. From this equation (with measured 
values of α = 15 and [prey] = 10 nM), the KD values predicted for coiled coil 
interactions (E5-K5, E5-K4, E4-K4, and E5-K3) closely approximated the KD values 
measured by SPR [17] (Table A.1). The quantitative nature of YS2H in measuring 
protein-protein interactions extends to antigen and antibody interactions. The binding 
affinity of scFv TS1/22 to the wild-type and HA I domain, scFv AL-57 to the HA I 
domain, and the F265S ranged between 148 and 237 nM KD, whereas it was 440 nM 
for the binding of L295P to scFv AL-57. SPR measurement of the binding of I domain 
variants to scFv AL-57 estimated that although F265S and HA I domains have 
comparable affinity to scFv AL-57, L295P showed much lower affinity (Figure A.7c 
& A.7d, Table A.1). The predicted affinity for VHH-B8 and VHH-G6 binding to A-
LC is 38 and 143 nM, compared with the measured KD of 2.3 and 230 nM, 
respectively. Overall, the affinity predicted by the level of antibody binding to Myc 
and FLAG tag in our system agreed well with the measured affinity in the range of 1 
nM to 1 μM KD (Table A.1).  
Although antibody binding to the Myc tag for protein-protein interactions  
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Table A.1: Comparison of equilibrium dissociation constants (KD) predicted from 
YS2H versus directly measured using surface plasmon resonance 
Interaction pairs Predicted from YS2H (means ± SE) SPR measurements 
 nM nM 
E3-K3 1269.5 ± 53 32000 ± 3000
 a
 
E5-K3 1292.8 ± 37 7000 ± 800
 a
 
E4-K4 150.7 ± 48 116 ± 8
 a
 
E5-K4 18.3 ± 3 14 ± 1
 a
 
E5-K5 0.49 ± 0.2 0.063 ± 0.005
 a
 
HA-AL57 150.9 ± 8 32.6 ± 0.28
 b
 
F265S-AL57 237.4 ± 11.6 15.7 ± 0.03
 b
 
L295P-AL57 439.7 ± 13.6 243 ± 3.9
 b
 
VHH-B8-A-LC 38.2 ± 13.3 2.3 ± 0.08
 b
 




 The values are from the paper by De Crescenzoet al. [17]. Shown are the means ± 95% confidence 
interval.  
b
 The values are measured from this study. Shown are the means ± SE, estimated from BIAevaulation 
software from Biacore.  
 
 
higher than 10 μM KD reduced to the level of background (Figure A.4a), the detection 
by GFP complementation spanned a larger range of affinities, exhibiting a linear 
decrease in the fluorescence with an increase in KD in log scale (Figure A.4b). This is 
attributed to the fact that reconstituted GFP does not dissociate (or complementation is 
irreversible), such that the complemented GFP is functional whether or not the prey 
and the bait exist as a complex on the cell surface. Therefore, the dominant factor that 
determines GFP reconstitution will be the rate at which two coils associate (on-rate) to 
initiate split GFP assembly. Notably, when the MFI of reconstituted GFP was plotted 
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against the measured on-rates [17] for E5-K5, E5-K4, E4-K4, and E5-K3 (on-rate is 
unavailable for E3-K3), a liner trend was obtained with a R
2
 value of 0.95 (Figure 
A.4d). However, the use of GFP complementation was limited to the study of coiled 
coil interactions, because the I domain fused to the split GFP did not express on the 
surface. Therefore, to apply a PCA technique to detect diverse protein-protein 
interactions through the secretory pathway, split GFP needs to be optimized not to 
interfere with the folding of the bait and prey proteins. The additional parameter to be 
optimized is the length of the linker connecting split GFP to the proteins to enable 
GFP complementation for a wide range of size variation in proteins and topological 
variation between the binding interface and the GFP fusion site [6].  
The fact that GFP complementation occurs by protein-protein interaction 
through the secretion process explains its quantitative correlation with the strength of 
protein-protein interactions. This is in contrast to a previous finding [4] that GFP 
complementation from protein interactions occurring in the cytosol only indicates the 
presence of the interaction, and fluorescence intensity is relatively invariant with the 
affinity of two proteins. Indeed, when the two coils were expressed in the cytosol with 
the deletion of the secretory signal sequence, we found that overall fluorescent 
intensity was higher, and the complementation of split GFP lacked correlation with the 
strength of coiled coil association (Figure A.3d & A.4c). Because of the irreversible 
complementation of split GFP, after 24–48 h of induction, it is the concentration of 
two interacting proteins in the cytosol that determines the GFP complementation 
rather than their interaction strength.  
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Systems such as ribosomal [26], phage [27], and yeast [14] displays provide 
efficient means to couple genotype and phenotype and to screen library for protein 
engineering and antibody discovery. A typical screening process of antibody libraries 
requires exogenous antigens in their soluble form. Co-expression of two proteins 
within the same display system, e.g. the fusion of antigen and antibody into split phage 
coat protein [28] and the expression of antigen and antibody in bacterial periplasm as 
bait and prey proteins [24], can be particularly useful if target antigens are hard to 
express or unstable in solution. Our new system will offer a method to select 
antibodies against antigens that need to be expressed in eukaryotes. Other applications 
of YS2H may include expression of heterodimeric proteins, as demonstrated by 
similar platforms for expression of heterodimeric mammalian proteins such as major 
histocompatibility complex II α and β subunits [29] and antibodies in Fab format [30]. 
The use of our system to quantify and discover protein-protein interactions is not 
necessarily limited to the study of secretory proteins, because many proteins in 
nonsecretory cellular compartments or cytosol will maintain native conformations and 
interactions.  
An in vivo tool to map protein interactions has generated a large set of protein 
interactions, particularly among yeast proteins [6]. The readouts from the assays such 
as yeast two-hybrid and PCA are of cell growth caused by the expression of 
auxotrophic markers or reconstitution of enzymes and fluorescent proteins and are 
suitable for determining the presence or absence of protein interactions. In the case of 
protein network “hubs” in the binary protein interactome, i.e. the proteins interacting 
with a large number protein partners, the information on the strength of pairwise 
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interactions may provide an important insight into the flow of biological signals 
orchestrated by the protein hubs. Our newly developed YS2H system is well poised to 
implement such tasks. For example, in YS2H the hub proteins and known interacting 
partners are expressed as a pair of the bait and the prey, respectively, and the strength 
of pairwise interactions can be quantitatively estimated by antibody binding to fusion 
tags. Additionally, one can discover unknown interaction partners by expressing a 
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CELL SURFACE ASSEMBLY OF HIV GP41 SIX HELIX BUNDLES FOR 
FACILE, QUANTITATIVE MEASUREMENTS OF HETERO-OLIGOMERIC 
INTERACTIONS 





Helix-helix interactions are fundamental to many biological signals and 
systems, found in homo- or hetero-multimerization of signaling molecules as well as 
in the process of virus entry into the host. In HIV, virus-host membrane fusion during 
in-fection is mediated by the formation of six helix bundle (6HB) from homotrimers of 
gp41, from which a number of synthetic peptides have been derived as antagonists of 
virus entry. Using yeast surface two-hybrid (YS2H) system, a platform designed to 
detect protein-protein interactions occurring through a secretory pathway, we 
reconstituted 6HB complex on yeast surface, quantitatively measuring equilibrium and 
kinetic constants of soluble 6HB and delineating the residues influencing homo-
oligomeric and hetero-oligomeric coiled-coil interactions. Hence, we present YS2H as 
a platform for facile characterization and design of antagonistic peptides for inhibition 
of HIV and many other enveloped viruses relying on membrane fusion for infection, 
as well as cellular signaling events triggered by hetero-oligomeric coiled coils.  
                                                 
5
 This part is modified from the following paper in submission: Hu X, Saha P, Chen X, Kim 
D, Devarasetty M, Varadarajan R, Jin MM. Cell surface assembly of HIV gp41 six helix 
bundles for facile, quantitative measurements of hetero-oligomeric interactions. Xiaoyue Chen 




B.2 Research summary 
Many proteins naturally fold into varying degrees of helix bundles, 
indispensible to normal physiology and the onset of diseased states [1]. Of the well-
known examples are viral membrane fusion proteins like influenza virus 
hemagglutinin (HA) and HIV-1 envelope glycoprotein gp41. HIV infection critically 
depends on the attachment and fusion to host cells through gp120/gp41 complex. The 
extracellular domain of gp41 consists of a fusion peptide, an N-terminal heptad repeat 
(NHR), a loop region, a C-terminal heptad repeat (CHR), and a membrane-proximal 
external region (MPER) (Figure B.1a). Binding of gp120 to CD4 and subsequent 
interaction with co-receptors (CCR5 or CXCR4) leads to dissociation of gp120 from 
gp41 and insertion of the viral gp41 fusion peptide into the target cell membrane, 
which then forms a prehairpin intermediate. Fusion of viral and cellular membrane is 
provided by the formation of a gp41 six helix bundle (6HB), a conformation described 
by three CHR packing in an antiparallel manner to a central three-stranded NHR 
coiled coil [2-3] (Figure B.1b-c). gp41 prehairpin intermediate is transiently accessible 
to viral fusion inhibitors derived from NHR or CHR, named as N or C peptide 
accordingly [2, 4-8] (Figure B.1c-d). T20 is one of the early C peptides developed for 
HIV fusion inhibition [9-10]. CP32M, a rationally designed C peptide, extends to the 
upstream region of CHR compared to T20, and contains mutations to enhance affinity 
to NHR. These resulted in higher thermostability and greater inhibition of viral 
infection against diverse HIV strains [11]. Compared with the inhibitors derived from 




































































































































































































































































































































































































































































































































































































































































Helix (5H) peptide generated by linking 6HB peptides in tandem without the last C 
peptides is used to mimic N peptide, and is shown to be highly stable and potent in 
viral inhibition [12]. Other N-peptide derivatives have been based on fusion to 
synthetic trimerization sequences [13]. While much of the interest has been on 
developing synthetic inhibition peptides, natural peptides circulating in the blood have 
been reported to possess a capacity to inhibit virus fusion [14]. 
Developing biochemical assays to examine the potency of inhibitors of 6HB 
formation have been hampered by low solubility of N- and C-peptides and their 
tendency to aggregation [15]. As a facile and quantitative platform to study 6HB 
formation and to aid in the design of antagonistic peptides, we used yeast surface two 
hybrid (YS2H) system and expressed gp41 N- and C-peptides on yeast cell surface. In 
YS2H, a system designed to express a pair of proteins for measuring protein-protein 
interactions [16-17], one protein is fused to yeast agglutinin, thereby displayed on 
yeast surface as the ‘bait’, while the other protein is expressed as a soluble form, 
serving as the ‘prey’ (Figure B.2a-b). In the presence of interaction, two proteins 
associate with each other within a secretory pathway, and the prey is captured on cell 
surface by the bait. The affinity of the interaction between the prey and the bait can be 
quantitatively estimated from the relative abundance of short tags fused to bait and 
prey, typically measured by flow cytometry [17]. This system has previously been 
used to study heterodimeric interactions; however, its applicability to study higher 
order, complex oligomerizations has not been demonstrated. 
In order to reconstitute gp41 6HB complex on yeast surface, we expressed N36 
and C34 [18], a peptide derived from a region in NHR and CHR, respectively (Figure 
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B.1d & Figure B.2a-c). Surface expression of N36, fused to Aga2 (a subunit of 
agglutinin) as the ‘bait’, was confirmed by antibody binding to Flag tag appended to 
the C-terminal of N36. With C34 co-expressed as the ‘prey’, antibody binding to Myc 
tag indicated that C34 was captured by N36 (denoted as N36/C34 to refer to a pair of 
Aga2-fused bait and soluble prey; Figure B.2b-c). N36/C34association was further 
recognized by 6HB-specific monoclonal antibodies (mAb) NC-1 [19] and D50 [20] 
(Figure B.2c). Although the major epitope for D50 is at the C-terminal of CHR 
(Ile642-Lys665) [20], fully included in C34, yeast cells expressing C34 alone (C34/-) 
were not recognized by D50, indicating that C34 without N36 did not adopt a 
conformation existing in the context of 6HB. With N36 and C34 swapped for the role 
of bait and prey (i.e., C34/N36), 6HB was also achieved indicated by the binding of 
tag-specific antibodies, and mAbs NC-1 and D50 (Figure B.2c). We have chosen to 
use N peptide as a fusion to Aga2 and C peptide as a soluble form, a configuration 
more suitable for evaluating the potency of C peptide-based antagonists.  
To show that N- and C-peptides were assembled into 6HB conformation 
previously seen in crystals [3, 21], and to examine if YS2H would provide a 
quantitative readout to a change in hetero-oligomeric interactions, we have introduced 
point mutations at various positions and measured the binding of antibodies against 
reporter tags and 6HB (Figure B.2d). Physical forces contributing to 6HB or coiled-
coil conformation in general are from the combination of van der Waals (vdW) or 
hydrophobic contacts at the helix-helix interface and electrostatic attraction among the 
residues positioned outside of the interface. In a homotrimeric coil of NHR, amino 




Figure B.2: Assembly of 
6HB on yeast surface. (a) A 
schematic view of 6HB 
displayed on yeast surface 
by YS2H is depicted. (b) In 
YS2H, bidirectional 
promoter Gal1/Gal10 drives 
the expression of surface-
anchored ‘bait’ as a fusion 
to Aga2 and secretory 
‘prey’, the level of which is 
measured by antibody 
binding to short epitope tag, 
Flag and Myc, fused to bait 
and prey, respectively. SS = 
signal sequence. (c&d) 
Immunofluorescence flow 
cytometry histograms of 
antibody binding to Flag 
and Myc tags and 6HB-
specific antibodies (D50, 
D5). White and grey filled 
curves are histograms of 
uninduced and induced 
yeast cells, respectively. ‘*’ 
denotes Aga2-fused bait; ‘-’ 






helix interface at the core (Figure B.1b). The residues at ‘e’ and ‘g’ of NHR would 
normally be those that promote electrostatic interaction, but instead they are mainly 
hydrophobic so that CHR packs onto NHR to form 6HB. The mutations that disrupt 
hydrophobic or electrostatic forces would completely or partially disrupt coiled-coil 
interactions. Mutations at the interface between NHR and CHR (e.g., L556A (at 
position ‘e’), A558G (‘g’), and V570D (‘e’) of NHR and S649D (‘a’) of CHR) led to a 
modest (A558G) to almost complete (L556A, V570D, S649D) loss of C34 association 
with N36 (Figure B.2d). 5HB-specific mAb D5 [22], which largely recognizes the 
hydrophobic pocket present at the C-terminal end of NHR, displayed binding to 6HB 
mutants different from anti-Myc and 6HB-specific antibodies. To cells expressing 
only N36 (N36/-), D5 showed strong binding (Figure B.2d), revealing that N36 
without an assembly with C34 have adopted a conformation seen in the context of 
6HB. This is an important result that underscores the utility of yeast display, which 
circumvents the difficulty with studying isolated N-peptide derivatives in solution 
because of their hydrophobic, aggregation prone nature. The mutations that disrupted a 
homotrimeric N peptide conformation (e.g., I559P and I573D at position of ‘a’ of 
NHR), therefore, led to a complete loss of both anti-Myc and D5 antibodies (Figure 
B.2d). L568A, a mutation introduced at position ‘c’ of NHR, least compromised 6HB 
formation. In contrast to various mutations that led to partial to complete perturbation 
of 6HB formation, N656L led to an increase in the level of Myc expression (Figure 
2d), attributed to the introduction of hydrophobic residue that would form vdW 















































































































































































































































































































































































































































































































































































































After validating the assembly and perturbation of gp41 6HB, we examined the 
pairing of N36 or full-length NHR (Met530-Gln590) with the variants of C34, such as 
T20 and CP32M as antagonistic C peptides developed for inhibiting HIV entry (Table 
B.1). N36/T20 helix-helix inter α helix 
(Figure B.1d), too short to produce a strong interaction, and this resulted in marginal 
binding of anti-Myc antibody and D50. In contrast, NHR/T20, spanning longer than 
four heptad repeats of α helix at the interface, resulted in the level of Myc expression 
comparable to or less than the levels seen in NHR/C34 and N36/C34. The observation 
that NHR/T20 led to maximum binding with mAb D50 is consistent with the fact that 
D50 epitope is at C-terminal end of CHR (Ile642-Lys665), fully included in T20 but is 
only partially present in C34 [20]. When paired with either N36 or NHR, CP32M, a 
peptide spanning Gln621 to Gln652 of CHR and containing mutations to enhance 
electrostatic and hydrophobic interactions with NHR, exhibited elevated levels of Myc 
expression. The lack of mAb D50 binding to N36/CP32M and NHR/CP32M is due to 
the epitope for D50 being almost absent in CP32M. In YS2H, the ratio of the levels of 
reporter tags (Myc & Flag) is directly related by Langmuir equation to equilibrium 
dissociation constant (KD) for the interaction between bait and prey, given as 
Flag/Myc = α(1+KD/[prey]), where α is the ratio of Flag/Myc for KD ~ 0. With the 
estimated values of α = 4 and [prey] = 10 nM in YS2H [17], the values of KD were 
obtained for NHR or N34 binding to C34, T20, or CP32M (Table B.1). Although 
direct measurements of solution affinity for these pairs are not available, the difference 
in affinity is consistent with reported potency of C-peptide based inhibitors in the 
order of CP32M > C34 > T20 [17]. The ability to quantitatively measure equilibrium 
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binding constants highlights YS2H as a facile platform for the prediction of the 
potency of antagonistic peptides. 
In addition, YS2H can be adapted for a platform for measuring dissociation 
kinetics for hetero-oligomeric interactions. To minimize rebinding of dissociated C 
peptides to N peptides, yeast cells were washed and resuspended in a much larger 
volume of binding buffer (333-fold dilution of yeast culture) and antibody binding to 
reporter tags was measured at different time points (Figure B.3). Notably, the decrease 
in antibody binding to Myc followed a biphasic behavior, characterized by a rapid 
reduction of Myc within the first 10 min, followed by a slower decrease. An initial 
rapid dissociation of C peptide may be due to a loss of small percentage (~15%) of C 
peptides that were associated with the N peptides through non-ideal 6HB 
conformation. When a two phase dissociation model (Y = A1×exp(-t/T1) + A2×exp(-
t/T2)) was used to fit the data, in agreement with the overall trend of dissociation, the 
slower kinetics were dominant (A1 ≈ 15 and A2 ≈ 85) for all interaction pairs measured 
(Table B.1). Following a similar trend with equilibrium affinities, a dissociation rate of 









), and a dissociation rate of NHR/C34 was 3.9-fold slower than 




). Notably, although CP32M exhibited equilibrium 









) (Table B.1), 
indicating that CP32M binding to N36 is comparatively dominated by its on-rate. 
However, the on-rate of CP32M was less apparent with NHR, presumably due to the 
fact that the mutations introduced in CP32M were those to enhance electrostatic 
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attraction with the residues belonging to N36, which may be counteracted by the 
residues outside of N36.  
 
Figure B.3: Dissociation kinetics of C peptide inhibitors measured in YS2H. The 
loss of antibody binding to Myc (MFIMyc) is plotted as a percentage after 
normalization to the level of antibody binding to Flag (MFIFlag) (n = 5). A two phase 




In summary, we demonstrated a construction of a pair of α helices into YS2H 
system, and the assembly of viral 6HB structure on yeast cell surface. The equilibrium 
binding strength between coiled coils within the bundle as well as the kinetics of 
soluble peptides could be directly and quantitatively characterized. Subtle alterations 
that resulted from single point mutations perturbing homo-trimeric as well as hetero-
oligomeric coiled coils could also be detected in YS2H, which would greatly 
contribute as a platform to design, optimization, and evaluation of antagonistic 
peptides as drug candidates. Besides HIV, many enveloped viruses including 
influenza, respiratory syncytial virus, and Ebola virus require helix bundles for 
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membrane fusion during virus entry into the host [23]. In the past, great effort has 
been made on de novo synthesis of various types of helix bundles [24-28]. The 
assembly of helix bundles or hetero-oligomeric peptides on yeast surface would allow 
rapid screening and design of candidate inhibitors, without the impediment from often 
unreliable in vitro protein refolding and costly chemical synthesis. 
 
B.3 Materials and methods 
B.3.1 Generation of YS2H constructs 
DNA encoding HIV-1 gp41 wild type N and C peptides were chemically 
synthesized. They were PCR amplified for adding the sequences homologous (~90 bp) 
to pCTCON at both ends. pCTCON vector was linearized by restriction digestion 
using NcoI/SalI for introduction of ‘bait’ and BamHI/SpeI for introduction of ‘prey’. 
Wild type N- and C-peptide cDNAs were then successively introduced into pCTCON 
through homologous recombination [29], achieved by co-transformation of E.coli 
HME68 [29] with cDNA fragments and linearized pCTCON vector. Plasmids were 
purified from E.coli and sequence-verified. The 6HB destabilizing mutants were 
introduced by amplifying the ‘bait’ and ‘prey’ fragments along with ~90bp homology 
to the pCTCON vector using overlap PCR [30], followed by homologous 
recombination with linearized pCTCON vector. 
B.3.2 Growth of yeast cells with protein displayed on surface 
YS2H plasmids were transformed into EBY100 yeast cells by Frozen E-Z 
transformation kit (Zymoresearh, CA). Transformed colonies were inoculated into 
SDCAA media (20 g/l dextrose, 6.7 g/l Difco yeast nitrogen base, 5 g/l Bacto 
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casamino acids, 5.4 g/l Na2HPO4 and 8.56 g/l NaH2PO4·H2O) and cultured at 30°C 
with shaking. After 24 hours of culture in SDCAA, EBY100 cells were transferred to 
SGCAA media (20 g/l galactose, 6.7 g/l Difco yeast nitrogen base, 5 g/l Bacto 
casamino acids, 5.4 g/l Na2HPO4, 8.56 g/l NaH2PO4·H2O) and cultured for another 24 
hours at 30°C with shaking to induce protein expression.  
B.3.3 Immunofluorescence flow cytometry 
Monoclonal antibodies used in this study include anti-Myc antibody 9E10 
(ATCC), anti-Flag antibody (Genscript, NJ), and phycoerythrin-labeled goat 
polyclonal anti-murine antibody (Santa Cruz Biotechnology, CA). HIV-1 antibodies 
NC-1 and D50 were obtained from NIH AIDS Research & Reference Reagent 
Program. Antibody D5 was a kind gift from Merck Research Laboratories. After 
induction, yeast cells were harvested, washed in 100 μl of labeling buffer (PBS 
containing 0.5% BSA with 1 mM MgCl2), and then incubated with primary antibodies 
in 50 μl of the labeling buffer for 20 min while shaking at 30°C. Cells were washed 
and incubated with secondary antibodies at 5 μg/ml in 50 μl of the labeling buffer for 
20 min at 4°C. At the final step, cells were washed once in 100 μl, suspended in 100 μl 
of the labeling buffer, and subjected to flow cytometry (Epics XL flow cytometer, 
Beckman Coulter, CA).  
B.3.4 Measurement of 6HB kinetics on yeast surface 
To measure the dissociation rate of C peptides, each of 3 μl induced yeast cells 
was briefly washed, incubated in 1 ml washing buffer (PBS containing 0.5% BSA with 
1 mM MgCl2) and rotated at room temperature. Samples were spun down at different 
time points and the cell pellets were stored on ice until all samples were harvested. For 
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samples incubated over 1 hour, washing buffer was changed once at 1 hour time point. 
All the cells were labeled using anti-Myc antibody and then phycoerythrin-labeled 
goat anti mouse antibody at the same time after all samples were collected. In order to 
calculate koff, dissociation curves were fitted using OriginPro 7.5 (OriginLab) by two-
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